Active versus expectant management for women in the third stage of labour by Begley, Cecily M et al.
This is a repository copy of Active versus expectant management for women in the third 
stage of labour.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/145294/
Version: Published Version
Article:
Begley, Cecily M, Gyte, Gillian Ml, Devane, Declan et al. (3 more authors) (2019) Active 
versus expectant management for women in the third stage of labour. Cochrane Database 
of Systematic Reviews. CD007412. ISSN 1469-493X 
https://doi.org/10.1002/14651858.CD007412.pub5
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Cochrane Database of Systematic Reviews
Active versus expectant management for women in the third
stage of labour (Review)
Begley CM, Gyte GML, Devane D, McGuire W, Weeks A, Biesty LM
Begley CM, Gyte GML, Devane D, McGuire W, Weeks A, Biesty LM.
Active versus expectant management for women in the third stage of labour.
Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No.: CD007412.
DOI: 10.1002/14651858.CD007412.pub5.
www.cochranelibrary.com
Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
27DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
32AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
63DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 1 Severe
primary postpartum haemorrhage (PPH) at time of birth (clinically estimated or measured blood loss ≥ 1000 mL). 90
Analysis 1.4. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 4 Maternal
Hb < 9 g/dL 24-72 hours postpartum. . . . . . . . . . . . . . . . . . . . . . . . . . 91
Analysis 1.5. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 5 Admission
to neonatal special/intensive care. . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Analysis 1.6. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 6 Neonatal
jaundice requiring phototherapy or exchange transfusion. . . . . . . . . . . . . . . . . . . . 93
Analysis 1.10. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 10 Primary
blood loss ≥ 500 mL at time of birth (clinically estimated or measured). . . . . . . . . . . . . . 94
Analysis 1.13. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 13 Mean
maternal blood loss (mL) at time of birth (clinically estimated or measured). . . . . . . . . . . . . 95
Analysis 1.16. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 16
Maternal blood transfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Analysis 1.18. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 18
Therapeutic uterotonics during third stage and/or within 24 hours. . . . . . . . . . . . . . . . 97
Analysis 1.19. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 19 Mean
length of third stage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Analysis 1.20. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 20 Manual
removal of placenta as defined by study authors. . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 1.21. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 21
Postnatal diastolic blood pressure > 90 mmHg between birth of baby and discharge from the labour ward. . . 100
Analysis 1.22. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 22
Postnatal vomiting between birth of baby and discharge from the labour ward. . . . . . . . . . . . 101
Analysis 1.23. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 23 Any
analgesia between birth of the baby and discharge from labour ward. . . . . . . . . . . . . . . . 102
Analysis 1.25. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 25
Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and up to 6 weeks). . . . . . 103
Analysis 1.27. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 27 Surgical
evacuation of retained products of conception. . . . . . . . . . . . . . . . . . . . . . . 104
Analysis 1.28. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 28
Afterpains - abdominal pain associated with the contracting uterus in the postpartum period. . . . . . . 105
Analysis 1.29. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 29 Apgar
score < 7 at 5 minutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
iActive versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.30. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 30
Birthweight. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Analysis 1.38. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 38
Exclusive breastfeeding at discharge from hospital. . . . . . . . . . . . . . . . . . . . . . 108
Analysis 1.40. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 40 Return
to hospital as in- or outpatient because of bleeding (not pre-specified). . . . . . . . . . . . . . . 109
Analysis 1.41. Comparison 1 Active versus expectant management of 3rd stage of labour (all women), Outcome 41
Postnatal maternal mean Hb (outcome not pre-specified). . . . . . . . . . . . . . . . . . . 110
Analysis 2.1. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 1
Severe primary PPH at time of birth (clinically estimated or measured blood loss ≥ 1000 mL). . . . . . . 111
Analysis 2.4. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 4
Maternal Hb < 9 g/dL at 24-72 hr. . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Analysis 2.5. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 5
Admission to neonatal special/intensive care. . . . . . . . . . . . . . . . . . . . . . . . 113
Analysis 2.6. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 6
Neonatal jaundice requiring phototherapy or exchange transfusion. . . . . . . . . . . . . . . . 114
Analysis 2.10. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 10
Primary blood loss ≥ 500 mL at time of birth (clinically estimated or measured). . . . . . . . . . . 115
Analysis 2.13. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 13
Mean maternal blood loss (mL at the time of birth, clinically estimated or measured. . . . . . . . . . 116
Analysis 2.16. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 16
Maternal blood transfusion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 2.18. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 18
Therapeutic uterotonics during third stage and/or within 24 hours. . . . . . . . . . . . . . . . 118
Analysis 2.19. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 19
Mean length of third stage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 2.20. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 20
Manual removal of placenta as defined by study authors. . . . . . . . . . . . . . . . . . . . 120
Analysis 2.21. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 21
Postnatal diastolic blood pressure > 90 mmHg between birth of baby and discharge from the labour ward. . . 121
Analysis 2.22. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 22
Postnatal vomiting between birth of baby and discharge from the labour ward.. . . . . . . . . . . . 122
Analysis 2.23. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 23
Any analgesia between birth of the baby and up to discharge from labour ward. . . . . . . . . . . . 123
Analysis 2.25. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 25
Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and up to 6 weeks). . . . . . 124
Analysis 2.27. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 27
Surgical evacuation of retained products of conception. . . . . . . . . . . . . . . . . . . . 125
Analysis 2.28. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 28
Afterpains - abdominal pain associated with the contracting uterus in the postpartum period. . . . . . . 126
Analysis 2.30. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 30
Birthweight. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Analysis 2.40. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 40
Return to hospital as in- or outpatient because of bleeding (not pre-specified). . . . . . . . . . . . . 128
Analysis 2.41. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk), Outcome 41
Postnatal maternal mean Hb (outcome not pre-specified). . . . . . . . . . . . . . . . . . . 129
Analysis 5.8. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 8 Maternal blood transfusion. . . . . . . . . . . . . . . . . 130
Analysis 5.9. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 9 Therapeutic uterotonics during third stage and/or within 24 hours. . . 131
Analysis 5.10. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 10 Mean length of third stage. . . . . . . . . . . . . . . . 132
iiActive versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.11. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 11 Manual removal of placenta as defined by study authors. . . . . . 133
Analysis 5.12. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 12 Surgical evacuation of retained products of conception. . . . . . . 134
Analysis 5.13. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 13 Birthweight. . . . . . . . . . . . . . . . . . . . . . 135
Analysis 5.14. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction), Outcome 14 Postnatal maternal mean Hb. . . . . . . . . . . . . . . . 136
Analysis 9.1. Comparison 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping
and no controlled cord traction) , Outcome 1 Severe primary PPH at time of birth (clinically estimated or measured
blood loss ≥ 1000 mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Analysis 9.10. Comparison 9 Active versus mixed management (uterotonic after placental delivery, immediate cord
clamping and no controlled cord traction) , Outcome 10 Primary blood loss ≥ 500 mL at time of birth (clinically
estimated or measured). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Analysis 9.16. Comparison 9 Active versus mixed management (uterotonic after placental delivery, immediate cord
clamping and no controlled cord traction) , Outcome 16 Maternal blood transfusion. . . . . . . . . . 139
Analysis 9.17. Comparison 9 Active versus mixed management (uterotonic after placental delivery, immediate cord
clamping and no controlled cord traction) , Outcome 17 Clinical signs of severe blood loss. . . . . . . . 140
Analysis 9.18. Comparison 9 Active versus mixed management (uterotonic after placental delivery, immediate cord
clamping and no controlled cord traction) , Outcome 18 Therapeutic uterotonics during third stage and/or within
24 hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Analysis 9.19. Comparison 9 Active versus mixed management (uterotonic after placental delivery, immediate cord
clamping and no controlled cord traction) , Outcome 19 Mean length of third stage. . . . . . . . . . 142
Analysis 10.1. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 1 Severe primary PPH at time of birth (clinically estimated or measured blood loss ≥ 1000
mL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
Analysis 10.4. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 4 Maternal Hb < 9 g/dL at 24-72 hr. . . . . . . . . . . . . . . . . . 144
Analysis 10.10. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 10 Primary blood loss ≥ 500 mL at time of birth (clinically estimated or measured). . 145
Analysis 10.13. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 13 Mean maternal blood loss (mL) at time of birth (clinically estimated or measured). 146
Analysis 10.16. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 16 Maternal blood transfusion. . . . . . . . . . . . . . . . . . . . 147
Analysis 10.18. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 18 Therapeutic uterotonics during third stage and/or within 24 hours. . . . . . 148
Analysis 10.19. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 19 Mean length of third stage. . . . . . . . . . . . . . . . . . . . 149
Analysis 10.20. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 20 Manual removal of placenta as defined by study authors. . . . . . . . . . 150
Analysis 10.28. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 28 Not prespecified: afterpains at 2 hours after birth (id 20458). . . . . . . . 151
Analysis 10.29. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 29 Not pre-specified: afterpains the day after birth (id 20458). . . . . . . . . 152
Analysis 10.31. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 31 Birthweight. . . . . . . . . . . . . . . . . . . . . . . . . 153
Analysis 10.42. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 42 Postnatal maternal mean Hb (outcome not pre-specified). . . . . . . . . . 154
Analysis 10.43. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 43 Severe primary PPH after placental delivery and up to 2 hours (clinically estimated or
measured blood loss ≥ 1000 mL) - not pre-specified. . . . . . . . . . . . . . . . . . . . . 155
iiiActive versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.44. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 44 Severe primary PPH at time of birth and up to 2 hours (clinically estimated or measured
blood loss ≥1000 mL) - not pre-specified. . . . . . . . . . . . . . . . . . . . . . . . . 156
Analysis 10.45. Comparison 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction), Outcome 45 Mean blood loss (mL) (clinically estimated or measured at birth and up to 2 hours (not
pre-specified). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
Analysis 11.4. Comparison 11 Active versus mixed management (no routine uterotonic, early cord clamping, controlled
cord traction), Outcome 4 Maternal Hb < 9 g/dL at 24-72 hr. . . . . . . . . . . . . . . . . . 158
Analysis 11.19. Comparison 11 Active versus mixed management (no routine uterotonic, early cord clamping, controlled
cord traction), Outcome 19 Mean length of third stage. . . . . . . . . . . . . . . . . . . . 159
Analysis 11.20. Comparison 11 Active versus mixed management (no routine uterotonic, early cord clamping, controlled
cord traction), Outcome 20 Manual removal of placenta as defined by study authors. . . . . . . . . . 160
160ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
163APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
163FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
165WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
165HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
166CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
166DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
167SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
167DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
169INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ivActive versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Active versus expectant management for women in the third
stage of labour
Cecily M Begley1, Gillian ML Gyte2, Declan Devane3, William McGuire4, Andrew Weeks5, Linda M Biesty3
1School of Nursing andMidwifery, Trinity College Dublin, Dublin, Ireland. 2Cochrane Pregnancy and Childbirth Group, Department
of Women’s and Children’s Health, University of Liverpool, Liverpool, UK. 3School of Nursing and Midwifery, National University
of Ireland Galway, Galway, Ireland. 4Centre for Reviews and Dissemination, University of York, York, UK. 5Department of Women’s
and Children’s Health, The University of Liverpool, Liverpool, UK
Contact address: Cecily M Begley, School of Nursing and Midwifery, Trinity College Dublin, 24 D’Olier Street, Dublin, Ireland.
cbegley@tcd.ie.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2019.
Citation: Begley CM, Gyte GML, Devane D, McGuire W, Weeks A, Biesty LM. Active versus expectant management for
women in the third stage of labour. Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No.: CD007412. DOI:
10.1002/14651858.CD007412.pub5.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Active management of the third stage of labour involves giving a prophylactic uterotonic, early cord clamping and controlled cord
traction to deliver the placenta. With expectant management, signs of placental separation are awaited and the placenta is delivered
spontaneously. Active management was introduced to try to reduce haemorrhage, a major contributor to maternal mortality in low-
income countries. This is an update of a review last published in 2015.
Objectives
To compare the effects of active versus expectant management of the third stage of labour on severe primary postpartum haemorrhage
(PPH) and other maternal and infant outcomes.
To compare the effects of variations in the packages of active and expectant management of the third stage of labour on severe primary
PPH and other maternal and infant outcomes.
Search methods
For this update, we searchedCochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov and theWorld healthOrganization
International Clinical Trials Registry Platform (ICTRP), on 22 January 2018, and reference lists of retrieved studies.
Selection criteria
Randomised and quasi-randomised controlled trials comparing active versus expectantmanagement of the third stage of labour. Cluster-
randomised trials were eligible for inclusion, but none were identified.
Data collection and analysis
Two review authors independently assessed the studies for inclusion, assessed risk of bias, carried out data extraction and assessed the
quality of the evidence using the GRADE approach.
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Main results
We included eight studies, involving analysis of data from 8892 women. The studies were all undertaken in hospitals, seven in higher-
income countries and one in a lower-income country. Four studies compared active versus expectant management, and four compared
active versus a mixture of managements. We used a random-effects model in the analyses because of clinical heterogeneity. Of the
eight studies included, we considered three studies as having low risk of bias in the main aspects of sequence generation, allocation
concealment and completeness of data collection. There was an absence of high-quality evidence according to GRADE assessments for
our primary outcomes, which is reflected in the cautious language below.
The evidence suggested that, for women at mixed levels of risk of bleeding, it is uncertain whether active management reduces the
average risk of maternal severe primary PPH (more than 1000 mL) at time of birth (average risk ratio (RR) 0.34, 95% confidence
interval (CI) 0.14 to 0.87, 3 studies, 4636 women, I2 = 60%; GRADE: very low quality). For incidence of maternal haemoglobin
(Hb) less than 9 g/dL following birth, active management of the third stage may reduce the number of women with anaemia after birth
(average RR 0.50, 95% CI 0.30 to 0.83, 2 studies, 1572 women; GRADE: low quality). We also found that active management of
the third stage may make little or no difference to the number of babies admitted to neonatal units (average RR 0.81, 95% CI 0.60 to
1.11, 2 studies, 3207 infants; GRADE: low quality). It is uncertain whether active management of the third stage reduces the number
of babies with jaundice requiring treatment (RR 0.96, 95% CI 0.55 to 1.68, 2 studies, 3142 infants, I2 = 66%; GRADE: very low
quality). There were no data on our other primary outcomes of very severe PPH at the time of birth (more than 2500 mL), maternal
mortality, or neonatal polycythaemia needing treatment.
Active management reduces mean maternal blood loss at birth and probably reduces the rate of primary blood loss greater than 500
mL, and the use of therapeutic uterotonics. Active management also probably reduces the mean birthweight of the baby, reflecting the
lower blood volume from interference with placental transfusion. In addition, it may reduce the need for maternal blood transfusion.
However, active management may increase maternal diastolic blood pressure, vomiting after birth, afterpains, use of analgesia from
birth up to discharge from the labour ward, and more women returning to hospital with bleeding (outcome not pre-specified).
In the comparison of women at low risk of excessive bleeding, there were similar findings, except it was uncertain whether there was
a difference identified between groups for severe primary PPH (average RR 0.31, 95% CI 0.05 to 2.17; 2 studies, 2941 women, I2 =
71%), maternal Hb less than 9 g/dL at 24 to 72 hours (average RR 0.17, 95% CI 0.02 to 1.47; 1 study, 193 women) or the need for
neonatal admission (average RR 1.02, 95% CI 0.55 to 1.88; 1 study, 1512 women). In this group, active management may make little
difference to the rate of neonatal jaundice requiring phototherapy (average RR 1.31, 95% CI 0.78 to 2.18; 1 study, 1447 women).
Hypertension and interference with placental transfusion might be avoided by using modifications to the active management package,
for example, omitting ergot and deferring cord clamping, but we have no direct evidence of this here.
Authors’ conclusions
Although the data appeared to show that active management reduced the risk of severe primary PPH greater than 1000 mL at the time
of birth, we are uncertain of this finding because of the very low-quality evidence. Active management may reduce the incidence of
maternal anaemia (Hb less than 9 g/dL) following birth, but harms such as postnatal hypertension, pain and return to hospital due to
bleeding were identified.
In women at low risk of excessive bleeding, it is uncertain whether there was a difference between active and expectant management
for severe PPH or maternal Hb less than 9 g/dL (at 24 to 72 hours). Women could be given information on the benefits and harms
of both methods to support informed choice. Given the concerns about early cord clamping and the potential adverse effects of some
uterotonics, it is critical now to look at the individual components of third-stage management. Data are also required from low-income
countries.
It must be emphasised that this review includes only a small number of studies with relatively small numbers of participants, and the
quality of evidence for primary outcomes is low or very low.
P L A I N L A N G U A G E S U M M A R Y
Delivering the placenta in the third stage of labour
What is the issue?
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The aim of this Cochrane Review was to look at different ways of delivering the placenta after the birth of the baby; expectant, active or
mixed management. We asked, what are the benefits and harms for all women, but specifically for women at low risk of severe bleeding
(haemorrhage)? We collected and analysed all relevant studies to answer this question (22 January 2018).
Why is this important?
Once a baby is born, the womb (uterus) continues to contract, causing the placenta to separate from the wall of the uterus. The mother
then delivers the placenta, or ’after-birth’. This is called expectant management of third stage of labour. Active management of third
stage involves three components: 1) giving a drug (a uterotonic) to help contract the uterus; 2) clamping the cord early (usually before,
alongside, or immediately after giving the uterotonic); 3) traction is applied to the cord with counter-pressure on the uterus to deliver
the placenta (controlled cord traction). Mixed management uses some, but not all, of the three components. Active management was
introduced to try to reduce severe blood loss at birth. This is a major cause of women dying in low-income countries where women are
more likely to be poorly nourished, anaemic and have infectious diseases. In high-income countries, severe bleeding occurs much less
often, yet active management has become standard practice in many countries.
What evidence did we find?
We found eight studies that contributed data and involved 8892 women and their babies. All studies were undertaken in hospital
settings, seven in higher-income countries and one in a lower-income country. Four studies compared active with expectantmanagement
and four compared active with mixed management.
Overall, the quality of the evidence was generally low or very low and we need more data to be confident in the findings. For all
women, irrespective of their risk of severe bleeding, active management may reduce severe bleeding and anaemia. However, it also may
reduce the baby’s birthweight and increase the mother’s blood pressure, afterpains, vomiting, and the number of women returning to
hospital with bleeding. Findings were similar for women at low risk of bleeding, though it was unclear if there was any difference in
the incidence of severe bleeding or anaemia.
What does this mean?
Women should be given information before they give birth to help them make informed choices. Some adverse effects experienced by
mothers may possibly be avoided by using specific drugs. Delaying cord clamping may benefit the baby by preventing the reduction in
birthweight from early cord clamping, but more research is needed. Also, it may be that just giving a uterotonic might reduce severe
bleeding, without using the other parts of active management. More research is needed, particularly in low-income countries.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Active versus expectant management of the third stage of labour (all women)
Population: all women who expected a vaginal birth at 24 weeks’ gestat ion or later and their babies
Setting: UK and Ireland, hospital sett ing. The countries were classif ied as ’higher-income’ and ’lower-income’, with the border between lower-m iddle-income and upper-m iddle-
income being the cut-of f . All studies included in this main analysis were undertaken in higher-income countries (def ined according to World Bank def init ions 2018).
Intervention: act ive management of the third stage of labour
Comparison: expectant management of the third stage of labour
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Expectant manage-
ment of the third stage
of labour
Active management of
the third stage of
labour
Severe primary PPH
(clinically est imated or
measured blood loss ≥
1000 mL at t ime of
birth)
24 per 1000 8 per 1000
(3 to 21)
RR 0.34
(0.14 to 0.87)
4636
(3 studies)
⊕©©©
Very lowa
Very severe primary
PPH
(clinically est imated or
measured blood loss ≥
2500 mL at t ime of
birth)
See comment See comment Not est imable 0
(0 studies)
See comment No data
Maternal mortality See comment See comment Not est imable 0
(0 studies)
See comment No data
Maternal Hb < 9 g/dL
24-72 hours postpar-
tum
71 per 1000 36 per 1000
(21 to 59)
RR 0.50
(0.3 to 0.83)
1572
(2 studies)
⊕⊕©©
Lowb
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Admission to SCBU/
NICU
52 per 1000 42 per 1000
(31 to 58)
RR 0.81
(0.60 to 1.11)
3207
(2 studies)
⊕⊕©©
Lowc
Neonatal jaundice re-
quiring phototherapy
or exchange transfu-
sion
49 per 1000 47 per 1000
(27 to 83)
RR 0.96
(0.55 to 1.68)
3142
(2 studies)
⊕©©©
Very lowd
Neonatal
polycythaemia treated
with dilutional ex-
change transfusion
See comment See comment Not est imable 0
(0 studies)
See comment No data
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; Hb: haemoglobin; NICU: neonatal intensive care unit ; PPH: primary postpartum haemorrhage; RR: risk rat io; SCBU: special care baby unit
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aRisk of bias: of the three studies providing data for this outcome, all are at low risk of bias for sequence generat ion (select ion
bias) and allocat ion concealment (select ion bias). All are at high risk of bias for lack of blinding for clinicians and women
and all are unclear for blinding of outcome assessment. Two studies are at low risk of bias for incomplete outcome data
(attrit ion bias), and one is unclear. Two are at high risk of select ive report ing (report ing bias) and one is unclear. One study
is at high risk of other bias and two are unclear (see ’Risk of bias’ tables and Figure 2). Downgraded 1.
Inconsistency: there is some overlap of conf idence intervals of the three studies, however, Tau² = 0.38, the P value for the
Chi² test of heterogeneity is 0.08 and I² = 60%. These suggest the presence of heterogeneity, which cannot be explained by
any of the subgroups or sensit ivity analyses performed. Downgraded 1.
Indirectness: direct ly answers the quest ion.
Imprecision: total (cumulat ive) sample size 4636 is less than the opt imal information size of 18,590 (assuming α = 0.05, 1-β
= 0.80, relat ive risk reduct ion (RRR) of 25% f rom control event rate). Events = 88, Downgraded 1.
Publication bias: assessment of funnel plot asymmetry not performed due to fewer than 10 studies included for this outcome.
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bRisk of bias: of the two studies providing data for this outcome, both are at low risk of bias for sequence generat ion
(select ion bias) and one is at low risk of bias for allocat ion concealment (select ion bias) and the other is unclear. Both are at
high risk of bias for lack of blinding of clinicians and women, both are unclear for blinding of outcome assessment (although
unlikely to af fect Hb measurements). One is at high risk of bias for incomplete outcome data (attrit ion bias) while the other is
unclear. One is high risk of bias for select ive report ing (report ing bias), the other is unclear. Both studies are at high risk of
other bias (see ’Risk of bias’ tables and Figure 2). Downgraded 1.
Inconsistency: the conf idence intervals of the two studies overlap. Tau² = 0.02, the P value for the Chi² test of heterogeneity
is 0.31 and I² = 3%. Although Tau² is non-zero, tests suggest an absence of unexplained heterogeneity.
Indirectness: direct ly answers the quest ion.
Imprecision: total (cumulat ive) sample size 1572 is less than the opt imal information size of 5804 (assuming α = 0.05, 1-β =
0.80, RRR of 25% f rom control event rate). Events = 94. Downgraded 1.
Publication bias: assessment of funnel plot asymmetry not performed due to fewer than 10 studies included for this outcome.
cRisk of bias: of the two studies providing data for this outcome, both are at low risk of bias for sequence generat ion
(select ion bias) and allocat ion concealment (select ion bias). Both are at high risk of bias for lack of blinding of clinicians
and women, both are unclear for blinding of outcome assessment. One is at low risk of bias for incomplete outcome data
(attrit ion bias), the other is unclear. Both are at high risk of bias for select ive report ing (report ing bias) and both are at high
risk for other biases (see ’Risk of bias’ tables and Figure 2). Downgraded 1.
Inconsistency: the conf idence intervals of the two studies overlap. Heterogeneity: Tau² = 0.00; Chi² P value = 0.40, I² = 0%.
This suggests an absence of unexplained heterogeneity.
Indirectness: direct ly answers the quest ion.
Imprecision: total (cumulat ive) sample size 3207 is less than the opt imal information size of 8066 (assuming α = 0.05, 1-β =
0.80, RRR of 25% f rom control event rate). Events = 152. Downgrade 1
Publication bias: assessment of funnel plot asymmetry not performed due to fewer than 10 studies included for this outcome.
dRisk of bias: of the two studies providing data for this outcome, both are at low risk of bias for sequence generat ion
(select ion bias) and allocat ion concealment (select ion bias). Both are at high risk of bias for lack of blinding of clinicians and
women, both are unclear for blinding of outcome assessment. One is low risk of bias for incomplete outcome data (attrit ion
bias), the other is unclear. Both are at high risk of bias for select ive report ing (report ing bias) and both are at high risk of
other biases (see ’Risk of bias’ tables and Figure 2). Downgraded 1.
Inconsistency: there is some overlap of conf idence intervals of the two studies. However, Tau² = 0.11, P value for heterogeneity
= 0.09 and I² = 66%, which suggest the presence of heterogeneity that cannot be explained by any of the subgroups or
sensit ivity analyses performed. Downgraded 1.
Indirectness: direct ly answers the quest ion.
Imprecision: total (cumulat ive) sample size 3142 is less than the opt imal information size of 8584 (assuming α = 0.05, 1-β =
0.80, RRR of 25% f rom control event rate). Events = 149. Downgraded 1.
Publication bias: assessment of funnel plot asymmetry not performed due to fewer than 10 studies included for this outcome.
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B A C K G R O U N D
Description of the condition
The third stage of labour is the time from the birth of the baby to
the expulsion of the placenta and membranes. Once the baby is
born, the uterus continues to contract and reduce in size. There is
a lack of full understanding of the physiology of the third stage of
labour, but recent work using ultrasonography has demonstrated
that the process of placental separation has three distinct phases
(Herman 2002). The first, or latent phase, consists of strong uter-
ine contractions, which lead to thickening of the uterine muscle,
thus causing a shearing force to occur between the elastic uter-
ine wall and the more rigid placenta (Herman 2002). Continued
contractions lead to gradual separation of the placenta, commenc-
ing at one of the poles (most commonly the lower) and spread-
ing slowly during the contraction or detachment phase until full
separation occurs. This is followed by delivery of the placenta in
the expulsion phase (Herman 2002). Muscle fibres surrounding
the maternal vessels contract to prevent excessive bleeding (Inch
1985), and the mother’s coagulation system is activated temporar-
ily (Bonnar 1970).
There is always some blood loss during the third stage of labour
as the placenta separates and is delivered, but what might be con-
sidered a normal amount of loss is the subject of debate (Gyte
1992). Nevertheless, some women can suffer from considerable
blood loss during or after the third stage of labour. This can be
a primary haemorrhage (within the first 24 hours; Mousa 2014),
or a secondary haemorrhage (between 24 hours and six weeks;
McDonald 2003). Postpartum haemorrhage (PPH) is commonly
defined as a blood loss in excess of 500 mL (WHO 2003), with se-
vere haemorrhage being a loss of 1000 mL or more and very severe
haemorrhage being a loss of 2500 mL or more (Bloomfield 1990;
Greer 1998; Penney 2005). However, the impact of blood loss at
birth on an individual woman can vary considerably and will de-
pend not only on the volume of blood lost, but also on her general
state of health, the speed of the loss, her haemoglobin (Hb) levels
at the time and her coagulation system. It is well documented that
blood loss is consistently under- or over-estimated by clinicians
(Razvi 2008), although many centres do try to measure and record
blood loss accurately. In well-nourished women, some consider
that, in general, there is little impact from a blood loss of 500 mL
(Bloomfield 1990), this being equivalent to a routine blood dona-
tion (Burnley 2006), but in women in low-income countries who
may be poorly nourished and anaemic, this loss can cause consider-
able morbidity or mortality. It has been estimated that at least 25%
of maternal deaths in a number of countries are due to haemor-
rhage; most due to PPH (Abouzaher 1998; Khan 2006). The vast
majority of these happen in the developing world, and PPH is the
leading cause of maternal mortality in sub-Saharan Africa (Lazarus
2005). However, a study in Mexico (Romero-Gutierrez 2007), re-
ported that while the leading cause of maternal death was haemor-
rhage, two-thirds of bleeding-related deaths resulted from placen-
tal abruption, placenta accreta, placenta praevia, and peripartum
hysterectomy, rather than uterine atony (poor contraction of the
muscles in the uterus). Significant morbidity does occur, though,
from major bleeding due to uterine atony, which is far more com-
mon than the other causes of bleeding listed above. The serious-
ness with which PPH is viewed by professionals is evidenced in
joint policy statements between the International Confederation
of Midwives (ICM) and the International Federation of Gynae-
cology and Obstetrics (FIGO) (ICM-FIGO 2003; ICM-FIGO
2006), and the World Health Organization (WHO 2003), all of
which have recommended active management of the third stage
of labour. Debate continues among women and practitioners on
the optimum method of management of the third stage of labour
to balance the benefits and harms.
There are two distinct approaches to the clinical management of
the third stage of labour: expectant and active management. How-
ever, a third approach is sometimes used that consists of a combi-
nation of components of both expectant and active management:
this has been referred to as ’mixed management’ or the ’piecemeal
approach’ (Prendiville 1989). Expectant, active and mixed man-
agement approaches, and comparisons of different types of active
management, have been the subject of a number of critical reviews
(Elbourne 1995; Gyte 1994; Maughan 2006; McDonald 2007a;
Prendiville 1989; Prendiville 1996; Soltani 2008).
Description of the intervention
(a) Expectant management of the third stage of
labour
Expectant management is also known as conservative or physio-
logical management and is popular in some northern European
countries (Nordstrom 1997), and in New Zealand (Dixon 2013).
It is also practised on occasion in midwife-led units and in home
births in the UK and Ireland (Begley 2009; Blackburn 2008; Fry
2007; Kanikosmay 2007), and is the usual practice when birthing
at home or in the community in some low-income countries. The
main principle of expectantmanagement is a ’hands off ’ approach,
where signs of placental separation are awaited and the placenta is
birthed spontaneously or with the aid of gravity, maternal pushing
(Begley 2012; Inch 1985) or, sometimes, nipple stimulation (Inch
1985) hence:
1. a prophylactic uterotonic agent is not administered;
2. ideally, the umbilical cord is neither clamped nor cut until
the placenta has been delivered but, at a minimum, caregivers
have waited until cord pulsation has ceased; and
3. the placenta is delivered spontaneously with the aid of
gravity and sometimes by maternal effort (Begley 2012; Rogers
1998).
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There can be variations within expectant management. For exam-
ple, some caregivers will wait for the placenta to be delivered before
clamping and cutting the cord whilst others, for convenience, just
wait until pulsation has finished. Breastfeeding or other means of
stimulating the physiological release of oxytocin, such as nipple
stimulation, is sometimes also used (Bullough 1989), but is not
an essential component of expectant management. Some ’expert’
midwives will use gentle traction on the cord once the placenta is
seen to be in the vagina (Begley 2012), with good results.
(b) Active management of the third stage of labour
In active management of the third stage of labour, the clini-
cian intervenes by using the following package of interventions
(Prendiville 1989):
1. the routine administration of a prophylactic uterotonic
drug just before, with, or immediately after, the birth of the baby;
2. early cord clamping and cutting* (i.e. prior to, alongside, or
immediately after administration of an oxytocic, which is before
cord pulsation ceases); and
3. controlled cord traction to deliver the placenta.
*currentWHO recommendations (WHO 2014), are to delay cord
clamping, and theNational Institute forHealth andClinical Excel-
lence (NICE) now recommends “deferred” cord clamping (NICE
2014).
These interventions are implemented routinely and prophylacti-
cally in an attempt to reduce the blood loss associated with the
third stage of labour and to reduce the risk of PPH. There are
many possible variations with this package of interventions.
1. There are different uterotonic drugs that can be used, for
example, oxytocin (intravenous (IV) or intramuscular (IM));
syntometrine (IM); ergometrine (IV or IM); misoprostol (IM;
Liabsuetrakul 2018; McDonald 2007b; Su 2012; Tunçalp 2012;
Westhoff 2013), carbetocin, or paired combinations of these
drugs (Gallos 2018). There is also debate over the route of
administration and dosage of the drugs used. Recent guidelines
from WHO, FIGO, ICM and NICE all recommend the use of
10 IU (international units) of oxytocin IM ((ICM-FIGO 2003;
NICE 2014; WHO 2012). Misoprostol is potentially the most
important uterotonic for use in some low-income countries
because it is stable at ambient temperatures and is inexpensive
(Parsons 2007). However, it does have adverse side effects
(Mousa 2014), such as shivering, nausea and headaches, and it
has been shown to be less effective than other agents (Tunçalp
2012). A recent network analysis, however, suggests that the
three most effective drugs for preventing PPH of 500 mL or
more are ergometrine and oxytocin, carbetocin, and misoprostol
combined with oxytocin (Gallos 2018).
2. There are differing timings for giving the prophylactic
uterotonic drug, for example, with the crowning of the baby’s
head; with the birth of the anterior shoulder; immediately after
the birth of the baby; after the birth of the baby but before the
placenta is delivered (Harris 2004), and after the placenta is
delivered (Winter 2007). The timing of administration of
uterotonic drugs is the subject of another Cochrane Review
(Soltani 2010).
3. There can be variation in the time when the cord is
clamped and cut; this can be immediately the baby is born;
within a set time after the birth, for example, within 30 seconds
or a minute; or anytime before umbilical cord pulsation ceases
(McDonald 2013; Rabe 2012; Van Rheenan 2007).
4. There are also different timings for the initiation of
controlled cord traction, such as waiting for signs of placental
separation or not (McDonald 2003).
5. There can also be a delay in using the whole package of
active management until after cord pulsation ceases, which has
been described as ‘delayed active management’ (Gyte 2006).
6. Some guidelines (e.g. ICM-FIGO 2003), add uterine
massage to the active management package although there is
little evidence to support this (Abdel-Aleem 2010).
Placental cord drainage is sometimes usedwith activemanagement
of the third stage. This involves releasing the clampon thematernal
end of the umbilical cord to allow the blood from the placental
side to drain, thus reducing the size of the placenta and thereby
hoping to help separation and reduce the chance of a retained
placenta (Prendiville 1989; Soltani 2011).
Some of these variations in the components of active management
of the third stage of labour may no longer be considered good
practice (e.g. early cord clamping), but may, nonetheless, be used
in included studies identified for this review.
(c) Mixed management of the third stage of labour
Mixed management of the third stage of labour, (or ’combined’
or ’piecemeal’ management), which consists of a mixture of some
of the components of both active and expectant management of
the third stage, but without exclusively containing all the com-
ponents of either. Although active management of the third stage
is usually recommended (ICM-FIGO 2006; NICE 2014; WHO
2003), there aremany variations, and in practice somewomenmay
actually receive mixed management (Harris 2006; Mercer 2000).
Mixed management of the third stage might include, for example:
(1) early uterotonic administration, cord clamping after pulsation
ceases and controlled cord traction; or (2) delayed uterotonic ad-
ministration until cord pulsation ceases, then cord clamping and
controlled cord traction. These forms of mixed management of
the third stage are of interest because of the evidence of bene-
fits from delayed cord clamping for the baby (McDonald 2013;
Mercer 2008; Rabe 2012).
How the intervention might work
Expectant management
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Expectant management of the third stage relies on the natural
contractions of the uterus, stimulated by a surge of physiological
oxytocin at birth, and anything that interferes with this oxytocin
release may reduce the effectiveness of the physiological process in
the third stage (Inch 1985). Release of oxytocin can, for example,
be inhibited by anxiety through the excess release of adrenaline
(Buckley 2004).
Hence, expectant management of the third stage of labour is com-
monly only considered appropriate following a labour where there
has been no interference with the natural release of oxytocin, for
example, where oxytocin augmentation, induction, epidural or
narcotic analgesia, or both, have not been used (Buckley 2004;
Fry 2007); but some will consider that these aspects still need to
be assessed in well-designed studies. This type of labour is more
likely when the woman has positive psychological support from
her midwife, or other trained supporter, who encourages her to
listen to her body’s messages about movement, positioning, hydra-
tion and nutrition (Bohren 2017; Buckley 2004; Sandall 2016).
Active management
In active management of the third stage of labour, it is sug-
gested that the prophylactic administration of a uterotonic will
reduce bleeding and the risk of severe haemorrhage (Greer 1998;
Prendiville 1989). The role of early cord clamping and controlled
cord traction in the reduction of bleeding is less clear, but it is
thought that once the uterotonic drug has been administered, it
is important to deliver the placenta quickly to prevent it being
retained. Applying a clamp to the cord thus gives the caregiver
something to grasp in order to deliver the placenta quickly by ap-
plying controlled cord traction. Active management of the third
stage has been standard practice in many parts of the world for
many years (Prendiville 1989). Recently, however, arguments have
been put forward for a delay in cord clamping, pointing out that it
is not an evidence-based part of the package of active management
(Weeks 2007). A Cochrane Review found that neither early nor
late cord clamping showed any significant difference in PPH rates
(McDonald 2013).
A number of Cochrane Reviews have been conducted examin-
ing different aspects of active management of the third stage of
labour. These include reviews on prophylactic oxytocin in the
third stage of labour (Westhoff 2013); prophylactic ergometrine-
oxytocin versus oxytocin for the third stage of labour (McDonald
2007b); prophylactic use of ergot alkaloids in the third stage of
labour (Liabsuetrakul 2018); prostaglandins for preventing PPH
(Tunçalp 2012); oxytocin agonists for preventing PPH (Su 2012);
timing of cord clamping in term infants (McDonald 2013) and
timing of cord clamping in preterm infants (Rabe 2012).
Potential adverse effects
Interventions used in active management of the third stage have
some adverse effects, due mainly to the uterotonic drugs used and
to the common practice of early clamping of the cord.
Uterotonic drugs can increase the risk of hypertension, nausea and
vomiting for women (Maughan 2006), and which appear to be
related to the use of ergometrine-based drugs. Active management
inmany countries has moved away from ergometrine-based utero-
tonics, for this reason, and possibly also due to clinicians’ fear of
retained placenta, although a review of ergometrine-based drugs
compared with other uterotonics showed no difference in rates of
manual removal of placentae (McDonald 2007b).
The potential consequences for the newborn infant of active man-
agement of the third stage of labour relate mainly to the timing
of cord clamping. The effects on the neonate of early versus de-
ferred cord clamping have been explored in Cochrane and other
systematic reviews (Hutton 2007; McDonald 2013; Rabe 2012).
Early cord clamping reduces the volume of placental blood trans-
fusion and thus reduces the baby’s blood volume at birth by about
20% for term infants (RCOG 2009; Werner 2005). This results
in lower blood haematocrit (HCT) levels and Hb concentrations
after birth in term infants but the long-term importance of this
effect is unknown (Hutton 2007; McDonald 2013; Prendiville
1989; Van Rheenan 2007). Potentially, placental transfusion may
be more important for infants born in low- and middle-income
settings where iron-deficiency anaemia exacerbated by nutritional
and infectious insults may have substantial and long-term adverse
effects on growth and development (Van Rheenan 2007). For
preterm infants, another specific concern is the effect of postnatal
placental transfusion on neonatal haemodynamic transition pro-
cesses. The Cochrane Review of early versus delayed cord clamp-
ing for preterm infants found some evidence that infants who had
early cord clamping had a higher risk of hypotension treated with
volume-transfusion and of intraventricular haemorrhage (Rabe
2012).
In contrast, early cord clamping also results in lower postnatal lev-
els of plasma bilirubin and a lower incidence of neonatal jaun-
dice that requires phototherapy (McDonald 2013; Rabe 2012).
Treatment of neonatal jaundice may result in mother-infant sepa-
ration that delays the initiation and establishment of breastfeeding
and disrupts early neonatal metabolic adaptation (Mercer 2001).
For infants born in low- or middle-income settings, or in rural
or remote settings distant from healthcare facilities, the need for
phototherapy (or its lack of availability) may be of greater clinical
importance.
If uterotonic drugs are administered before delivery of the infant,
for example, inadvertently prior to the birth of an undiagnosed
twin, then disruption of the placental-uterine wall interface and
interruption of placental-umbilical blood flow may cause acute
perinatal asphyxia compromisingneonatal cardio-respiratory tran-
sition. Newborn infants compromised at birth are more likely to
need transition support (cardio-respiratory resuscitation). If an as-
phyxial insult has been severe or prolonged (for example, if ex-
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acerbated by obstructed labour such as shoulder dystocia) then
other potential consequences may include neonatal encephalopa-
thy, with its associated risk of mortality and long-term neurode-
velopmental morbidity.
Why it is important to do this review
We undertook this review because of the need to determine if
active, expectant management, or a mixed management package,
was most likely to be of overall benefit. It is important to assess the
impact of all these forms of care on both the mother and baby. We
believe that this review is highly relevant to families and clinicians,
as women frequently enquire about the differences in third-stage
management during the antenatal period. This is an update of
review last published in 2015 (Begley 2015).
O B J E C T I V E S
1. To compare the effects of active versus expectant
management of the third stage of labour on severe primary
postpartum haemorrhage (PPH) and other maternal and infant
outcomes.
2. To compare the effects of variations in the packages of
active and expectant management of the third stage of labour on
severe primary PPH and other maternal and infant outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised, and quasi-randomised, controlled
trials of active versus expectant management of the third stage of
labour. Cluster-randomised trials were eligible for inclusion, but
none were identified.
Types of participants
All women who expected a vaginal birth at 24 weeks’ gestation or
later. We looked at women in higher-income settings separately
from women in lower-income settings.
Types of interventions
(a) Active management of the third stage of labour, which is here
defined as the package of interventions comprising:
1. the administration of a prophylactic uterotonic just before,
with, or immediately after the birth of the baby;
2. early cord clamping and cutting (from immediately after
the birth of the baby’s head in the case of a nuchal cord, or
immediately after the birth of the baby to, usually, within a
minute of birth);
3. controlled cord traction to aid the delivery of the placenta.
(b) Expectant management of the third stage of labour, which is
here defined as:
1. no prophylactic administration of a uterotonic;
2. the umbilical cord is neither clamped nor cut until the
placenta has been delivered or until cord pulsation has ceased;
and
3. the placenta is delivered spontaneously with the aid of
gravity and sometimes by maternal effort.
4. None of the components of active management, described
above, are employed routinely.
(c) Mixed management of the third stage of labour consists of a
mixture of some of the components of both active and expectant
management of the third stage, but without exclusively containing
all the components of either (Table 1).
Comparisons
1. Active versus expectant management of the third stage of
labour: all women
2. Active versus expectant management of the third stage of
labour: women at low risk of bleeding
3. Active versus mixed management of the third stage of
labour, with early prophylactic uterotonic administration,
delayed cord clamping and controlled cord traction
4. Active versus mixed management of the third stage of
labour, with delayed prophylactic uterotonic administration,
delayed cord clamping and controlled cord traction
5. Active versus mixed management of the third stage of
labour, with delayed prophylactic uterotonic administration,
delayed cord clamping, no controlled cord traction
6. Expectant versus mixed management of the third stage of
labour, with early prophylactic uterotonic administration,
delayed cord clamping and controlled cord traction
7. Expectant versus mixed management of the third stage of
labour, with delayed prophylactic uterotonic administration,
delayed cord clamping and controlled cord traction
8. Expectant versus mixed management of the third stage of
labour, with delayed prophylactic uterotonic administration,
delayed cord clamping, no controlled cord traction
9. Active versus mixed management of the third stage of
labour with uterotonic after placental delivery, immediate cord
clamping, no controlled cord traction
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10. Active versus mixed management of the third stage of
labour with no routine uterotonic, early cord clamping, no
controlled cord traction
11. Active versus mixed management of the third stage of
labour with no routine uterotonic, early cord clamping, and
controlled cord traction
We included comparisons three to eight because of the review
team’s awareness of these different forms of clinical management
of the third stage of labour and following the results of two reviews
that indicated the benefits of delaying cord clamping for the baby
(McDonald 2013;Rabe 2012). There are other variations ofmixed
management that could also be considered, for example, variations
in controlled cord traction (Hofmeyr 2015), but we considered
the above to be the most commonly used and thus important to
review. We included comparisons nine to 11 because we added
studies that had used these comparisons to this review update.
Types of outcome measures
We selected outcome measures in order of importance with due
recognition of the core data set of outcome measures identified by
Devane 2007.
Primary outcomes
Maternal
1. *Severe primary postpartum haemorrhage (PPH) at time of
birth (clinically estimated or measured blood loss greater than or
equal to 1000 mL)
2. *Very severe primary PPH at time of birth (clinically
estimated or measured blood loss greater than or equal to 2500
mL)
3. Maternal mortality
4. Maternal Hb concentration less than 9 g/dL 24 to 72 hours
postpartum
Infant
1. Admission to neonatal special care or intensive care unit
2. Neonatal jaundice requiring phototherapy or exchange
transfusion
3. Neonatal polycythaemia treated with dilutional exchange
transfusion
Secondary outcomes
Maternal
1. *Severe primary PPH after delivery of placenta and up to
24 hours (clinically estimated or measured blood loss greater
than or equal to 1000 mL)
2. *Severe primary PPH at time of birth and up to 24 hours
(clinically estimated or measured blood loss greater than or equal
to 1000 mL)
3. *Primary blood loss equal to or greater than 500 mL at time
of birth (clinically estimated or measured)
4. *Primary blood loss equal to or greater than 500 mL after
delivery of placenta and up to 24 hours (clinically estimated or
measured)
5. *Primary blood loss equal to or greater than 500 mL at time
of birth and up to 24 hours (clinically estimated or measured)
6. *Mean blood loss (mL) at time of birth (clinically estimated
or measured)
7. *Mean blood loss (mL) after delivery of placenta and up to
24 hours (clinically estimated or measured).
8. *Mean blood loss (mL) at time of birth and up to 24 hours
(clinically estimated or measured)
9. Maternal blood transfusion
10. Clinical signs of severe blood loss at the time of birth, for
example, woman feeling breathless, weak, faint, pale, exhausted
11. Therapeutic uterotonics during the third stage or within the
first 24 hours, or both
12. Mean length of the third stage (minutes)
13. Manual removal of the placenta as defined by study authors
14. Diastolic blood pressure greater than 90 mmHg between
birth of baby and discharge from the labour ward
15. Vomiting between birth of baby and discharge from the
labour ward
16. Any analgesia between birth of the baby and discharge from
the labour ward
17. Women’s assessment of pain during the third stage as
reported by study authors
18. Secondary blood loss/any vaginal bleeding needing
treatment (after 24 hours and before six weeks)
19. Amount of lochia either estimated or measured after 24
hours and up to discharge from hospital
20. Surgical evacuation of retained products of conception
21. Afterpains - abdominal pain associated with the contracting
uterus in the postpartum period
Infant
1. Apgar score less than 7 at five minutes
2. Birthweight
3. Neonatal encephalopathy assessed using Sarnat staging
(Sarnat 1976; Table 1)
4. Neonatal mortality (not pre-specified)
5. Intraventricular haemorrhage - papillae grade III/IV (for
infants born before 34 weeks’ gestation only)
6. Number of infants who received a red blood cell transfusion
7. Infant Hb level at 24 to 72 hours
8. Infant Hb level at three to six months
9. Infant iron indices (ferritin) at three to six months
10. Exclusive breastfeeding at discharge
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11. Neurodevelopmental, cognitive or developmental outcomes
assessed after age 18 months
*All PPH amounts and mean blood losses are now expressed at
three time periods, ’at the time of the birth’, ’after delivery of the
placenta and up to 24 hours’, and ’at the time of birth and up to
24 hours’.
Search methods for identification of studies
The following search methods section of this review is based on a
standard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searchedCochrane Pregnancy and Childbirth’s
Trials Register by contacting their Information Specialist (22 Jan-
uary 2018).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used
to populate Pregnancy and Childbirth’s Trials Register including
the detailed search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL; the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service, please follow this link to the editorial informa-
tion about the Cochrane Pregnancy and Childbirth.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains studies
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Two people screen search results and review the full text of all
relevant study reports identified through the searching activities
described above. Based on the intervention described, the Infor-
mation Specialist assigns each study report a number that corre-
sponds to a specific Pregnancy andChildbirth review topic (or top-
ics), and then adds it to the Register. The Information Specialist
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform ( ICTRP) for unpub-
lished, planned and ongoing study reports (22 January 2018) us-
ing the search methods described in Appendix 1.
Searching other resources
We retrieved additional relevant references cited in papers identi-
fied through the above search strategy and assessed their suitability
for inclusion in the review.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see Begley
2015.
For this update, we used the following methods for assessing the
five reports that we identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
We obtained all potentially eligible studies identified by the search
strategy as full-text papers and two review authors assessed each
study for potential inclusion. We resolved any disagreements
through discussion with at least one additional review author.
None of the potentially eligible studies required translation. We
sought and received additional information from Yildirim 2016.
Data extraction and management
Weused the data extraction form designed for the previous version
of this review (Begley 2015), to extract data. Two review authors
extracted the data independently from the included study using the
form. We resolved discrepancies through discussion with at least
one additional review author. In the previous version of this review,
two review authors (Gillian Gyte (GG), Declan Devane (DD)),
and amember of the Cochrane Pregnancy and Childbirth Group’s
staff independently reviewed Begley’s paper (Begley 1990), and
the lead author of this review was not involved in any discussions
of the paper’s inclusion, or assessment of its risk of bias status. We
used the Review Manager software (Review Manager 2014), to
enter all data, which were checked independently.
Assessment of risk of bias in included studies
Two review authors (GG and LB) independently assessed risk of
bias as a measure of methodological quality of included studies
using the criteria outlined in theCochraneHandbook for Systematic
Reviews of Interventions (Higgins 2017). We resolved discrepan-
cies through discussion with at least one additional review author.
When information regarding any of the criteria was unclear, we
contacted the authors of the original reports to provide further
details. Where these data were unobtainable, and the missing data
were thought to introduce serious bias, we explored the impact of
including such studies in the overall assessment of results by sen-
sitivity analysis. We used the following criteria in the assessment
of bias.
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(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
It is not possible to blind participants or personnel in these trials,
as the fact that a uterotonic has been given (rather than a placebo,
or nothing) is usually apparent to both women (who feel a strong
contraction or pain) and clinicians (who can see or feel a strongly
contracted uterus) following injection of a uterotonic. In addition,
it is clear, in many cases, to both women and clinicians if early
versus late cord clamping is practised or if cord traction versus
maternal effort is used. It is usually possible to blind technicians
who conduct laboratory tests, but this does not always happen so
cannot be presumed to be so.
We assessed the methods as:
• high risk of bias for participants;
• high risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes. It is usually possible to blind
technicians who conduct laboratory tests, but this does not always
happen so cannot be presumed to be so.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete data collection (checking for possible
attrition bias due to the amount, nature and handling of
incomplete outcome data)
We describe for each included study and for each outcome the
completeness of data, including attrition and exclusions from the
analysis. We state whether attrition and exclusions were reported,
the numbers included in the analysis at each stage (compared
with the total randomised participants), reasons for attrition or
exclusion where reported, and whethermissing data were balanced
across groups or were related to outcomes. Where sufficient in-
formation was reported or was sought and supplied by the trial
authors, we re-included missing data in the analyses. No studies
required re-analysis with the original allocated treatment groups
being restored to their correct groups. Following these steps, stud-
ies were assessed as:
• low risk of bias - less than 10% attrition at any stage, or
10% to 15% attrition in small sections of data, equal in both
groups and due to natural fall-out of long-term follow-up;
• high risk of bias - more than 20% attrition, or more than
15% exclusion at any stage when the reason for missing data was
likely to be related to true outcomes;
• unclear risk of bias.
Acknowledging that with long-term follow-up, complete data are
difficult to attain, we discussed whether missing data greater than
20% might (a) be reasonably expected, and (b) impact on out-
comes; if the latter, we excluded such studies. We subjected studies
where attrition levels were unclear, or missing data greater than
15% occurred, to sensitivity analysis.
(5) Selective reporting bias
We describe for each included study how we examined the possi-
bility of selective outcome reporting bias and we assessed reporting
methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would be expected to have
been reported);
• unclear risk of bias.
(6) Other sources of bias
We also assessed and describe for each included study any impor-
tant concerns we had about other possible sources of bias (e.g.
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specific study design, trial stopped early; extreme baseline imbal-
ances). We thus assessed studies as being:
• low risk of bias;
• high risk of bias (problems detailed);
• unclear risk of bias.
(7) Overall risk of bias
We made explicit judgements about whether or not studies were,
overall, at high risk of bias, according to the criteria given in the
CochraneHandbook for Systematic Reviews of Interventionswith ref-
erence to (1) to (6) above (Higgins 2017). As necessary, we ex-
plored the impact of the level of bias through undertaking sensi-
tivity analyses.
Assessment of the quality of the evidence using
GRADE
We assessed the quality of the evidence using the GRADE ap-
proach as outlined in theGRADEHandbook in order to assess the
quality of the body of evidence relating to the following outcomes
for the main comparison (GRADE 2013).
1. Maternal *severe primary PPH at time of birth (clinically
estimated or measured blood loss greater than or equal to 1000
mL)
2. *Very severe primary PPH at time of birth (clinically
estimated or measured blood loss greater than or equal to 2500
mL)
3. Maternal mortality
4. Maternal Hb concentration less than 9 g/dL 24 to 72 hours
postpartum
5. Infant admission to neonatal special care or intensive care
unit
6. Neonatal jaundice requiring phototherapy or exchange
transfusion
7. Neonatal polycythaemia treated with dilutional exchange
transfusion
We used the GRADEpro Guideline Development Tool (
GRADEpro GDT 2015), to import data from Review Manager
5 (Review Manager 2014), in order to create ’Summary of find-
ings’ tables. We produced a summary of the intervention effect
and a measure of quality for each of the above outcomes using
the GRADE approach. The GRADE approach uses five consid-
erations (study limitations, consistency of effect, imprecision, in-
directness and publication bias) to assess the quality of the body
of evidence for each outcome. The evidence can be downgraded
from ’high quality’ by one level for serious (or by two levels for very
serious) limitations, depending on assessments for risk of bias, in-
directness of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
(RR) with 95% confidence intervals (CIs).
Continuous data
For continuous data, we used the mean difference (MD) as out-
comes were measured in the same way between studies. We
planned to use the standardised mean difference (SMD) to com-
bine studies that measured the same outcome, but used different
scales, but this was not required.
Unit of analysis issues
Cluster-randomised trials
We identified no cluster-randomised trials in this review.
In future updates, we will include cluster-randomised trials in the
analyses along with individually-randomised studies. We will ad-
just their sample sizes using themethods described in theCochrane
Handbook for Systematic Reviews of Interventions (section 16.3.4
or 16.3.6), using an estimate of the intracluster correlation co-
efficient (ICC) derived from the study (if possible), from a similar
study or from a study of a similar population (Higgins 2011). If
we use ICCs from other sources, we will report this and conduct
sensitivity analyses to investigate the effect of variation in the ICC.
If we identify both cluster-randomised trials and individually-ran-
domised studys, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
This is not an eligible study design for this review.
Dealing with missing data
We analysed data on all participants with available data in the
group to which they were allocated, regardless of whether or not
they received the allocated intervention. If, in the original reports,
participants were not analysed in the group towhich theywere ran-
domised, and there was sufficient information in the study report
or in information obtained from the study authors, we planned
to restore them to the correct group and analyse accordingly (i.e.
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intention-to-treat (ITT) analysis). No studies required re-analy-
sis with the original allocated treatment groups being restored to
their correct groups. We used the number of women randomised
minus the number of participants known to have missing data as
the denominators. Where loss to follow-up was greater than 20%,
or where study authors had excluded participants at a level greater
than 15% and for reasons that were deemed to impact on out-
comes, we excluded that study.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² (Higgins 2003), and Chi² statistics. We regarded het-
erogeneity as substantial if the Tau² was greater than zero and ei-
ther an I² statistic was greater than 30% or there was a low P value
(< 0.10) in the Chi² test for heterogeneity (Deeks 2017).
Assessment of reporting biases
If there had been 10 or more studies in the meta-analysis, we
would have investigated reporting biases (such as publication bias)
using funnel plots.We would have assessed funnel plot asymmetry
visually. If asymmetry was suggested by a visual assessment, we
would have performed exploratory analyses to investigate it (Sterne
2017).
Where we suspected reporting bias (see ’Selective reporting bias’
above), we contacted study authors asking them to providemissing
outcome data. If this had not been possible, and the missing data
were thought to introduce serious bias, we would have explored
the impact of including such studies in the overall assessment of
results by conducting a sensitivity analysis.
Data synthesis
We carried out statistical analysis using the Review Manager 5
software (Review Manager 2014). We used random-effects meta-
analyses for combining data because we considered that there was
clinical heterogeneity sufficient to expect that the underlying treat-
ment effects would differ between studies. We treated the ran-
dom-effects summary as the average of the range of possible treat-
ment effects and we have discussed the clinical implications of
treatment effects differing between studies. If we had considered
that the average treatment effect was not clinically meaningful, we
would not have combined studies. We have presented the results
as the average treatment effect with its 95% CI, and the estimates
of Tau², P value for the Chi² test and I² statistic (Deeks 2017).
We found significant clinical and methodological heterogeneity
between studies sufficient to suggest that treatment effects might
differ between studies, which supported our choice of random-
effects meta-analysis.
Subgroup analysis and investigation of heterogeneity
We did not undertake any interaction tests (Deeks 2001), as we
were unable to conduct subgroup analyses as planned, due to lack
of usable data. We had planned the following subgroup analyses:
1. spontaneous versus operative vaginal birth;
2. nulliparous versus multiparous women;
3. lower-income versus higher-income setting;
4. full-term versus preterm birth (including outcomes specific
to preterm babies).
For this update, we deleted the fifth subgroup analysis, ‘low risk
of PPH versus high risk of PPH’, as we realised that the analysis
we had undertaken of the low-risk group was in fact a separate
comparison rather than a subgroup analysis. We decided to split
the countries into ’higher-income’ and ’lower-income’, based on
the World Bank definitions, with the border between lower-mid-
dle-income and upper-middle-income being the cut-off. All the
included studies in the main analysis were undertaken in higher-
income countries (defined according to World Bank definitions
2018).
Sensitivity analysis
We performed sensitivity analysis based on study quality, sepa-
rating high-quality studies from studies of lower quality. ’High
quality’ was, for the purposes of this sensitivity analysis, defined
as a study having adequate sequence generation, allocation con-
cealment and an attrition rate of less than 20%, given the stated
importance of attrition as a quality measure (Tierney 2005).
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1. Study flow diagram
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The updated 2018 search retrievedfive records to assess andwe also
re-assessed one report awaiting classification in the previous section
of the review (Rosario 1973).We included one new study (Yildirim
2016), excluded one study (Neri-Mejia 2016) and linked three
clinical trials registry reports to studies already assessed (Hoffman
2006; Jangsten 2011; Rogers 1998). We are still unable to source
the full-text of Rosario 1973.
Included studies
We included eight studies involving 8892 women (analysed)
(Begley 1990; Jangsten 2011; Jerbi 2007; Khan 1997; Prendiville
1988; Rogers 1998; Thilaganathan 1993; Yildirim 2016). In-
cluded studieswere conducted in theUK (Prendiville 1988;Rogers
1998; Thilaganathan 1993), Abu Dhabi (Khan 1997), Ireland
(Begley 1990), Sweden (Jangsten 2011), Tunisia (Jerbi 2007), and
Turkey (Yildirim 2016) . All studies took place in hospital settings.
(See Characteristics of included studies.)
Four studies (4829 women) compared active versus expectant
management (Begley 1990; Prendiville 1988; Rogers 1998;
Thilaganathan 1993), and four studies (4063 women) compared
active versusmixedmanagement (Jangsten 2011; Jerbi 2007;Khan
1997; Yildirim 2016). In all studies, participants were healthy
pregnant women expected to give birth vaginally. Four studies
included only women classified as being at low risk of bleeding
or its effects (Begley 1990; Rogers 1998; Thilaganathan 1993;
Yildirim 2016), and four (Jangsten 2011; Jerbi 2007; Khan 1997;
Prendiville 1988) included women irrespective of their risk of
bleeding.
Studies were conducted from January 1986 to January 1987
(Prendiville 1988); from October 1987 to October 1988 (Begley
1990); from January 1988 to February 1990 (Thilaganathan
1993); June 1993 to December 1995 (Rogers 1998); January to
June 1995 (Khan 1997); February to March 2005 (Jerbi 2007);
November 2006 to April 2008 (Jangsten 2011); and “in 2010”
(Yildirim 2016). Funding sources were; the Maternity and Child
Division at theWorld Health Organization, Geneva, and support
for the National Perinatal Epidemiology Unit from the DHSS
(Prendiville 1988); the Research and Development Trust of the
Coombe Hospital (Begley 1990); the Public Health and Opera-
tional Research Committee of the Anglia and Oxford Regional
Health Authority, and support for theNational Perinatal Epidemi-
ology Unit from the DHSS (Rogers 1998); Research and Devel-
opment Board in Göteborg and Bohuslän Baby Bag and the SU
foundation (Jangsten 2011); and Kanuni Sultan Suleyman Educa-
tion and ResearchHospital (Yildirim 2016). Three studies gave no
information on funding (Jerbi 2007; Khan 1997; Thilaganathan
1993). Only two studies gave any declarations of interest (Jangsten
2011; Yildirim 2016), both stating that there were none.We noted
considerable differences in the protocols for both active and ex-
pectant management in the various studies (Table 2).
Interventions in the ‘active’ management groups
The studies used various uterotonic regimens. These were in-
travenous (IV) ergometrine 0.5 mg (Begley 1990), intramuscu-
lar (IM) syntometrine (5 units oxytocin + 0.5 mg ergometrine;
Thilaganathan 1993), IM syntometrine (5 units oxytocin + 0.5
mg ergometrine) or IM 10 units oxytocin if the woman had raised
blood pressure (Prendiville 1988; Rogers 1998), IM 10 units oxy-
tocin for all women (Khan 1997; Yildirim 2016), IV oxytocin 5
units (Jerbi 2007) and IV oxytocin 10 units (Jangsten 2011). The
descriptions of the timing of administration of uterotonic agent
also varied and included, “at the delivery of the anterior shoulder”,
“as soon as possible after birth of anterior shoulder”, “immediately
after the birth of the anterior shoulder” (which in practice proba-
bly equates to the same time), “immediately following birth”, “as
soon as baby is born” (which is, in practice, very similar in tim-
ing to the preceding descriptions, perhaps 10 to 20 seconds later),
“within the first minute after delivery” and “within 2 minutes of
birth”.
All studies stated that the cord was clamped and cut either within
30 seconds or “immediately” or “early”, which in practice is likely
to be approximately similar timing. All studies attempted con-
trolled cord traction once the uterus was contracted. Two stud-
ies included maternal effort as an option (Jangsten 2011; Rogers
1998), and one included fundal pressure (Jerbi 2007).
Protocols in the ‘expectant’ management groups
In all studies, no uterotonic was to be given routinely prior to
delivery of the placenta. However, in one study, an IV infusion
of oxytocin 10 units in 500 mL normal saline was given slowly
to all women following delivery of the placenta (Khan 1997).
One study administered 2 mL of placebo (saline solution) in-
travenously within two minutes (Jangsten 2011). Practice varied
widely as to how many women did, in fact, receive a uterotonic,
either prophylactically: 0% (Begley 1990), 2.5% (Rogers 1998),
and 20% (Jangsten 2011; Prendiville 1988), and/or as a treatment
9% (Yildirim 2016), 14% (Begley 1990), 21% (Rogers 1998),
30% (Prendiville 1988), and 38% (Jangsten 2011), with no in-
formation given in the other three studies.
In four studies, clinicians were asked to try not to cut or clamp the
cord until after pulsation ceased (Begley 1990; Prendiville 1988;
Rogers 1998; Thilaganathan 1993), although this was achieved
in only 42% to 70% of participants. In one study the cord was
clamped after “cord pulsation had slowed down ” (Yildirim 2016).
In three studies, the cord was to be clamped and cut after birth
of the baby (Jangsten 2011; Jerbi 2007; Khan 1997). Maternal
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effort was to be used in six studies (Begley 1990; Jangsten 2011;
Prendiville 1988; Rogers 1998; Thilaganathan 1993, Yildirim
2016), with the option in some of gentle controlled cord traction
once the placenta had separated (Begley 1990), or assisting the
placenta out once it was felt in the vagina (Thilaganathan 1993).
Maternal effort was used by 32% to 88% of participants, across
the six studies.One study used controlled cord tractionwith gentle
fundal pressure (Jerbi 2007), and another used uterine massage
after placental delivery (Jangsten 2011).
Given the differences in uterotonics used in the active groups and
the wide variation in the proportion of women in expectant man-
agement groups who actually received a uterotonic, it was decided
to use a random-effects model due to the degree of clinical het-
erogeneity.
Excluded studies
We excluded 10 studies (Abdel-Aleem 2010; Deneux-Tharaux
2013; Gulmezoglu 2012; Hoffman 2006; Kashanian 2010;
Magann 2006; Muller 1996; Ramirez 2001; Vasegh 2005 Neri-
Mejia 2016 (see Characteristics of excluded studies)). One study
was only available as a conference abstract with no information
on the number of women randomised to each group, and the au-
thors of the previous version of the review had been unable to
obtain further information from the study authors (Muller 1996).
Although we were able to contact one of the authors, we obtained
no further useful information. One study assessed the timing for
manual removal of the placenta, so did not fit the criteria for in-
clusion (Magann 2006). We excluded the third study because of
the high number of women excluded after randomisation (48%)
(Kashanian 2010).We excluded the fourth study (Hoffman 2006),
due to concerns regarding the number of women withdrawn, af-
ter randomisation, due to caesarean section. Only a conference
abstract was available, but we obtained further information on
methodology from the authors. We excluded the fifth study due
to insufficient information on the numbers included in each of
the three arms, and the method of management for the expectant
arm (Ramirez 2001). We excluded Vasegh 2005 due to insuffi-
cient information in the published study and inability to elicit a
response from the authors. One study (Neri-Mejia 2016), eval-
uated three different types of oxytocin administration (IM, IV
and infusion) and two studies that looked at active management
with or without controlled cord traction (Deneux-Tharaux 2013;
Gulmezoglu 2012), were excluded as we deemed them more ap-
propriate for inclusion in the Cochrane Review on controlled cord
traction (Hofmeyr 2015).
Risk of bias in included studies
Other than for themedication, it is not possible to blind personnel
and participants to active or expectant management of the third
stage. None of the studies used a placebo, and so we assessed all
studies as high risk of bias for blinding. Of the eight studies in-
cluded, we considered three studies as having low risk of bias in
the main aspects of sequence generation, allocation concealment
and completeness of data collection (Begley 1990; Jangsten 2011;
Rogers 1998), these being our criteria for overall quality for sensi-
tivity analyses. We assessed one study as having low risk of bias in
sequence generation and allocation concealment, and high risk of
bias for lack of blinding and other biases (Prendiville 1988). We
considered one study at high risk of bias for completeness of data
collection, lack of blinding and other biases and ’unclear’ for allo-
cation concealment and selective reporting (Thilaganathan 1993),
and assessed one study as unclear on five of the assessment crite-
ria (Khan 1997). We assessed one study as unclear for sequence
generation and blinding of outcome assessment, at high risk of
bias for allocation concealment, blinding of participants, selective
reporting and other biases, but acceptable for completeness of data
(Jerbi 2007), and the final study was unclear on four of the assess-
ment criteria, at high risk of bias for blinding of participants but
had a low risk of bias for sequence generation and completeness
of data collection (Yildirim 2016). See Figure 2 and Figure 3 for
a summary of risk of bias assessments.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six studies used adequate sequence generation using ran-
dom-number tables or computer random-number generators
(Begley 1990; Jangsten 2011; Prendiville 1988; Rogers 1998;
Thilaganathan 1993; Yildirim 2016) and in two the method was
unclear (Jerbi 2007; Khan 1997). We judged allocation conceal-
ment as low risk of bias in four studies (Begley 1990; Jangsten
2011; Prendiville 1988; Rogers 1998), and as unclear risk in three
(Khan 1997; Thilaganathan 1993; Yildirim 2016). One study did
not conceal allocation and so we assessed it as high risk of bias
(Jerbi 2007).
Blinding
Blinding was not possible when assessing themanagement of third
stage of labour, for either women or clinicians (Characteristics of
included studies). The assessment of many outcomes, particularly
blood loss, could, therefore, have been unconsciously affected by
people’s beliefs. Having chosen maternal Hb less than 9 g/dL as a
hard outcome relating to blood loss at the protocol stage, we have
now also included the mean postnatal Hb values to help in un-
derstanding the blood loss estimations. Haemoglobin assessment
would usually be performed by a technician whowould be blinded
to the study allocation.
Begley 1990 and Jangsten 2011, the Dublin and Swedish studies
respectively, measured blood loss, but all the other studies esti-
mated it, and are therefore open to subjective inaccuracies, which
should, however, have been the same across both groups; in ad-
dition, both blood loss estimation and measurement were open
to bias. For certain outcomes such as Hb concentration, which
could be measured by a blinded outcome assessor, we attempted
to assess how such blinding had occurred. In practice, we found
that almost all studies did not mention how they blinded such
assessors.
Incomplete outcome data
Five studies presented complete outcome data (Begley 1990;
Jangsten 2011; Jerbi 2007; Rogers 1998; Yildirim 2016), with ac-
ceptable levels of attrition except for some follow-up measures,
such as postnatalHb levels.However, one of these studies excluded
women post randomisation (2.2%) who had a postpartum haem-
orrhage (PPH) due to deep vaginal lacerations and so we assessed it
as being at unclear risk of bias (Yildirim 2016).We considered one
study at high risk of bias for complete data in that it was not clear
how many women were randomised, and an unknown number
of women were withdrawn following randomisation, due to cae-
sarean section, operative delivery and cervical tears (Thilaganathan
1993). One study had high levels of missing data for some out-
comes, for example, 19% of Hb results missing in the active arm
and 18% in the expectant, but for other outcomes data were more
complete and so we assessed this study as being at unclear risk of
bias (Prendiville 1988). In the remaining study, it was also unclear
how many data were missing (Khan 1997). In all three of these
studies (Khan 1997; Prendiville 1988; Thilaganathan 1993), and
in the study that excluded women with deep vaginal lacerations
(Yildirim 2016), the denominator used was the number given by
study authors as taking part in the study after withdrawals had
been made.
Selective reporting
We did not assess any studies as free of selective reporting bias. We
categorised five as ’unclear’ (Begley 1990; Jangsten 2011; Khan
1997; Thilaganathan 1993; Yildirim 2016), as it was not apparent
from the published papers that they had reported all outcomes,
and we were unable to check study protocols. We judged three
studies as high risk of reporting bias due to some outcomes being
reported which were not listed in the methods section (Jerbi 2007;
Prendiville 1988; Rogers 1998).
Other potential sources of bias
We judged one study as free of other apparent sources of bias
(Begley 1990). One of the remaining studies (Prendiville 1988),
included women at increased risk of PPH (high parity, all age
groups, previous PPH, epidural, long labour, operative delivery).
This was also a problem with another study (Khan 1997).Women
at increased risk of PPH will have a higher blood loss, by defi-
nition, using expectant management; clinicians experiencing this
may respond by anxiety in subsequent births, even of low-risk
women, which may result in higher intervention (mixed manage-
ment) rates. In Prendiville 1988, 50% of the expectant manage-
ment group received an oxytocic, a proportion of intervention in-
compatible with the philosophy of expectant management. In one
study, although 11,000 women were available, of whom at least
half would usually be considered potentially eligible, only 1802
were entered into the study (Jangsten 2011). Themajority were ex-
cluded due to “excessive workload”. This has the potential to have
biased the study, as midwives would have had the choice of not
asking the women to participate and may unconsciously have not
offered participation to some women who they felt were not suit-
able for expectant management. Jerbi 2007 reported that women
were allocated to the two groups after placental delivery, yet they
described the active management group as having had oxytocin
with the anterior shoulder. One other study had no power calcu-
lation, did not use a null hypothesis, and the study groups were
quite different sizes (103 and 90). In addition, they described the
variables age, birthweight and parity as equal between the groups
but did not give any details (Thilaganathan 1993).
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Midwives in all studies, (except Yildirim 2016), were more used to
using active than expectant management, which is likely to have
had an influence on results in the expectant arm. This influence
may have been that they a) reverted to a type of active manage-
ment, potentially reducing blood loss and narrowing the differ-
ence between study arms in terms of blood loss outcomes or b)
usedmixed management, which, from the data, was more likely to
increase blood loss or c) would have conducted a type of expectant
management that was not ideal and resulted in increased blood loss
in the expectant arm. Rogers 1998 administered a questionnaire
to 92 of the 153 midwives prior to the study commencement,
which showed that 84% felt “very confident” of active manage-
ment, whilst only 41% were “very confident” of expectant man-
agement. Similarly, Prendiville 1988 states that, before the study
commenced, the midwives were trained in the use of expectant
management. Only six (13%), however, said that they were very
confident in using expectant management before the study started
and 22 (46%) afterwards. In addition, of 49 midwives respond-
ing to a questionnaire regarding this study, 30 (61%) had never
managed a third stage expectantly. Among the remaining 19, only
one had practised expectant management as defined in the report
(Harding 1989). In Begley 1990, the PPH rate in the expectant
arm fell during the study from 21% in the pilot study and 12%
over the first four months, to 7% in the last six months, as mid-
wives developed their skill (Begley 1990). In contrast to training
in the use of expectant management, additional information pro-
vided by the lead author of one study (Yildirim 2016), noted that
they had to train practitioners for “the active management pro-
tocol (especially for controlled cord traction)”. The other studies
did not provide any information on skill levels, nor on whether
practitioners had training in both expectant and active manage-
ment of third stage of labour.
Finally, Prendiville 1988 changed the protocol after 425 births,
but included all births in the results, which may have affected the
findings.
Effects of interventions
See: Summary of findings for the main comparison Active
versus expectant management of the third stage of labour (all
women)
The review includes eight studies involving 8892 women. We
used a random-effects model for pooling data because of clinical
heterogeneity seen in the included studies. In the forest plots, for
six of the outcomes the “Favours expectant” label is on the left
rather than the right. Thiswas dictated bywhetherwe are reporting
negative (e.g. PPH) or positive (e.g. breastfeeding) outcomes.
1. Active versus expectant management of third stage
of labour: all women (four studies, 4829 women)
This comparison included four studies (Begley 1990; Prendiville
1988; Rogers 1998; Thilaganathan 1993). Three studies included
only women at low risk of bleeding (Begley 1990; Rogers 1998;
Thilaganathan 1993) and one study included women irrespective
of risk of bleeding (Prendiville 1988). We assessed two studies as
being of high quality (Begley 1990; Rogers 1998); one raised con-
cerns regarding high risk of bias in terms of midwives’ comfort
with expectant management, and other possible biases (Prendiville
1988); and we considered one study to have high risk of bias in
terms of incomplete outcome data and selective reporting bias
(Thilaganathan 1993).We used random-effects meta-analyses due
to the clinical heterogeneity involved. The random-effects sum-
mary gives an average for ’active’ methods versus ’expectant’ meth-
ods, and it is important to note that the treatment effect found by
comparing any two specific techniques may differ from this. For a
number of outcomes, there was very little statistical heterogeneity
found (Tau² = 0 and I² = 0%), so there appears to be a single
common treatment effect for these outcomes. We have assessed
the overall quality of the evidence using GRADE (GRADE 2013;
Summary of findings for the main comparison).
Primary outcomes
For women
Compared with expectant management, it is uncertain whether
active management reduces the incidence of severe PPH:
• severe primary PPH, 1000 mL or more at time of birth
(average risk ratio (RR) 0.34, 95% confidence interval (CI) 0.14
to 0.87, 3 studies, 4636 women, random-effects (Tau² = 0.38,
Chi² P = 0.08, I² = 60%) very low-quality evidence; Analysis
1.1).
However, active management may reduce the number of women
who are anaemic after birth:
• maternal Hb less than 9 g/dL at 24 to 72 hours (average RR
0.50, 95% CI 0.30 to 0.83, 2 studies, 1572 women, random-
effects (Tau² = 0.02, Chi² P = 0.31, I² = 3%) low-quality
evidence; Analysis 1.4).
None of the studies reported on the other primary maternal out-
comes of very severe primary PPH (≥ 2500 mL), except Begley
1990, who found no instances of such extreme blood loss in either
group, or maternal mortality.
For babies
Compared with expectant management, active management may
make little or no difference to:
• admission to neonatal special care or intensive care unit
(average RR 0.81, 95% CI 0.60 to 1.11, 2 studies, 3207 infants,
random-effects (Tau² = 0.00, Chi² P = 0.40, I² = 0%) low-
quality evidence; Analysis 1.5);
and it is uncertainwhether activemanagement reduces or increases
the number of babies with jaundice requiring treatment:
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• neonatal jaundice requiring phototherapy or exchange
transfusion (average RR 0.96, 95% CI 0.55 to 1.68, 2 studies,
3142 infants, random-effects (Tau² = 0.11, Chi² P = 0.09, I² =
66%) very low-quality evidence; Analysis 1.6).
None of the studies reported on the other primary neonatal out-
come of neonatal polycythaemia treated with dilutional exchange
transfusion.
It should be noted that the evidence presented on the primary out-
comes selected is based on results of a small number of studies with
relatively small numbers of participants. The lack of consistent
quality of evidence for these outcomes should be borne in mind
when considering the overall results (see Summary of findings for
the main comparison).
Secondary outcomes
Compared with expectant management, active management (with
high-quality evidence) reduces:
• mean maternal blood loss (mean difference (MD) in mL
−78.80, 95% CI −95.96 to −61.64, 2 studies, 2941 women,
random-effects (Tau² = 34.93, Chi² P = 0.26, I² = 22%) Analysis
1.13).
Also, active management (with moderate-quality evidence) prob-
ably reduces:
• primary blood loss 500 mL or more, clinically estimated or
measured at birth (average RR 0.34, 95% CI 0.27 to 0.44, 3
studies, 4636 women, random-effects (Tau² = 0.02, Chi² P =
0.23, I² = 32%) Analysis 1.10);
• therapeutic uterotonics during the third stage and/or within
the first 24 hours (average RR 0.19, 95% CI 0.15 to 0.23, 4
studies, 4829 women, random-effects (Tau² = 0.00, Chi² P =
0.47, I² = 0%) Analysis 1.18);
• mean birthweight (MD in g −76.90, 95% CI −108.51 to
−45.30, 2 studies, 3207 infants, random-effects (Tau² = 0.00,
Chi² P = 0.58, I² = 0%) Analysis 1.30).
In addition, active management (with low-quality evidence) may
reduce:
• maternal blood transfusion (average RR 0.35, 95% CI 0.22
to 0.55, 4 studies, 4829 women, random-effects (Tau² = 0.00,
Chi² P = 0.46, I² = 0%) Analysis 1.16).
Compared with expectant management, active management (with
low-quality evidence) may increase:
• postnatal diastolic blood pressure more than 90 mmHg up
to discharge from labour ward (average RR 4.10, 95% CI 1.63
to 10.30, 3 studies, 4636 women, random-effects (Tau² = 0.32,
Chi² P = 0.14, I² = 49%) Analysis 1.21);
• vomiting from birth of baby to discharge from labour ward
(average RR 2.47, 95% CI 1.36 to 4.48, 3 studies, 4636 women,
random-effects (Tau² = 0.14, Chi² P = 0.09, I² = 59%) Analysis
1.22);
• administration of any analgesia from birth up to discharge
from labour ward (RR 2.53, 95% CI 1.34 to 4.78, 1 study, 1429
women; Analysis 1.23);
• afterpains (RR 2.53, 95% CI 1.34 to 4.78, 1 study, 1429
women; Analysis 1.28);
• return to hospital as an in- or outpatient because of
bleeding (outcome not pre-specified) (average RR 2.21, 95% CI
1.29 to 3.79, 2 studies, 2941 women, random-effects (Tau² =
0.00, Chi² P = 0.82, I² = 0%) Analysis 1.40);
• postnatal maternal Hb (outcome not pre-specified) (MD
0.52, 95% CI 0.44 to 0.60, 3 studies, 4062 women, random-
effects (Tau² = 0.00, Chi² P = 0.66, I² = 0%) Analysis 1.41).
Compared with expectantmanagement, active management (with
moderate-quality evidence) probably makes little or no difference
to:
• exclusive breastfeeding at discharge (RR 1.01, 95% CI 0.96
to 1.07, 1 study, 1695 women; Analysis 1.38).
Also, active management (with low-quality evidence) may make
little or no difference to:
• mean length of the third stage in minutes (MD −0.30,
95% CI −1.87 to 1.27, 1 study, 1429 women; Analysis 1.19);
• secondary blood loss/any vaginal bleeding needing
treatment after 24 hours and before six weeks (average RR 1.10,
95% CI 0.40 to 2.99, 3 studies, 4636 women, random-effects
(Tau² = 0.67, Chi² P = 0.0005, I² = 87%) Analysis 1.25);
• surgical evacuation of retained products of conception
(average RR 0.74, 95% CI 0.32 to 1.71, 3 studies, 4636 women,
random-effects (Tau² = 0.26, Chi² P = 0.15, I² = 47%) Analysis
1.27).
In addition, we are uncertain if active management (with very low-
quality evidence) improves the incidence of:
• manual removal of placenta (average RR 1.78, 95% CI
0.57 to 5.56, 4 studies, 4829 women, random-effects (Tau² =
0.82, Chi² P = 0.01, I² = 73%) Analysis 1.20);
• Apgar scores less than 7 at five minutes (RR 1.00, 95% CI
0.38 to 2.66, 1 study, 1695 infants; Analysis 1.29).
Authors of the included studies did not assess any of the review’s
other secondary outcomes.
2. Active versus expectant management of third stage
of labour: women at low risk of bleeding (three
studies, 3134 women)
This comparison included three studies (Begley 1990; Rogers
1998; Thilaganathan 1993). We considered two studies to be of
high methodological quality (Begley 1990; Rogers 1998) and one
study to have high risk of bias in terms of incomplete outcome
data and selective reporting bias (Thilaganathan 1993). All meta-
analyses used random-effects meta-analyses due to the clinical het-
erogeneity involved. For a number of outcomes, there was very
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little heterogeneity found (Tau² = 0 and I² = 0%), so there appears
to be a single common treatment effect for these outcomes.
Primary outcomes
For women at low risk of PPH: compared with expectant manage-
ment, it is uncertain whether active management (with very low-
quality evidence) reduces:
• severe primary PPH, 1000 mL or more at time of birth
(average RR 0.31, 95% CI 0.05 to 2.17, 2 studies, 2941 women,
random-effects (Tau² = 1.46, Chi² P = 0.06, I² = 71%) Analysis
2.1);
• maternal Hb less than 9 g/dL at 24 to 72 hours (RR 0.17,
95% CI 0.02 to 1.47, 1 study, 193 women; Analysis 2.4).
None of the studies reported the other primary outcomes of: very
severe primary PPH (≥ 2500 mL) except Begley 1990, who found
no instances of such extreme blood loss in either group, ormaternal
mortality.
Also, active management (with low-quality evidence) may make
little or no difference to:
• neonatal jaundice requiring phototherapy or exchange
transfusion (RR 1.31, 95% CI 0.78 to 2.18, 1 study, 1447
infants; Analysis 2.6).
In addition, it is uncertain if active management (with very low-
quality evidence) makes any difference to:
• admission to neonatal special care or intensive care unit (RR
1.02, 95% CI 0.55 to 1.88, 1 study, 1512 infants; Analysis 2.5).
None of the studies reported the other primary outcome of neona-
tal polycythaemia.
Secondary outcomes
For women at low risk of PPH: compared with expectant manage-
ment, active management (with moderate-quality evidence) prob-
ably reduces:
• therapeutic uterotonics during the third stage and/or within
the first 24 hours (average RR 0.15, 95% CI 0.11 to 0.21, 3
studies, 3134 women, random-effects (Tau² = 0.00, Chi² P =
0.98, I² = 0%) Analysis 2.18).
Also, active management (with low-quality evidence) may reduce:
• primary blood loss 500 mL or more, clinically estimated or
measured at time of birth (average RR 0.33, 95% CI 0.20 to
0.56, 2 studies, 2941 women, random-effects (Tau² = 0.10, Chi²
P = 0.10, I² = 63%) Analysis 2.10);
• mean maternal blood loss (mL) (MD −78.80, 95% CI
−95.96 to −61.64, 2 studies, 2941 women, random-effects
(Tau² = 34.93, Chi² P = 0.26, I² = 22%) Analysis 2.13);
• maternal blood transfusions (average RR 0.30, 95% CI
0.10 to 0.88, 3 studies, 3134 women, random-effects (Tau² =
0.14, Chi² P = 0.32, I² = 11%) Analysis 2.16);
• mean birthweight in g (MD −67.00, 95% CI −114.13 to
−19.87, 1 study, 1512 infants; Analysis 2.30).
Compared with expectantmanagement, active management (with
moderate-quality evidence) probably increases:
• postnatal maternal mean Hb (outcome not pre-specified)
(MD in g/dL 0.50, 95% CI 0.41 to 0.59, 2 studies, 2683
women, random-effects (Tau² = 0.00, Chi² P = 1.00, I² = 0%)
Analysis 2.41).
Also, active management (with low-quality evidence) may in-
crease:
• postnatal diastolic blood pressure more than 90 mm Hg
(average RR 7.00, 95% CI 2.99 to 16.43, 2 studies, 2941
women, random-effects (Tau² = 0.00, Chi² P = 0.89, I² = 0%)
Analysis 2.21);
• administration of any analgesia between birth of the baby
and discharge from labour ward (RR 2.53, 95% CI 1.34 to 4.78,
1 study, 1429 women; Analysis 2.23);
• afterpains (RR 2.53, 95% CI 1.34 to 4.78, 1 study, 1429
women; Analysis 2.28);
• return to hospital as an in- or outpatient because of
bleeding (outcome not pre-specified) (average RR 2.21, 95% CI
1.29 to 3.79, 2 studies, 2941 women, random-effects (Tau² =
0.00, Chi² P = 0.82, I² = 0%) Analysis 2.40).
In addition, active management (with moderate-quality evidence)
probably slightly increases:
• secondary blood loss/any vaginal bleeding needing
treatment after 24 hours and before six weeks (average RR 1.78,
95% CI 0.69 to 4.60, 2 studies, 2941 women, random-effects
(Tau² = 0.39, Chi² P = 0.01, I² = 84%) Analysis 2.25).
However, active management (with low-quality evidence) may
make little or no difference to:
• length of the third stage in minutes (MD −0.30, 95% CI
−1.87 to 1.27, 1 study, 1429 women; Analysis 2.19);
• manual removal of placenta (average RR 3.58, 95% CI
0.42 to 30.61, 3 studies, 3134 women, random-effects (Tau² =
2.58, Chi² P = 0.02, I² = 75%) Analysis 2.20);
• postnatal vomiting (average RR 5.63, 95% CI 0.69 to
46.08, 2 studies, 2941 women, random-effects (Tau² = 1.60,
Chi² P = 0.12, I² = 60%) Analysis 2.22);
• surgical evacuation of retained products of conception
(average RR 0.69, 95% CI 0.12 to 3.98, 2 studies, 2941 women,
random-effects (Tau² = 1.17, Chi² P = 0.06, I² = 72%) Analysis
2.27).
Authors of the included studies did not assess any of the review’s
other secondary outcomes.
3. Active versus mixed management of third stage: all
women, early uterotonic, delayed cord clamping,
controlled cord traction (no studies)
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There were no studies that assessed this comparison.
4. Active versus mixed management of third stage of
labour: all women, delayed uterotonic, delayed cord
clamping, controlled cord traction (no studies)
There were no studies that assessed this comparison.
5. Active versus mixed management of third stage of
labour: all women, delayed uterotonic, delayed cord
clamping, no controlled cord traction (one study, 654
women)
This comparison included one study (Yildirim 2016).
Primary outcomes
The study did not report any of the review’s primary outcomes:
severe primary PPH (≥ 1000 mL time of birth); very severe pri-
mary PPH (≥ 2500 mL); maternal mortality; maternal Hb less
than 9 g/dL at 24 to 72 hours; admission to neonatal special care
or intensive care unit; neonatal jaundice requiring phototherapy
or exchange transfusion; neonatal polycythaemia treated with di-
lutional exchange transfusion. The study authors’ own primary
outcome was one of this review’s secondary outcomes.
Secondary outcomes
Compared with mixed management, active management (with
low-quality evidence) may slightly reduce:
• mean length of the third stage in minutes (MD −5.15,
95% CI −5.71 to −4.59, 1 study, 654 women; Analysis 5.10);
• postnatal maternal mean Hb (MD in g/dL 0.69, 95% CI
0.58 to 0.80, 1 study, 654 women; Analysis 5.14).
Also, activemanagement (with low-quality evidence) -may slightly
increase:
• birthweight in g (MD 68, 95% CI 23.87 to 112.13, 1
study, 654 infants; Analysis 5.13).
Compared with mixed management, it is uncertain if active man-
agement (with very low-quality evidence) makes any difference,
improves, or reduces:
• maternal blood transfusions (RR 0.75, 95% CI 0.17, 3.32,
1 study, 654 women; Analysis 5.8);
• therapeutic uterotonics during the third stage and/or within
the first 24 hours (RR 0.90, 95% CI 0.55 to 1.48, 1 study, 654
women; Analysis 5.9);
• manual removal of placenta (RR 0.67, 95% CI 0.11 to
3.96, 1 study, 654 women; Analysis 5.11);
• surgical evacuation of retained products of conception (RR
7.00, 95% CI 0.36 to 134.98, 1 study, 654 women; Analysis
5.12).
The authors of this study did not assess any of the review’s other
secondary outcomes.
6. Expectant versus mixed management of third stage
of labour: all women, early uterotonic, delayed cord
clamping, controlled cord traction (no studies)
There were no studies that assessed this comparison.
7. Expectant versus mixed management of third stage
of labour: all women, delayed uterotonic, delayed
cord clamping, controlled cord traction (no studies)
There were no studies that assessed this comparison.
8. Expectant versus mixed management of third stage
of labour: all women, delayed uterotonic, delayed
cord clamping, no controlled cord traction (no
studies)
There were no studies that assessed this comparison.
9. Active versus mixed management of third stage of
labour: all women, immediate cord clamping, no
controlled cord traction, uterotonic after placental
delivery (one study, 1648 women; comparison not
pre-specified)
This comparison included one study with 1648 women (Khan
1997). We had not pre-specified this comparison.
Primary outcomes
Compared with mixed management, it is uncertain whether active
management (with very low-quality evidence) reduces:
• severe primary PPH, blood loss1000 mL or more at time of
birth (RR 0.23, 95% CI 0.09 to 0.55, 1 study, 1648 women;
Analysis 9.1).
The study did not report the other primary outcomes of: very
severe primary PPH (≥ 2500 mL); maternal Hb less than 9 g/dL
at 24 to 72 hours; maternal mortality, neonatal jaundice requiring
phototherapy or exchange transfusion; or neonatal polycythaemia
treated with dilutional exchange transfusion.
Secondary outcomes
Compared with mixed management, it is uncertain whether active
management (wit−h very low-quality evidence) reduces:
• primary blood loss of 500 mL or more, clinically estimated
or measured at time of birth (RR 0.53, 95% CI 0.38 to 0.74, 1
study, 1648 women; Analysis 9.10);
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• therapeutic uterotonics during the third stage and/or within
the first 24 hours (RR 0.45, 95% CI 0.26 to 0.77, 1 study, 1648
women; Analysis 9.18);
• length of the third stage in minutes (MD −10.00, 95% CI
−10.24 to −9.76, 1 study, 1648 women; Analysis 9.19).
Also, it is uncertain if active management (with very low-quality
evidence) reduces or improves:
• maternal blood transfusions (RR 0.25, 95% CI 0.03 to
2.22, 1 study, 1648 women; Analysis 9.16);
• clinical signs of severe blood loss (RR 0.25, 95% CI 0.05 to
1.17, 1 study, 1648 women; Analysis 9.17).
Authors of the included study did not assess any of the review’s
other secondary outcomes.
10. Active versus mixed management of third stage of
labour: all women, no routine uterotonic, immediate
cord clamping, no controlled cord traction (one
study, 1631 women, comparison not pre-specified)
This comparison included one study (Jangsten 2011). We judged
this study to be at low risk of bias for sequence generation, al-
location concealment and incomplete outcome data, unclear for
selective reporting bias, but high risk of bias for other biases (see
Characteristics of included studies).
Primary outcomes
Compared with mixed management, it is uncertain if active man-
agement (with very low-quality evidence) reduces:
• severe primary PPH at time of birth of 1000 mL or more
(RR 0.78, 95% CI 0.48 to 1.24, 1 study, 1621 women; Analysis
10.1).
Also, active management (with very low-quality evidence) may
slightly improve:
• maternal Hb less than 9 g/dL at 24 to 72 hours (RR 1.23,
95% CI 0.75 to 2.01, 1 study, 1631 women; Analysis 10.4).
The study did not report the other primary outcomes of: very
severe primary PPH (≥ 2500 mL); maternal mortality; neonatal
jaundice requiring phototherapy or exchange transfusion; neonatal
polycythaemia treated with dilutional exchange transfusion.
Secondary outcomes
Compared with mixed management, active management (with
moderate-quality evidence) probably reduces:
• therapeutic uterotonics during the third stage and/or within
the first 24 hours (RR 0.39, 95% CI 0.33 to 0.48, 1 study, 1631
women; Analysis 10.18);
• severe primary PPH at time of birth and up to two hours
after, clinically estimated or measured blood loss of 1000 mL or
more (RR 0.60, 95% CI 0.47 to 0.78, 1 study, 1621 women,
Analysis 10.44); we had not pre-specified this outcome);
• mean maternal blood loss after delivery of the placenta and
up to two hours (outcome not pre-specified) (MD in mL
−49.00, 95% CI −75.52 to −22.48, 1 study, 1621 women;
Analysis 10.45).
Also, active management (with low-quality evidence) may reduce:
• primary blood loss of 500 mL or more at time of birth,
clinically estimated or measured at birth (RR 0.51, 95% CI 0.40
to 0.66, 1 study, 1621 women; Analysis 10.10);
• mean maternal blood loss at time of birth (MD in mL
−94.00, 95% CI −126.57 to −61.43, 1 study, 1621 women;
Analysis 10.13);
• mean length of third stage in minutes (MD−1.60, 95% CI
−3.08 to −0.12; Analysis 10.19);
• severe primary PPH after delivery of placenta and up to two
hours, clinically estimated or measured blood loss of 1000 mL or
more (RR 0.54, 95% CI 0.39 to 0.74, 1 study, 1621 women;
Analysis 10.43); we had not pre-specified this outcome.
Compared with mixed management, active management (with
low-quality evidence) may increase:
• postnatal maternal mean Hb (MD in g/dL 0.28, 95% CI
0.14 to 0.42, 1 study, 1631 women; Analysis 10.42); we had not
pre-specified this outcome.
Compared with mixed management, active management (with
low-quality evidence) may make little or no difference to:
• mean birthweight (MD in g 15.00, 95% CI -28.88 to
58.88; Analysis 10.31).
Also, it is uncertain whether active management (with very low-
quality evidence) improves or reduces:
• maternal blood transfusion (RR 0.79, 95% CI 0.43 to
1.46; Analysis 10.16);
• manual removal of placenta (RR 1.25, 95% CI 0.71 to
2.21; Analysis 10.20).
The study did not assess any of the review’s other secondary out-
comes, including, afterpains - abdominal pain associated with the
contracting uterus in the postpartumperiod.However, we assessed
two similar, non-prespecified outcomes (Jangsten 2011), and ac-
tive management (with low-quality evidence) may reduce:
• afterpains at two hours after birth (RR −2.80, 95% CI
−4.62 to −0.98, 1 study, 1425 women; Analysis 10.28);
• afterpains the day after birth (RR −3.00, 95% CI −5.33 to
−0.67, 1 study, 1336 women; Analysis 10.29).
11. Active versus mixed management of third stage of
labour: all women, no routine uterotonic, immediate
cord clamping, controlled cord traction (one study,
130 women, comparison not pre-specified)
This comparison included one study (Jerbi 2007).
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Primary outcomes
Compared with mixed management, it is uncertain whether active
management (with very low-quality evidence) reduces:
• maternal Hb less than 9 g/dL at 24 to 72 hours (RR 0.80,
95% CI 0.34 to 1.90; Analysis 11.4).
The study did not report on the other primary outcomes of: se-
vere primary PPH (≥ 1000 mL time of birth); very severe pri-
mary PPH (≥ 2500 mL); maternal mortality; neonatal jaundice
requiring phototherapy or exchange transfusion; neonatal poly-
cythaemia treated with dilutional exchange transfusion.
Secondary outcomes
Compared with mixed management, it is uncertain if active man-
agement (with very low-quality evidence) reduces:
• mean length of the third stage in minutes (MD −8.12 95%
CI −9.72 to −6.52; Analysis 11.19).
Also, it is uncertain if active management (with very low quality
evidence) makes any difference to the incidence of:
• manual removal of placenta (RR 1.00, 95% CI 0.06 to
15.65; Analysis 11.20).
The study did not assess any of the review’s other secondary out-
comes.
Sensitivity analysis
We undertook sensitivity analyses including only the four stud-
ies with adequate sequence generation, allocation concealment
and complete outcome reporting (Begley 1990; Jangsten 2011;
Prendiville 1988; Rogers 1998). Removing the studies at high risk
of bias did not change the overall findings.
D I S C U S S I O N
This review includes eight studies conducted in hospital settings
in five countries involving 8892 women. None of the included
studies reported any maternal deaths, nor any very severe (greater
than 2500 mL) postpartum haemorrhages (PPH), and also no
neonatal mortality. It should be noted that the random-effects
summaries presented are the average effects found for ’active’ versus
’expectant’ management. Thus, it may not necessarily be true that
all methods of active management will have the reported size of
advantage in terms of PPH, or other outcomes, over all methods
of expectant management.
Summary of main results
Active versus expectant management of the third
stage of labour in women, irrespective of their risk of
bleeding
It is uncertain whether active management in hospitals in higher-
income settings leads to a reduction in severe primary PPH of
1000 mL or more, and it may reduce the number of women with
maternal Hb less than 9 g/dL at 24 to 72 hours postnatal. Indices
of maternal blood loss may be improved; for example, mean Hb
may be higher by 0.5 g/dL in the active group. However, the av-
erage difference may not be clinically important, as routine blood
donation reduces Hb levels by approximately 0.6 g/dL (Burnley
2006), without ill effects, and postnatal women undergo a diure-
sis postnatally that reverses the haemodilution of pregnancy, thus
increasing their Hb levels within a few days after birth (Hytten
2001; Taylor 1981). The more clinically important effects are the
possible reduction in severe PPH rate, need for transfusion and
uterotonic therapy, which suggests (with very low-quality) its ef-
fectiveness in lessening the severe bleeding that can prove life-
threatening if left untreated.
However, active management (with moderate-quality evidence)
probably reduces average birthweight for the baby (possibly due
to decreased placental transfusion at birth arising from the early
cord clamping component, Farrar 2009a), and (with low-quality
evidence) may increase the incidence of maternal postpartum di-
astolic blood pressure greater than 90 mmHg (possibly due to the
use of ergometrine-based uterotonics), afterpains, need for post-
partum analgesia in the labour ward, and women having to return
to hospital because of bleeding. Using data from only the high-
quality studies showed similar results.
The main findings may also be presented using the ’number
needed to treat for an additional harmful outcome’. There would
be one fewer severe PPH for every 66 women who had active man-
agement (95% CI 44 to 127) and one woman fewer with a post-
natal Hb under 9 g/dL for every 28 women who had active man-
agement (95% CI 17 to 73). Conversely, there would be one more
woman with a diastolic blood pressure greater than 90 mmHg for
every 52 women who had active management (95% CI 38 to 83)
and one more woman who had to return to hospital because of
bleeding for every 65 women who had active management (95%
CI 39 to 192).
Although this analysis considers women irrespective of risk of
bleeding, the studies mainly included women at low risk of bleed-
ing, with just one out of the four studies specifically including
women of any risk. There were no specific data on women con-
sidered to be at high risk of bleeding.
Overall, active management may reduce the risk of severe bleed-
ing, and it would be important to investigate if this benefit arose
from the uterotonic component of the active management alone.
The negative effects of active management appear, in the main, to
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be due either to 1) the administration of a specific uterotonic (e.g.
hypertension due to ergometrine-containing preparations and hy-
potension due to intravenous oxytocin boluses (Lewis 2007)), or
2) possibly to controlled cord traction leading to retained shreds
of membrane or placenta, thus causing the increased incidence
of return to hospital due to bleeding, or 3) early cord clamping
leading to a 20% reduction in the baby’s blood volume. Different
uterotonics will have differing effects, and clinicians will need to
assess the optimum one to use according to the circumstances.
Recent international guidelines have turned to intramuscular oxy-
tocin as a uterotonic that provides effective prophylaxis but with-
out the associated side effects (ICM-FIGO 2003; NICE 2014;
WHO 2012) and a recent network meta-analysis has suggested
that the most effective drugs for preventing PPH of 500 mL of
more could be ergometrine and oxytocin, carbetocin, or misopros-
tol combinedwith oxytocin (Gallos 2018).However,most of these
studies group together intramuscular and intravenous oxytocin,
and a recent randomised study suggests that the intravenous route
may be more effective (Adnan 2018). In this Cochrane Review, of
the eight studies, three administered the drug intravenously and
five intramuscularly. Thus some of the oxytocics may have been
less effective and so reduced the overall efficacy of the prophylaxis.
The possible increased incidence of women in the active man-
agement group having to return to hospital due to bleeding is of
concern, as such bleeding takes place away from immediate access
to medical assistance. This would, again, be of greater significance
for women in low-income countries.
The probable reduction in the average birthweight of babies fol-
lowing activemanagement is possibly due to a reduction in placen-
tal transfusion following early cord clamping (McDonald 2013;
Rabe 2012; RCOG 2009). The evidence from the studies we iden-
tified is that the average volume of transfused blood was 77 mL
(45 to 108 mL) based on differences in the birthweight between
the groups. This estimate is consistent with historical data (Yao
1974), and also with more recent data (Farrar 2009a). Farrar’s
small study (n = 26) weighing babies at birth on accurate scales
to calculate placental transfusion showed that 79 mL (interquar-
tile range 50 to 163 mL) of extra blood was transfused to babies
following vaginal births and 84 mL (interquartile range 59 to 165
mL) following caesarean births. Placental transfusion for most of
these babies was completed by about three minutes after birth,
but transfusion continued for up to five minutes for some babies
(Farrar 2009a). As all babies in this study breathed normally at
birth, further studies are necessary to ascertain whether or not the
cord remains pulsating for longer if the baby has not commenced
respiration.
With expectant management, term infants receive about 80 mL
more blood from placental transfusion than with active manage-
ment, with its early cord clamping - thus adding about 20% more
to the infant’s blood volume (Werner 2005). This may be asso-
ciated with a lower incidence of anaemia in infancy (Cernadas
2006; Chaparro 2006; McDonald 2013; Van Rheenan 2007). It
is possible that anaemia in early infancy may have adverse effects
for the infant’s longer-term growth and development, particu-
larly for infants born in low-income countries. Although it is also
plausible that placental transfusion with expectant management
may increase the risk of neonatal jaundice requiring photother-
apy (McDonald 2013), there was no evidence for this in the two
studies that assessed this outcome. Finally, it needs to be consid-
ered that in the context of the administration of a powerful utero-
tonic, early cord clamping may protect the baby by preventing a
sudden increase of blood volume into the transitional circulation,
that might disrupt physiological processes such as duct closure,
lung fluid reabsorption and cerebral haemodynamic autoregula-
tion. This may be particularly important to infants who are slow
to breathe (Mercer 2008). This problem can be avoided by giv-
ing the uterotonic drug immediately following the deferred cord
clamping. The included studies did not report on these specific
neonatal adverse outcomes, but this review did not find evidence
that admission rates to special care baby units (SCBU) or neonatal
intensive care units (NICU) were affected by the types of third-
stage management included (average RR 0.81, 95% CI 0.60 to
1.11, 2 studies, 3207 babies).
In the three studies that documented both severe PPH (≥ 1000
mL) and number of blood transfusions (Begley 1990; Prendiville
1988; Rogers 1998), it is noted that a total of 78 out of the 4636
women had a severe PPH, whereas 94 received a blood transfu-
sion, perhaps indicating an over-use of this treatment in a healthy
population, under-estimation of blood loss, or undetected low an-
tenatal haemoglobins in some women. Given that a woman’s body
is well prepared for normal blood loss at birth by the haemodilu-
tion of pregnancy (Mims 2005), and that 600 mL to 750 mL of
diluted blood is equivalent to a routine blood donation, it is possi-
ble that the impact of blood losses less than 750 mL are not severe
in normal, healthy women, but this needs investigation. In addi-
tion, the decrease in plasma volume in the early days after birth
increases postnatal Hb concentration in a reversal of haemodilu-
tion (Hytten 2001; Mims 2005; Taylor 1981).
Active versus expectant management of the third
stage of labour in women at low risk of bleeding
In hospitals in higher-income settings, we found that it was uncer-
tain whether active management (with very low-quality evidence)
reduced maternal primary PPH greater than 1000 mL, although
the number of women was insufficient to assess this outcome with
confidence (two studies, 2941 women) and further studies would
be needed to study this association.
One small study (n = 193) compared the number of women with
Hb levels less than 9 g/dL postnatally (Thilaganathan 1993) but
the high risk of bias identified means that we cannot rely on the
findings. None of the studies assessed Apgar scores less than 7 at
five minutes. Other indices of maternal blood loss (with low-qual-
ity evidence) may be reduced with the use of active management
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in this population. Active management again resulted (with mod-
erate-quality evidence) in a probable lower birthweight (possibly
due to reduced placental transfusion), and (with low-quality evi-
dence) might result in an increase in the incidence of postpartum
diastolic blood pressure greater than 90 mmHg, afterpains, need
for postpartum analgesia in the labour ward, and having to return
to hospital as an in- or outpatient because of bleeding.
Mixed managements around the timing of cord
clamping in combination with the timing of
uterotonic drug
Active versus mixed management of third stage of labour:
all women, delayed prophylactic uterotonic administration,
delayed cord clamping, no controlled cord traction (one
study, 654 women)
The one study included (Yildirim 2016), was of low quality (un-
clear on four of the assessment criteria, and at high risk of bias
for lack of blinding). The women were all at low risk of bleeding.
The results indicated that, compared withmixedmanagement, ac-
tive management (with low-quality evidence) may slightly reduce
mean length of the third stage, and slightly increase birthweight.
It is uncertain if active management (with very low-quality evi-
dence) makes any difference, improves, or reduces rates of mater-
nal blood transfusions, therapeutic uterotonics during the third
stage or within the first 24 hours, manual removal of placenta, or
surgical evacuation of retained products of conception.
Active versus mixed management of the third stage of
labour: all women, immediate cord clamping, no controlled
cord traction and uterotonic after placental delivery (one
study, 1648 women, comparison not pre-specified)
The one study (Khan 1997), assessing this comparison was of
uncertain quality (sequence generation was unclear). The results
indicated that it is uncertain whether active management (with
very low-quality evidence) showed a reduction in severe primary
PPH. It is also uncertain whether active management (with very
low-quality evidence) showed a reduction in the rate of blood loss
greater than 500 mL, use of therapeutic uterotonics postpartum
and length of the third stage, and it is uncertain if active man-
agement (with very low-quality evidence) reduces or improves the
number of blood transfusions (Figure 2).
Active versus mixed management of third stage of labour:
all women, no routine uterotonic, immediate cord clamping,
no controlled cord traction (one study, 1631 women,
comparison not pre-specified)
The one study includedwas of high quality (Jangsten 2011). Com-
pared with mixed management, it is uncertain if active manage-
ment (with very low-quality evidence) reduces severe primary PPH
or rates of maternal Hb less than 9 g/dL at 24 to 72 hours. Active
management (with low-quality evidence) may reduce the rate of
blood loss greater than 500 mL and mean length of the third stage,
may make little or no difference to mean birthweight, and (with
moderate-quality evidence) probably reduces the use of therapeu-
tic uterotonics during the third stage. It is uncertain whether active
management (with very low-quality evidence) improves or reduces
the number of maternal blood transfusions or rate of manual re-
moval of placenta.
Active versus mixed management of third stage of labour:
all women, no routine uterotonic, immediate cord clamping,
controlled cord traction (one study, 130 women, comparison
not pre-specified)
The one study included was of moderate quality (Jerbi 2007). The
results indicated that it is uncertain whether active management
(with very low-quality evidence) reduces maternal Hb less than
9 g/dL at 24 to 72 hours, compared to mixed management. It is
uncertain if active management (with very low-quality evidence)
showed a reduction inmean length of the third stage, or makes any
difference to the incidence of rates of manual removal of placenta.
Overall completeness and applicability of
evidence
Four studies compared active versus expectant management of the
third stage of labour and four compared active versus mixed man-
agement. All were conducted in hospitals, seven in higher-income
settings, and one in a lower-income setting (n = 130). Four studies
involved women at low risk of bleeding and four included women
irrespective of their risk of bleeding. Given these factors, the results
of the meta-analysis can only be applied to care given in higher-
income settings. As only four studies (two of uncertain quality),
compared active versus mixed management, and all mixed man-
agements differed, we are unable to draw firm conclusions on any
apparent differences between these two managements. Also, for
many of the outcomes there is heterogeneity in the treatment ef-
fects, so there is no information as to the specific factors that might
affect the difference between active and expectant management.
Quality of the evidence
The evidence presented on the primary outcomes selected is based
on results of a small number of studies with relatively small num-
bers of participants. The lack of consistent high-quality evidence
for these outcomes should be borne in mind when considering the
overall results (see Summary of findings for themain comparison).
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We assessed the methodological quality of the included studies as
‘high quality’ in terms of sequence generation, allocation conceal-
ment and complete outcome data for three studies (Begley 1990;
Jangsten 2011; Rogers 1998). We undertook sensitivity analysis
by study quality to assess for any substantial difference in the main
results. This made little difference to the overall findings except to
indicate that there was no high-quality evidence for the results of
comparisons between active management andmixedmanagement
of the third stage of labour.
In all studies, there is the problem of assessment of blood loss by
clinicians where no blinding is possible. However, studies used
other indices of blood loss, such as postnatal Hb, which may have
been assessed by technicians blinded to treatment allocation. For
this reason, we included an outcome that had not been pre-speci-
fied, mean postnatal Hb, in addition to comparing the number of
women with Hb levels less than 9 g/dL at 24 to 72 hours, which
not all studies had measured.
Adherence to intervention protocols and, in particular, to theman-
agement proposed for the two study arms was mixed (Table 2).
In the three high-quality studies (Begley 1990; Jangsten 2011;
Rogers 1998), the majority of women in the active management
arm (93% to 100%) received a uterotonic as directed. In the ex-
pectant management arm, however, practice varied widely, with
86% receiving “no uterotonic” in one study (Begley 1990), 76.5%
in another (Rogers 1998), and 62% in the third (Jangsten 2011).
Only 50% of women in the expectant management arm in one
study (Prendiville 1988), received “no uterotonic”, with no infor-
mation given in the other three studies. The intervention protocol
for the expectant arm of Prendiville 1988 did allow for adminis-
tration of a uterotonic if necessary, as it stated, “Try not to give
a uterotonic”; however, the actual proportion that received the
drug appears incompatible with a philosophy of expectant man-
agement. In addition, the fact that the administration of the same
uterotonic that constituted the main treatment in active manage-
ment to half of the ’expectant’ management group as well, does
raise questions as to the usefulness of the findings. The resulting
’mixed’ management may also increase levels of blood loss and
other complications, as changing the study protocol after the first
425 births to exclude participants when mixed management had
to be used (due to cutting the cord early because of nuchal cord,
concerns about meconium or baby needing resuscitation) resulted
in a decrease in PPH rate.
In addition, Prendiville 1988 included women at increased risk of
bleeding. The total numbers involved are not clear, but 84 (5%)
had previous third-stage problems, 212 (13%) had an epidural in
labour, and 230 (14%) had assisted births. As these women are
likely to have a higher blood loss when expectant management is
used, clinicians experiencing this may respond by anxiety in subse-
quent births using expectant management, even for women at low
risk of bleeding, and be more likely to give a uterotonic early; this
may have increased the intervention or ’mixed management’ rates
in women allocated to expectant management in this study (30%
received uterotonic for treatment, and 20% prophylactically), and
would also have decreased the opportunity for those midwives to
keep up their skill level in expectant management.
A second study, comparing active with mixed management, also
included women at increased risk of bleeding (Jangsten 2011),
with similar possible results as above: 7% (n = 131) had a caesarean
section, 714 (40%) had an epidural in labour, and 148 (8%) had
a ventouse birth.
The skill of the midwives in both forms of care in all studies is
of interest. The midwives in Rogers 1998 were said to be “sim-
ilarly confident” in active and expectant management. However,
the questionnaire administered to 92 of the 153 midwives prior
to the study commencement showed that, whereas 84% felt “very
confident” of active management, only 41%were “very confident”
of expectant management. Similarly, Prendiville 1988 states that,
before the study commenced, the researchers sought the advice of
midwives in the UK who were “known to practise physiological
management” and then used this advice to train the midwives.
Only six (13%) of the midwives in this study, however, said that
they were very confident of physiological management before the
study started and 22 (46%) afterwards. Harding 1989 found that,
of 49midwives responding to a questionnaire regarding this study,
30 (61%) had never managed a third stage physiologically. Among
the remaining 19, only one had practised physiological manage-
ment as defined in the study. Those in Begley 1990 were also more
used to active management and the PPH rate in the expectant arm
fell during the study from 21% in the pilot study to 7% in the
last six months, as they developed their skills. Yildirim 2016 was
unique in that the authors had to train clinicians for the active
management protocol, particularly in how to perform controlled
cord traction, as it was not common practice in the hospital at the
time.
Midwives’ skill and the accurate measurement of blood loss obvi-
ously has an impact on documented blood loss in the third stage
of labour. For example, the mean (estimated) blood loss in the ac-
tive arm of Rogers 1998 (269 mL, standard deviation (SD) 246),
was actually greater than the mean (measured) blood loss in the
expectant arm of Begley 1990 (235 mL, SD 224). This indicates
that results of all these studies need to be examined in conjunction
with local practice, to ascertain whether or not similar results will
be found in different settings.
Finally, Prendiville 1988 changed the protocol after 425 births,
but included all births in the results, which may have affected the
findings.
We examined the quality of the body of evidence for our four
primary outcomes for which we found data (severe primary PPH
(≥ to 1000 mL at time of birth), maternal Hb < 9 g/dL 24 to
72 hours postpartum, admission to SCBU or NICU, neonatal
jaundice requiring phototherapy or exchange transfusion) using
GRADE. The GRADE assessments were of either low or very low
quality. Downgrading decisions were based on inconsistency in
two of the outcomes, and risk of bias and imprecision in all four
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- see Summary of findings for the main comparison.
Potential biases in the review process
All the authors of this review have an interest in third-stage man-
agement, and each brings different views on the methods that
might be used. C Begley conducted one of the studies included in
the review, and is a member of a team who conducted a systematic
review for the International Confederation of Midwives (ICM)
on expectant management of the third stage of labour. G Gyte has
written on the third stage and is a involved in a study on timing
of cord clamping in preterm birth, and other members have writ-
ten on third-stage management. W McGuire is also involved in
further studies on timing of cord clamping. A Weeks is involved
in running clinical studies of the timing of cord clamping and
misoprostol for third-stage prophylaxis in low-resource settings.
However, the review authors’ views differed and, during the review
process, discussion and consensus was necessary to reach a final
conclusion acceptable to all. Although all humans bring potential
biases to any endeavour, we did try to ensure that our eventual
conclusion arose solely from the data. Feedback from an interna-
tional audience will serve to improve the next review update.
Agreements and disagreements with other
studies or reviews
Previous version of this review
Our assessment of the evidence differs from the first published
version of this review (Prendiville 2000), which concluded that
active management was “superior” to expectant management. For
the main comparison, we have no additional studies but we anal-
ysed four studies (Jangsten 2011; Jerbi 2007; Yildirim 2016; Khan
1997), in different categories of ’active comparedwithmixedman-
agement’, which were not included in the main analysis. We have,
however, used the recent methodology introduced for Cochrane
Reviews, which assesses risk of bias in the individual studies more
carefully than in the past (Higgins 2017). We also chose to use a
random-effects model for analysis due to the clear variations in the
specific forms of both active and expectant management used in
the included studies (clinical heterogeneity). Our findings, there-
fore, differ for some outcomes because of this decision (particu-
larly for the group of women at low risk of bleeding) but we have
reported Tau² and I² statistic, regardless of level of heterogeneity.
We believe the evidence shows both benefits and harms for active
management, and believe it is now critical to look at the advan-
tages and disadvantages of the individual components of third-
stage management to see if the benefits can be achieved with fewer
harms.
The previous authors of this review recommended active man-
agement of the third stage due to the benefit identified in terms
of reduced incidence of severe bleeding. We agree that bleeding
is a very important component when balancing the benefits and
harms of active compared to expectant management of the third
stage of labour. However, we consider that the number of harms
caused by active management also deserve consideration. In par-
ticular, the increased rate of hypertension, increased numbers of
mothers returning to hospital due to bleeding, and the possible
decrease in average blood volume of newborns reflected in the
lower birthweight for babies where the mother has received active
management of the third stage, are of concern. In the population
of women at low risk of bleeding, such harms are of more con-
cern, as there was no statistical evidence that severe bleeding was
reduced by active management. Further studies would be needed
to confirm if there is a difference or not. Our analysis of women at
low risk of bleeding differs from the previous version of the review
in that we excluded the Prendiville data (Prendiville 1988), as we
considered there to be a high risk of bias because the randomisa-
tion was not stratified by high and low risk of bleeding and there
were no specific data in the published study to enable us to use
the data had we chosen to do so.
Other systematic reviews on active versus expectant
management of the third stage of labour
Active management in the included studies involved, in general,
clamping and cutting the cord soon after the baby’s birth. A num-
ber of women in the expectant management groups also had their
baby’s cord clamped and cut before pulsation had ceased. Another
Cochrane Review has recommended that, in future, the umbili-
cal cord should not be clamped and cut until after pulsation has
ceased, regardless of the type of management used (McDonald
2013); if this change in practice is implemented it may negate the
harms of active management due to early cord clamping. How-
ever, the optimum timing of the administration of the uterotonic
still needs to be determined clearly. Despite the evidence from the
Cochrane Review regarding timing of cord clamping (McDonald
2013), a survey of 1176 members of the Royal College of Obste-
tricians and Gynaecologists (RCOG) and 1445 members of the
Royal College of Midwives (RCM) in the UK found that the ma-
jority (94% and 71%, respectively) ’always’ or ’usually’ use active
management, and 73% and 40% clamp the cord within 20 sec-
onds (Farrar 2009b). It would thus appear that there is consider-
able variation in practice and not all practitioners use the complete
package of ‘active’ or ‘expectant’ management as described in these
studies.
Drawing on evidence from the Cochrane Review on ’Prophylac-
tic ergometrine-oxytocin versus oxytocin for the third stage of
labour’ (McDonald 2007b), and other research on ergot com-
pounds (Maughan 2006), we would expect that omitting the er-
got component of the prophylactic uterotonic drug used as part
of active management of the third stage should reduce the adverse
effects of hypertension identified for active management.
31Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Guidelines issued by various policy-making bodies promote dif-
ferent aspects of third-stage management. The RCM provides in-
formation on the benefits and harms of both methods, drawing
on the published literature, including the previous version of the
Cochrane Review. They recommend providing information for
women and state that expectant/physiological management of the
third stage can be seen as the logical ending to a normal labour
(RCM 2008). The National Institute for Health and Clinical Ex-
cellence (NICE) contains recommendations on the management
of the third stage of labour in their guideline on intrapartum care
(NICE 2014). Using the previous Cochrane Review and other
published research evidence, NICE conclude that active manage-
ment of the third stage is to be recommended, including the use
of oxytocin (10 international units by intramuscular injection),
deferred clamping and cutting of the cord and controlled cord
traction. They recommend that women should be told the ben-
efits and harms of both active and expectant management. It is
recommended that women who request expectant management
and are at low risk of PPH “should be supported in their choice”
(NICE 2014 p 183), but the guideline does not acknowledge the
findings of the previous Cochrane Review, in women at low risk of
PPH, that show no difference in severe PPH or rates of maternal
Hb less than 9 g/dL at 24 to 72 hours postnatal between those
receiving expectant or active management. TheWorldHealth Or-
ganization (WHO) also bases its recommendations on the previ-
ous Cochrane Review, promoting the offering of active manage-
ment to all women, provided they are cared for by skilled atten-
dants (WHO 2012). The International Confederation of Mid-
wives states that, “Every midwife is required to attend the birth of
the placenta without the aid of uterotonics” and that knowledge
of expectant/physiological management of the third stage is “a ba-
sic midwifery competency”. It further recommends that “when a
womanmakes an active choice to experience a non-interventionist
placental birth, the midwife will ensure the woman and her family
have all the information necessary on which to make the decision”
(ICM 2008).
Two issues bear further discussion in relation to published work:
the experience of midwives in using expectant management and
the use of expectant management of the third stage when the first
and second stages of labour have not been normal. The RCM de-
fines a normal birth as one where a woman commences, continues
and completes labour physiologically at term (RCM 2004 Part 4e).
Anecdotally, midwives experienced in expectant management say
that only women who have had a normal, physiological labour and
birth should have expectant management of the third stage. It has
also been suggested in the literature that women who require in-
duction or augmentation of labour with oxytocin (Sheiner 2005),
or misoprostol (Phillip 2004), are prone to higher blood loss post-
partum. In three of the four studies included in this review, high
percentages of women had received a uterotonic for induction or
acceleration of labour, and in all of them expectant management
was not the norm for the midwives involved. It was recommended
at the time of the first Cochrane Review on this topic that studies
be conducted in areas where midwives were skilled at using ex-
pectant or physiological management. The Netherlands and New
Zealand are two such places, and observational studies emanating
from these countries are worth examining as their results indicate
no increase in blood loss in conjunction with the use of expectant
management.
In Holland, a descriptive study was conducted to determine the
incidence and risk factors for PPH in 3464 nulliparous women
giving birth vaginally. The women were stratified for high and
low risk factors for PPH, with 1416 stratified as low risk (41%)
(Bais 2004). Approximately 50% of these women received pro-
phylactic oxytocin and 50% did not, with no significant differ-
ence found in blood loss (Bais 2004). The New Zealand College
of Midwives conducted a population-based, retrospective cohort
study, which reported on the management provided by midwives
during the third stage of labour (NZCM 2009). The study in-
cluded 33,752 women who experienced a expectant/physiologi-
cally normal labour and birth. Almost half of the women (48.1%)
had expectant management in the third stage while 51.9% had an
actively managed third stage. Women who had expectant manage-
ment were more likely to have a blood loss of less than 500 mL
(96.3%) than those who had active management (93.1%). Mean
blood loss was 213.6 mL (95% CI 211.6 mL to 215.5 mL) for
the expectant management group and 241.6 mL (95% CI 239.4
mL to 243.8 mL) for active management. Similar findings were
seen in an Irish study comparing midwife-led with consultant-led
care (Begley 2009; Begley 2011a). Thirty per cent (n = 136) of
the 446 women who received midwife-led care throughout their
pregnancy and birth, and received no epidurals or oxytocin in
labour, had expectant management. None of these 136 women
had a PPH, whereas the PPH rate for the women having active
management was 1% (Begley 2009). A more recent study in the
same Irishmidwife-led unit (MLU), over a six-year period, showed
that, of 1878 women birthing in theMLU, 50% had physiological
management of the third stage compared with 5% of 900 similarly
low-risk women who were transferred to the hospital labour ward
and had a spontaneous vaginal birth. The PPH rates were 2.9%
and 7.2%, respectively (Dencker 2017).
Although these are observational data, there is an interesting link
here between normal blood loss and expectant management of
the third stage, when such management follows a physiologically
normal first and second stage, and care is given bymidwives skilled
in the technique. This is an area that would benefit from further
research.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Active management of the third stage of labour in hospitals in
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higher-income settings may bring benefits to women of mixed lev-
els of risk of bleeding in terms of reducing mean maternal blood
loss and probably reducing blood loss (greater than 500 mL) al-
though it is uncertain if it reduces severe blood loss (greater than
1000 mL). It probably reduces the use of therapeutic uterotonics,
but it may also cause harm, such as postnatal hypertension, pain
and return to hospital due to bleeding. In addition, active man-
agement is probably associated with a reduction in birthweight
possibly reflecting a reduction in neonatal blood volume due to
early cord clamping.
In women at low risk of bleeding, we found that it was uncer-
tain whether active management reduced severe blood loss (greater
than 1000 mL) although there was still a reduction in other in-
dices of maternal blood loss (low-quality evidence). Active man-
agement again resulted in a probable lower birthweight (moderate-
quality evidence) and an increase in the incidence of postpartum
diastolic blood pressure greater than 90 mmHg (with low-quality
evidence), afterpains, need for postpartum analgesia in the labour
ward, and having to return to hospital as an in- or outpatient be-
cause of bleeding. It must be emphasised that this review includes
only a small number of studies with relatively small numbers of
participants, and the quality of evidence for primary outcomes is
low or very low.
In the context of these studies, in higher-income settings with high
levels of clinician expertise and adequate access to emergency care,
healthy women do not appear to suffer unduly from the results
of above average blood loss (about 500 mL) that does not reach
the level of severe (greater than 1000 mL) primary postpartum
haemorrhage (PPH; Bloomfield 1990). There are both benefits
and harms from active management of the third stage and it is also
unclear whether all three components of the active management
package are required to gain the benefit of reduced PPH.
Healthcare providers could, therefore, present information to all
women in the antenatal period on the advantages and disadvan-
tages of bothmethods of third-stagemanagement to facilitate their
discussion and informed choice of care. This information could
include not only the benefits of active management (reduces the
risk of severe blood loss and postnatal anaemia in women at mixed
risk of bleeding) but also the harms to the mother (increases the
risk of hypertension if using ergot compounds, increases after-
pains, need for analgesia, and bleeding following discharge). In
addition, information regarding the effects on the baby of early
versus deferred cord clamping could be provided whilst acknowl-
edging the uncertainty deferred cord clamping brings due to the
lack of evidence around optimal timing of the prophylactic utero-
tonic.
Although the studies in the review did not assess women at
increased risk of bleeding specifically, it can be deduced from
Prendiville 1988 that for these women the benefit of reduced blood
loss is likely to outweigh the harms. This may lead clinicians to
suggest active management of the third stage with a prophylactic
uterotonic that contains no ergot, and also deferred cord clamp-
ing, though women’s choice should always be respected.
Women at low risk of bleeding could be informed of the potential
benefits and adverse effects of both expectant and active manage-
ment of the third stage of labour, and how adverse effects can be
minimised. When expectant management is used, it is important
that the option of using a uterotonic (non-ergot based initially) as
treatment at any time is available if excess bleeding occurs. These
results cannot, and should not, be extrapolated to other contexts
such as low-income countries where access to care is often severely
restricted, or those countries with insufficient trained clinicians or
inadequate emergency care
Implications for research
In the next update of this review we will assess the use of the
agreed core outcome set on PPH (Meher 2019). Future studies
could consider the results of the Cochrane Review on timing of
cord clamping (McDonald 2013), and consider inclusion of the
element of leaving the cord unclamped until it has stopped pulsat-
ing (or has gone ’white’, indicating the vein has emptied) in their
protocols for both active and expectant management. Individual
components of both types of management could be examined in
further studies. All future studies could aim to include maternal,
fetal and infant outcomes, as listed in this review, or in the core
outcome set on PPH, or both (Meher 2019), as far as is practicable.
Studies are needed in low-income or resource-constrained coun-
tries. Studies could establish whether, in order to reduce bleeding
for the mother, a uterotonic drug is what is needed rather than all
three components of active management of the third stage. Stud-
ies similar to two recent studies that looked at active management
with or without controlled cord traction (Deneux-Tharaux 2013;
Gulmezoglu 2012), will assist in answering this question.
It is also critical to establish whether or not a routine uterotonic
is really necessary for healthy women at low risk of bleeding, and
what is the optimum time for administration (i.e. before or after
cord clamping). The concept of ’secondary prophylaxis’ usedwhen
necessary in conjunction with expectant management, where the
uterotonic is given at the first sign of excessive blood loss (e.g. 350
mL), deserves further exploration as a way of reducing the rate
of side effects for healthy women. In addition, it is important to
consider the adverse effects on the mother’s blood pressure, pain,
and returning to hospital after the birth because of bleeding.
Future studies may compare different types of expectant manage-
ment; for example, comparing expectant management with ex-
pectant management followed by uterotonic, or expectant man-
agement using maternal effort only with expectant management
using maternal effort and gentle cord traction. Given the possibil-
ity that women who require induction or augmentation of labour
with a uterotonic are prone to higher postpartum blood loss, re-
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searchers could consider if such women should be excluded from
future studies including an expectant management arm, as the
natural release of oxytocin may be inhibited by the administration
of exogenous oxytocics or other uterotonics.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Begley 1990
Methods RCT with randomisation of individual women
Participants Irish hospital setting. High-income country
Inclusion criteria: all women at low risk of haemorrhage (< 35 years; parity < 5; 1st
stage of labour < 15 hours; no previous history of PPH; Hb > 11 g/dL (or 10.6 g/dL for
capillary sample)) with singleton, cephalic presentation, 35 to 36 weeks at recruitment;
no medical complications that would contraindicate ergometrine or would increase the
risk of bleeding (cardiac disease, use of heparin, hypertension), and expected to give birth
vaginally
1429 women randomised out of 2901 eligible
Exclusion criteria: women with hypertension in pregnancy or 1st or 2nd stage; epidural
anaesthesia (included in separate study); APH; 1st stage > 15 hours; OVB; women
attending private care
Clinician responsible for third stage: midwives
Interventions Intervention: active management of third stage (N = 705)
• prophylactic ergometrine 0.5 mg IV immediately following birth (once 2nd twin
excluded)
• try to clamp cord within 30 s
• delivery of the placenta by CCT when uterus contracted
• try not to give any special instructions re posture
For retained placenta: 1 h after birth:
• ensure empty bladder
• attempt delivery again using CCT
• manual removal of placenta under GA
Comparison: expectant management of 3rd stage (N = 724)
• no oxytocic drug to be given routinely
• try to leave cord attached to baby until pulsation has ceased. When cord is cut
milk any placental blood into bowl and discard
• encourage mother to breastfeed
• watch for signs of placental separation and ask women to tell you when she feels a
contraction or urge to push. DO NOT touch the abdomen or manipulate the uterus at
this stage
• placenta may be delivered by maternal effort or gentle CCT
• if mother does not experience a contraction within 8 min, place hand gently on
fundus to determine intrauterine bleeding and await separation
Special circumstances: if baby’s cord is clamped and cut before pulsation ceases (due to
cord round neck, asphyxia, etc) do not give ergometrine. Milk any placental blood into
bowl and discard it. Watch for signs of placental separation and deliver placenta by CCT
Retained placenta > 1 h after birth:
• ensure empty bladder
• attempt delivery again using CCT
• give ergometrine 0.5 mg IV and re-attempt delivery
• manual removal under GA
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Begley 1990 (Continued)
Data entered into comparisons 1 and 2
Outcomes Pre-specified outcomes: manual removal of placenta; PPH (> 500 mL); mean blood
loss; length 3rd stage; Hb < 10 g/dL at 48-72 h; and difference between 32 weeks and
48-72 h PP: PP blood transfusions; side effects 1-2 h post birth; PP complications;
breastfeeding; serum prolactin; women’s views. No neonatal outcomes
(Information from Oxford Database of Perinatal Trials registration sheet) and from
Begley 1990): morbidity; blood loss during 3rd stage; method of placental delivery;
complications occurring in first 1-2 h post birth (haemorrhage, nausea, vomiting, raised
BP, pain); Hb on 3rd postnatal day; prolactin levels on 3rd postnatal day, duration of
breastfeeding
Notes Between 1 October 1987 and 31 October 1988, 2901 women were deemed eligible for
initial inclusion, 2650 agreed to take part. 1221 of these were excluded prior to randomi-
sation because of epidural (399); OVB (354); CS (132); rapid birth (95); hypertension
(77); missed (53); low Hb (40); woman’s request (28); miscellaneous (23); breech (20)
Actual management used in the active arm: all given IV ergometrine 0.5 mg before
delivery of placenta; 89% cord clamped and cut; 93% CCT and 5% maternal effort;
7% upright and 93% recumbent
Actual management used in the expectant arm: 14% got ergometrine for treatment,
not prophylactically, 6 (0.83%) before placenta delivered; cord left unclamped till pul-
sation ceased 42%; placenta delivered by maternal effort 32% and CCT 66%; 11%
upright
Dates of study: 1 October 1987-31 October 1988
Funding sources: “This study was funded by the Research and Development Trust of
the Coombe Hospital”
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Unpublished information from study au-
thor: random number tables were used
(Fleiss 1981). The 1st number was selected
from the table by a disinterested observer
and the numbers were allocated in blocks
of 100 following in sequence
Allocation concealment (selection bias) Low risk Quote: “...a numbered, sealed envelope
containing the randomly allocated group
was stapled to the woman’s chart in readi-
ness for admission... The envelope re-
mained sealed until the women was in sec-
ond stage of labour and the midwife was
certain a normal delivery would ensue. The
envelope was then opened...”
Quote: “When a woman was excluded
from the study, her envelope was returned,
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Begley 1990 (Continued)
unopened, to the researcher. All returned
envelopes were re-allocated in numerical
order prior to starting the next batch of 100
envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind women or clin-
icians in this study. The outcome assessor
was often the caregiver for many important
outcomes, e.g. blood loss and PPH. Even
though blood loss was measured and not
estimated, theremay have beenbias inmea-
suring
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Describes the differences in measuring
blood loss in non-blinded staff and at-
tempts to standardise methods. Hb mea-
surement was conducted by assessors
blinded to allocation (personal communi-
cation) thus some outcomes were blinded
but for some it was not possible
Incomplete outcome data (attrition bias)
All outcomes
Low risk Some missing data for some postnatal Hb
measurements (618 out of 705 in the active
group (12% attrition) and 645 out of 724
in the expectant (11% attrition)
ITT not mentioned but no loss to follow-
up for outcomes measured during labour.
Some outcome data are taken from the un-
published thesis
Selective reporting (reporting bias) Unclear risk All outcomes listed in the methods are re-
ported, but no protocol for the study is
available
Other bias Low risk No significant difference in baseline char-
acteristics, but more women in the physio-
logical arm had pethidine in labour (46%
compared with 52%, P = 0.05). This may
impact on outcomes in the physiological
arm where the sight and sound of the baby
may be the stimulus for the hormonal re-
lease needed for natural 3rd stage andpethi-
dine may impact here
1st and 2nd stage management similar and
no obvious differences overall
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Jangsten 2011
Methods RCT with randomisation of individual women
Participants Setting: university hospital, Sweden. High-income country
Inclusion criteria: healthy women with normal pregnancies, a gestational age of 34-43
weeks, singleton, cephalic presentation and expected vaginal birth (included ventouse
deliveries)
Exclusion criteria: non-Swedish speaking, previous PPH, elective CS, pre-eclampsia,
grand multiparity (> 5) or IUFD
Subgroups: high-income, not low-risk
Clinician responsible for third stage: midwives
Interventions Experimental intervention: active management of third stage (N = 903, but analysed
810)
• Uterotonic drug/dose/route/timing: oxytocin 10 U, IV, within 2 min of birth
• Cord clamping timing: immediate
• CCT: yes, and encouragement to push
• Uterine massage: after expulsion of placenta
Control/comparison intervention: mixed management of 3rd stage (N = 899, but
analysed 821)
Description: mixed: (no routine uterotonic; early cord clamping, no CCT)
• clamping the cord immediately after birth
• administration of 2 mL saline solution, IV within 2 min
• waiting for signs of placental detachment and encouraging the mother to push
out the placenta without cord traction
• uterine massage after placenta delivered
Data used in comparison 11
Outcomes Pre-specified outcomes: primary outcome was the incidence of blood loss > 1000 mL
during the 3rd stage of labour. Other outcomes: Hb at 24 h and women’s views
Reported outcomes: blood loss > 1000 mL and > 500 mL during the 3rd stage of
labour, blood loss > 1000 mL and > 500 mL in first 2 h PP, Hb at 24 h, change
in Hb from antenatal to 24 h postnatal, retained placenta/retained part of placenta
or membranes, additional uterotonics, duration of 3rd stage. Blood transfusion, units
transfused, experience of mothers, afterpains
Outcomes obtained by email response 28 April 2011: manual removal of placenta alone,
cross-over in additional uterotonics, Hb < 9 g/dL at 24-48 h, length of 3rd stage > 60
min
Outcomes obtained by email response 26 May 2011 clarification of cross-over in ad-
ditional uterotonics, blood loss > 500 mL and > 1000 mL during 3rd stage of labour
separated from blood loss > 500 mL and > 1000 mL in first 2 h PP
Notes We wrote to the study author for additional information which was provided as follows:
“In the active group, 41 women had extra Synt, therapeutically, before the placenta
(some went on to have a second dose, and/or Methergin) = 41
767 had no extra Synt before the placenta. Of these, 26 had a second dose after the
placenta was delivered, 6 had a second dose of Synt and a dose of Methergin and 48 had
Methergin but no Synt = 80
IN TOTAL, IN THE ACTIVE GROUP, 121 WOMEN HAD THERAPEUTIC
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Jangsten 2011 (Continued)
UTEROTONICS.
In the expectant group, 160 women had a dose of Synt, therapeutically, before the
placenta (some went on to have a second dose, and/or Methergin) = 160
655 had no Synt before the placenta. Of these, 102 had a dose of Synt after the placenta
was delivered, 32 had a dose of Synt and a dose of Methergin and 17 had Methergin but
no Synt. = 151
IN TOTAL, IN THE EXPECTANT GROUP, 311 WOMENHAD THERAPEUTIC
UTEROTONICS.”
In further correspondence, the author replied:
“Blood loss before and during placenta delivery: IN ACTIVE GROUP: 0 to 500 mL
= 86.57% (n = 696) > 500 mL = 13.43% (n = 108) and 0 to 1000 mL = 96.39% (n =
775) > 1000 mL = 3.61% (n = 29)
Blood loss before and during placenta delivery: IN EXPECTANT GROUP: 0 to 500
mL = 76.25% (n = 623) > 500 mL = 23.75% (n = 194) and 0 to 1000 mL = 95.3% (n
= 779) > 1000 mL = 4.65% (n = 38)”
And also:
Question: Number of women having retained placenta and manual removal of placenta
(excluding those who had retained pieces of membrane, etc, if possible)
Answer: “in total 47 manual removal of the placenta were performed. In active group
26 in expectant group 21.”
Question: Number of maternal haemoglobin <9gm/dl at 24-48 hrs
Answer: “In total there were 62 women with Hb < 90. In active group 34 women, and
in expectant group 28 women”
Question: Number of lengths of third stage > 60 minutes.
Answer: “In total there were 54 women with third stge that exceede 60 min. In active
group 31 women and in expectant group 23 women.”
Question: Was ’mean blood loss before placenta’ actually ’blood loss up to and including
expulsion of placenta’?
Answer: “mean bloodloss before placenta was expelled is refered to as before and during
expulsion.”
Dates of study: November 2006-April 2008
Funding sources: “The study was supported by grants from the Research and Develop-
ment Board in Göteborg and Bohuslän Baby Bag and the SU foundation”
Declarations of interest: “The authors have no conflicts of interest and are independent
from industrial funding”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Sealed envelopes containing the computer-
generated randomisation group were pre-
pared in consecutive order and kept in
another unit. At randomisation, midwives
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Jangsten 2011 (Continued)
phoned the staff at the other unit who
opened the sealed envelopes and disclosed
the assigned intervention and study num-
ber
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Received an injection in both groups to
“blind”, but expectant group were asked to
push and did not have CCT, active group
had CCT
Clinicians not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Clinicians not blinded and clinicians in-
volved in many important outcomes de-
cisions/assessments, e.g. blood loss, ther-
apeutics uterotonics, blood transfusions.
Other outcomes could have been blinded,
e.g. Hb
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 903 women randomised to the ac-
tive group and 899 women randomised to
the mixed management group:
• 4 women withdrew from the active
group and 2 from the mixed management
group
• 75 women had CS in active group
and 56 in the mixed management group,
so were excluded
• A further14 women in the active
group and 20 in the mixed management
group were lost to follow-up
Overall 10% and 9%
The analysis was ITT, apart from above ex-
clusions
Selective reporting (reporting bias) Unclear risk All outcomes listed in the methods are re-
ported, but no protocol for the study is
available.
Other bias High risk There were more inductions in the active
group (10% versus 7%).
Describe any differential diagnosis: none
Although 11,000 women were potentially
eligible, of whom at least half would usually
be considered eligible, only 1802 were en-
tered into the study.Numbers excludeddue
to ineligibility are not recorded, and other
reasons given are “excessive workload” or
“admission in advanced labour”
Email response from Jangsten 28 April
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Jangsten 2011 (Continued)
2001: “the hard workload was one reason
that the women were not included and that
all eligible women were not asked to partic-
ipate. Few women refused in participating
but I don’t have the number”
This has the potential to have biased the
study, as midwives would have had the
choice of not asking the women to par-
ticipate and may unconsciously have not
offered participation to some women who
they felt were not suitable for physiological
management
Jerbi 2007
Methods RCT of individual women in low-income setting
Participants Setting: Sousse, Tunisia. Low-income country
Women with singleton pregnancies expecting to give birth vaginally
Exclusion criteria: placenta praevia, APH, non-cephalic presentation, intrauterine
death, parity > 5, uterine fibroids, anticoagulation therapy, history of PPH, history of
CS
Interventions Intervention: active management of 3rd stage (N = 65)
• IV flash injection of 5 IU oxytocin at time of delivery of anterior shoulder
• immediate cord clamping and cutting
• CCT with gentle fundal pressure when signs of separation appeared
• manual removal if not delivered by 30 min or if haemorrhaging
Comparison: mixed management of 3rd stage (N = 65)
• no routine uterotonic (not stated in publication, but study author provided
information on 19 March 2011)
• immediate cord clamping and cutting
• CCT plus gentle fundal pressure when signs of separation appeared
• manual removal if not delivered by 30 min or if haemorrhaging
Data included in comparison 12
Outcomes Pre-specified: reduction in HCT and Hb
Notes We contacted the study authors again on 14 March 2011, for further information on
the management in the comparison arm, the methodology they used and data obtained.
Reply received 19 March 2011. No publication has emanated, no further data were
provided, but methodology was clarified
Dates of study: February-March 2005
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As per www.randomization.com (not
stated in publication but information pro-
vided by study author on 19 March 2011)
Allocation concealment (selection bias) High risk Not concealed in any way (not stated in
publication, but in information provided
by study author on 19 March 2011)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk None. Unblinded assessment made
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss described in publication and con-
firmed by information from study author
on 19March 2011. Study authors also pro-
vided information that the analysis was by
“intention to treat”
Selective reporting (reporting bias) High risk No study protocol found. Some outcomes
reported but not noted inmethods of paper
Other bias High risk Women reported to have been allocated to
groups after placental delivery yet active
management group supposedly had oxy-
tocin with the anterior shoulder
Khan 1997
Methods RCT with randomisation of individual women
Participants Abu Dhabi hospital setting. High-income country
Inclusion criteria: all women expected to give birth vaginally. 1657 women randomised
out of a possible 4239
Exclusion criteria: refusal or CS in second stage (9 excluded, final sample 1648)
Interventions Intervention: active management of 3rd stage (N = 827)
• prophylactic oxytocin 10 units IM at birth of anterior shoulder (or if breech, soon
after delivery of baby)
• cord clamped and cut immediately
• CCT as soon as the uterus was contracted firmly. Repeated every 2-3 min.
Comparison: mixed management of 3rd stage (N = 821)
• no IM/IV oxytocic
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Khan 1997 (Continued)
• cord clamped and cut after delivery
• no cord traction. No fundal massage or pressure. Signs of separation awaited, then
maternal expulsion of placenta
• IV infusion of oxytocin 10 units in 500 mL normal saline given slowly after
delivery
In both groups, if placenta not delivered after 30min, CCT or digital removal attempted,
with IV oxytocin infusion if bleeding present
Data included in comparison 10
Outcomes Primary: PPH
Secondary: duration of 3rd stage, retained placenta, shock, blood transfusion, methy-
lergonovine or 15-methyl-a-prostaglandin to control haemorrhage
Notes Not readily comparable to other studies as IV oxytocin infusion given to all women in
expectant management group after delivery of placenta. This is the practice in the USA
but not elsewhere
Dates of study: January-June 1995
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail
Allocation concealment (selection bias) Unclear risk Numbered, sealed, opaque envelopes.
However, if sequence generation is not ran-
dom then allocation cannot be concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Attempted with 2nd MW recording blood
loss - however, no guarantee that the 1st
MW could/would not have altered the
amount of blood in the receptacle, so not
any better than just 1 clinician measuring
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Presumed blinded, but unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2582 excluded prior to randomisation due
to refusal
9 excluded after randomisation due to
emergency CS
Selective reporting (reporting bias) Unclear risk All outcomes listed in the methods are re-
ported, but there is no protocol for the
study available
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Other bias High risk 2582 out of 4239 refused to participate.
Those that did agree may have been biased
It is unknown whether or not themidwives
had sufficient training in physiological 3rd
stage before the study started
This study has been criticised for includ-
ing all women (including high parity, all
age groups, previous PPH, epidural, long
labour, operative delivery) and not con-
fining inclusion criteria to women who
were low risk. Women at high risk of PPH
will have a higher blood loss using expec-
tant management; clinicians experiencing
this may respond by anxiety in subsequent
births, even of low-risk women, which may
result in higher intervention (mixed man-
agement) rates
Also, the minimal intervention (control)
group had the cord clamped and cut im-
mediately after delivery, which is suspected
to lead to an increase in blood loss
Prendiville 1988
Methods RCT with randomisation of individual women
Participants UK hospital setting. High-income country
Inclusion criteria: all women expected to give birth vaginally. 1695 women randomised
out of a possible 4709
Exclusion criteria: refusal, cardiac disease, APH, non-cephalic presentation, multiple
pregnancy, IUFD, if clinician had good reason not to include women
After the first 5 months, exclusions included women with ritodrine given 2 h before
birth; anticoagulant treatment; any condition needing a particular management of 3rd
stage (e.g. meconium-stained liquor, dural tap)
Interventions Intervention: active management of 3rd stage (N = 846)
• prophylactic syntometrine (5 units oxytocin + 0.5 mg ergometrine) (or 10 units
syntocinon if mother had raised BP), administered immediately after birth of anterior
shoulder
• cord clamping and cutting within 30 s of birth
• delivery of the placenta by CCT when uterus contracted
Comparison: expectant management of 3rd stage (N = 849)
• try not to give oxytocic
• try to leave cord attached to baby until placenta delivered
• try not to use CCT or any manual interference with uterus at the fundus.
Following signs of separation encourage posture aiding delivery by gravity, and
maternal effort
Data included in comparison 1
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Prendiville 1988 (Continued)
Outcomes Pre-specified outcomes: PPH (and “more objective measures of blood loss”, presumably
Hb); length 3rd stage; need for therapeutic oxytocics; manual removal placenta; ERPC;
side effects of oxytocics (nausea, vomiting, headaches, hypertension); Apgar scores; PCV;
SCBU; jaundice; breastfeeding. Views of a subsample of women
Notes Actual management used in the active arm: 99% given prophylactic uterotonic before
delivery of placenta; 99% cord clamped and cut before delivery of placenta; 99% CCT;
26% upright
Actual management used in the expectant arm: 30% received uterotonic for treat-
ment, and 20% prophylactically; cord left unclamped till pulsation ceased 48%; placenta
delivered by maternal effort 60% and CCT 40%; 49% upright
Dates of study: 1 January 1986-31 January 1987
Funding sources: “The maternity and child division at theWorld Health Organisation,
Geneva, provided some additional funds. The national perinatal epidemiology unit is
supported by the DHSS”
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No description of the randomisation given.
However, verbal assurances from study au-
thors that sequence generation was random
Allocation concealment (selection bias) Low risk Quote: “On admission to the labour
ward... Correspondingly numbered, sealed
opaque envelopes were placed in the
woman’s notes...”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind the women or the
clinicians in any of the studies
Quote: “We were concerned that clinical
estimates of blood lossmight also be subject
to systematic bias between the two study
groups as the observer could not be blinded
to the management allocated. We there-
fore studied three maternal haematologi-
cal variables - namely, postpartum (24-48
hrs) haemoglobin concentration ≤ 90g/L,
mean postpartum packed cell volume and
mean change in haemoglobin concentra-
tion between about 34 weeks gestation and
post partum”
Primary outcome though is still PPH > 500
mL which is subject to systematic bias
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Prendiville 1988 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data for some outcomes, e.g. 19%
of Hb results missing in active arm and
18% in the physiological
Apparently no women were excluded af-
ter randomisation but 182 are described
as having not entered in the study due to
the cord being cut early for fetal safety rea-
sons. The allocation details, however, state
that when the clinician was ready to pre-
pare for delivery, the envelope was opened
and “all women for whom an envelope was
opened were deemed to have entered the
study and were followed up”. The envelope
would have been opened before any neona-
tal need for attention became apparent
Selective reporting (reporting bias) High risk No study protocol found. A large num-
ber of outcomes reported but not noted in
methods of paper
Other bias High risk Protocol was modified after 5 months (425
births), due to high blood loss in expec-
tant management group, to allow women
in the control arm who needed some active
management to be switched to fully active
management. However, data for the first 5
months were still included in analysis
Study was stopped early because of poten-
tial harm. Sample sizewasmeant to be 3900
but stopped after 1695
30 women in the control group gave a late
maternal refusal, whereas only 1 in the ex-
perimental group did so. The outcomes of
these women are included in analysis
It is questioned whether the midwives
had sufficient training in physiological 3rd
stage before the study started. Harding et
al found that, of 49 midwives respond-
ing to a questionnaire, only 1 had prac-
tised physiological management as defined
in the study. Only 6 (13%) of the mid-
wives said that they were very confident of
physiologicalmanagement before the study
and 22 (46%) afterwards (Harding 1989;
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Prendiville 1988 (Continued)
Prendiville 1988 paper).
This study has been criticised for includ-
ing all women (including high parity, all
age groups, previous PPH, epidural, long
labour, operative delivery) and not con-
fining inclusion criteria to women who
were low risk. Women at high risk of PPH
will have a higher blood loss using expec-
tant management; clinicians experiencing
this may respond by anxiety in subsequent
births, even of low-risk women, which may
result in higher intervention (mixed man-
agement) rates
Only 47% (403/849) of women in phys-
iological arm received the full physiologi-
cal package (a problem with other studies
also). But, in particular, 168/849 = 20%
had prophylactic oxytocic, which is a large
number for a “prophylactic” treatment as
opposed to one in response to clinical need.
In addition, 252 (30%) had a uterotonic as
a treatment, so in total, 50% of the expec-
tant management group received an oxyto-
cic
However, 99% (838/846) of women in ac-
tive management group received allocated
management
Rogers 1998
Methods RCT with randomisation of individual women in balanced blocks, with allocation to 1
of 2 delivery postures within each arm
Participants UK hospital setting. High-income country
Inclusion criteria: 1512 women at low risk of PPH giving birth at study hospital
(including water births)
Exclusion criteria: placenta praevia, previous PPH, APH after 20 weeks’ gestation, Hb
< 10 g/dL or MCV < 75 fL, non-cephalic presentation, multiple pregnancy, intrauterine
death, epidural anaesthesia, parity > 5, uterine fibroid, oxytocin augmentation infusion,
anticoagulation therapy, intended instrumental or OVB, duration of gestation < 32
weeks, (plus any other contraindication, in clinician’s view)
Interventions Intervention: active management of 3rd stage (N = 748)
2 arms: active management - upright position (N = 374); active management - supine
position (N = 374)
• prophylactic oxytocin (19.5%) or “oxytocin + ergometrine” (75%) as soon as
possible after birth of anterior shoulder (within 2 min of birth). Number of units/mL
not given, nor reason for the difference
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Rogers 1998 (Continued)
• immediate cord clamping and cutting
• delivery of the placenta by CCT or maternal effort
Control: expectant management of 3rd stage (N = 764)
2 arms: expectant management - upright position (N = 381); expectant management -
supine position (N = 383)
• no prophylactic administration of uterotonic drug
• no cord clamping until after pulsation ceased
• delivery of placenta within 1 h by maternal effort
Data included in comparisons 1 and 2
Outcomes Pre-specified outcomes: PPH (> 500 mL) as assessed/estimated by the attending MW
(used for power calculation); severe PPH 1000 mL), blood transfusion, iron tablets
postnatally, Hb at 24-48 h P/N, self-completed questionnaire on maternal fatigue and
depression at 6 weeks P/N, nausea, vomiting, headache, hypertension, manual removal
of placenta, ERPC, neonatal outcomes, views of mothers and staff
Notes Actual management used in the active arm: 699 (93.4%) had full active management;
95% given prophylactic uterotonic before delivery of placenta; 93% cord clamped before
pulsation ceased; 46% CCT; 44% upright
Actual management used in the expectant arm: 488 (63.9%) had full expectant man-
agement; 21% received oxytocic for treatment, and 2.5% prophylactically; cord left un-
clamped till pulsation ceased 70%; placenta delivered by CCT 12%; 43% upright
The setting is described as one where the midwives were “similarly confident” in active
and expectant management. However, the questionnaire administered to 92 of the 153
midwives prior to the study commencement showed that, whereas 84% felt “very confi-
dent” of active management, only 41% were “very confident” of expectant management
Maternal mean Hb levels were reported with SEs and so we calculated SDs
Dates of study: June 1993-December 1995
Funding sources: “The study was supported by a grant from the Public Health and
Operational Research Committee of the Anglia and Oxford Regional Health Authority.
The NPEU is supported by the Department of Health”
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Variable sized balanced blocks “...randomi-
sation envelopes were prepared in advance.
.” in an external academic unit - National
Perinatal Epidemiology Unit, Oxford
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed en-
velopes stored on the ward. Entry to the
study occurred when an envelope was
opened
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Rogers 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Partly blinded. The technicians who did
antenatal and postnatal blood tests were
unaware of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data available on 1507 out of 1512 at
discharge (< 0.5% attrition, approximately
equal losses in both groups)
At 6 weeks’ follow-up < 5% attrition
Selective reporting (reporting bias) High risk No study protocol found. A large num-
ber of outcomes reported but not noted in
methods of paper
Other bias High risk • Initial power calculation suggested a
sample size of 2000. Interim analysis
showed a higher PPH rate than expected,
so sample size was revised to 1500 and the
study stopped earlier than expected
• Similar at baseline
• 93.4% of active management group
received active management. Only 63.9%
of women in expectant management
group received expectant management
Also:
• MWs not confident re 1 arm, so
observer bias
• the hypothesis was phrased in favour
of active management lowering PPH rate
and other complications, rather than
being a null hypothesis
• setting is described as one where the
midwives were “similarly confident” in
active and expectant management.
However, the questionnaire administered
to 92 of the 153 midwives prior to the
study commencement showed that,
whereas 84% felt “very confident” of
active management, only 41% were “very
confident” of expectant management
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Thilaganathan 1993
Methods RCT with randomisation of individual women
Participants UK hospital setting. High-income country
Inclusion criteria: women at ”low risk of PPH” (defined only by the exclusion criteria
for study) and at term (37-42 weeks). 193 women randomised, from an unknown
population
Exclusion criteria: grand multiparity; malpresentation, multiple pregnancy; previous
CS or PPH; APH; pregnancy-induced hypertension and IUFD
Then after randomisation: women who had had augmentation, instrumental or OVB,
3rd degree tear and cervical laceration
Interventions Intervention: active management of 3rd stage (N = 103):
• 1 mL syntometrine (not stated whether IM or IV) as soon as baby born
• cord “was immediately clamped”
• placenta delivered by CCT
Comparison: expectant management of 3rd stage (N = 90):
presumed no oxytocic, though not stated in the published paper
Authors’ information by letter states:
• “No oxytocics or placebos were given to the physiological group”
• cord not cut or clamped until after pulsation ceased (unless there were
contraindications, e.g. cord round neck, after clamping, maternal end clamp removed
as soon as possible to allow drainage)
• once there were signs of placental separation mother was encouraged to adopt an
upright position and bear down, “when the placenta could be felt in the vagina, the
midwife could then assist delivery of the placenta”
Both groups: if placenta not delivered in 30min, bladder emptied andmedical assistance
sought. If delivery not imminent manual removal performed. Medical assistance sought
for any excessive blood loss
Data included in comparisons 1 and 2
Outcomes Pre-specified outcomes: estimated blood loss; Hb in labour and 3rd postnatal day;
length of 3rd stage; complications
Reported outcomes: as above plus therapeutic uterotonics, blood transfusion
Notes Drop in Hb is not calculated correctly.
Maternal mean postnatal Hb reported as median and range. Active: 11.7 g/dL (10.7-12.
6 g/dL) and expectant 11.7 g/dL (10.9-12.6 g/dL)
Worrying problems with methodology and analysis
Dates of study: January 1988-February 1990
Funding sources: not reported
Declarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...randomly allocated using stan-
dard randomisation tables...”
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Allocation concealment (selection bias) Unclear risk Not described. Not clear when randomisa-
tion occurred
Quote: “...the midwife responsible for the
management of her patient was not aware
of the proposed allocation until her patient
was entered into the study” (authors’ infor-
mation states: “randomised in the late 1st
stage of labour when it was apparent that
they were likely to delivery normally”)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants and per-
sonnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unknown
Incomplete outcome data (attrition bias)
All outcomes
High risk It is not clear how many were randomised.
P. 20 states “A total of 193 women com-
pleted the study AND had all results avail-
able for complete analysis”. This could
mean that a larger number were included
but that some of their results were miss-
ing, and they were therefore excluded. This
could lead to significant bias. It is very un-
likely that all participants received the al-
located management, yet this is not pre-
sented. The study groupswere also very dif-
ferent sizes (103 and 93), which sounds un-
likely
Women withdrawn after randomisation
for operative delivery, third-degree tears
and cervical lacerations. Numbers were not
given; there is a significant risk of bias here
It is not stated in the published paper
whether or not ITT analysis was used, but
the response to Diana Elbourne’s letter of
April 1991 states that they did not analyse
on “intention to treat” as it would not an-
swer the aims of this preliminary study
Selective reporting (reporting bias) Unclear risk All outcomes listed in the methods are re-
ported, but there is no protocol available
for the study
Other bias High risk Variables age, birthweight andparity said to
be equal between the groups but no details
given. No power calculation done
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Not a null hypothesis
The study groups were very different sizes
(103 and 90)
Yildirim 2016
Methods RCT with randomisation of individual women
Participants Setting: Istanbul Bakirkoy Maternity and Children’s Hospital, Turkey. Upper-middle-
income country (World Bank), so classed as higher-income setting
Inclusion criteria: absence of risk factors for PPH; gestational age of 36-42 weeks; a
singleton pregnancy; live fetus; cephalic presentation; expected fetal birthweight of 2500-
4500 g; maternal age of < 40 years; parity (min-max) 0-3
Exclusion criteria: acute fetal distress, conversion to abdominal delivery during labour,
need for labour augmentation, persistent high BP (> 140/90 mmHg), placenta praevia,
ablatio placenta or uterine bleeding of any other cause encountered during pregnancy or
labour; previous CS; uterine scar; PPH in previous pregnancies; hydramnios; symptoms
of maternal infection; drug use in labour; abnormal placentation (accreta, increta or
percreta), coagulation defects, forceps or vacuum extraction, Hb concentration of < 8
g/dL; use of anticoagulants and tocolytics during pregnancy, multiple gestations, any
known uterine malformations, and deep vaginal lacerations
Interventions Intervention: active management of the 3rd stage
Total number randomised: n = 333, but 327 were analysed
• managed in accordance with WHO recommendations (WHO 2007)
• 10 IU oxytocin IM injection within the 1st min after delivery
• early umbilical cord clamping
• application of CCT with uterine massage
Control: expectant management of the 3rd stage (’mixed management’ in our review)
Total number randomised: n = 336, but 327 were analysed
• umbilical cord clamping after cord pulsation had slowed down, placental
separation signs were expected (a sudden gush of blood from the vagina, lengthening of
the umbilical cord into a lower segment, rise of the uterus in the abdomen)
• the placenta was allowed to fall by maternal effort and gravity
• 10 IU oxytocin IM injection was administered after placental expulsion
Outcomes Prepartum Hb and HCT levels, postpartum Hg-HCT levels, reductions in Hg levels of
> and < 3 g/dL, prolonged 3rd stage of labour, transfusion requirement, requirement
of additional uterotonics, additional interventions including manual removal of the
placenta, and the requirement of additional surgery or curettage
Notes Dates of study: 2010
Funding sources: Kanuni Sultan Suleyman Education and Research Hospital (email
from lead author)
Declarations of interest: “The authors declare that they have no conflicts of interest
with any third party and that they have no financial disclosure to be made”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The abstract reports “women were ran-
domly assigned” however, no description is
given in relation to this process. We con-
tacted the lead author who responded: “We
prepared 1000 sealed opaque envelopes as-
signed for each group; 500 were tagged with
‘active management’, and the other 500 with
‘expectant management’. We shuffled the en-
velopes and put them in a box… Allocation
took place when vaginal delivery was immi-
nent, at the end of the second stage of labor
by pulling out one of the envelopes out of the
box randomly.”
Allocation concealment (selection bias) Unclear risk Quote: “Allocation concealment was made
using sealed opaque envelopes and took
place when vaginal delivery was imminent,
at the end of the second stage of labor.”
Additional information from the lead au-
thor stated, quote: “We shuffled the en-
velopes and put them in a box. Allocation
took place when vaginal delivery was im-
minent, at the end of the second stage of
labor by pulling out one of the envelopes
out of the box randomly….We tagged pa-
pers with active or expectant management.
Thenwe put them in to the envelopes (with
nothing written on the outside). Thus, the
performer was not able to see which proto-
col was written inside the envelope.”
Although the sequence generated was ran-
dom, the envelopes were not sequentially
numbered and so the random sequence
could not be guaranteed as per theCochrane
Handbook of Systematic Reviews of Interven-
tions, which says, “If investigators use en-
velopes, they should develop and moni-
tor the allocation process to preserve con-
cealment. In addition to use of sequen-
tially numbered, opaque, sealed envelopes,
they should ensure that the envelopes are
opened sequentially, and only after the en-
velope has been irreversibly assigned to the
participant.” (Higgins 2017)
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Women and clinicians cannot be blinded to
the differentmanagement of care associated
with active and expectant management
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “only the analyser of the outcome
data was blinded to the study groups be-
cause the performer could not be blinded to
the allocatedmanagement protocol”.How-
ever, we deemed this domain to be of un-
clear risk of bias as non-blinded clinicians
were involved in many important outcome
decisions
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15 women out of 669 women (2.2%) were
excluded after randomisation due to deep
vaginal lacerations
Selective reporting (reporting bias) Unclear risk No protocol for the study is available. All
outcomes reported in the methods are re-
ported plus one outcome (atony) reported
but not mentioned in methods
Other bias Unclear risk Baseline characteristics were similar (age,
gestational week, body mass index, parity,
episiotomy, and mean length of labour).
However, there is little methodological in-
formation in the publication on which to
judge potential for bias - mostly the infor-
mation is about clinical care
The study authors do not identify the pro-
fession of the clinicians, nor is it clear if
the healthcare practitioners received any
education/training in relation to expectant
and active management of the 3rd stage of
labour before this published study. How-
ever, the lead author provided clarification
on this reporting: “We had to train the per-
formers for the active management proto-
col (especially for the controlled cord trac-
tion) which was not a common practice in
our hospital then.”
Exclusion of women with PPH due to
deep vaginal lacerations (6/333 in active
management group and 9/336 in expec-
tant management group), although num-
bers are low, this could contribute to bias
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APH: antepartum haemorrhage; BP: blood pressure; CCT: controlled cord traction; CS: caesarean section; ERPC: evacuation of
retained products of conception; fL: femtolitre;GA: general anaesthesia; g/dL: grams/decilitre;Hb: haemoglobin;HCT: haematocrit
(= packed cell volume); IM: intramuscular; ITT: intention-to-treat; IU: international units; IUFD: intrauterine fetal death; IV:
intravenous;MCV:mean corpuscular volume;mL:millilitre;MW:midwife;OVB: operative vaginal birth; PCV: packed cell volume
(= haematocrit); P/N: postnatal; PPH: postpartum haemorrhage; PP: postpartum; RCT: randomised controlled trial; SCBU: special
care baby unit; SD: standard deviation; SE: standard error;WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdel-Aleem 2010 This study looked at uterine massage vs active management vs active management plus uterine massage, so
it was not a comparison of active and expectant management within the definitions used in the review
Deneux-Tharaux 2013 This study was an RCT of active management with and without CCT, so it was not a comparison of active
and expectant management within the definitions used in the review
Gulmezoglu 2012 This study was an RCT of active management with and without CCT, so it was not a comparison of active
and expectant management within the definitions used in the review
Hoffman 2006 Conference abstract available only, but further information on methodology obtained from study authors.
Concerns re number of women withdrawn, after randomisation, due to CS
Kashanian 2010 48% of participants excluded in both arms following randomisation
Magann 2006 This study looked at different times of undertaking manual removal of placenta to try to reduce PPH, so
it was not a comparison of active and expectant management within the definitions used in the review
Muller 1996 French conference abstract only, no full publication identified. The translation provided no information
on the number of women randomised to each group and so it was not possible to use these data. Previous
review authors wrote for further information but had no response. We wrote and received a response from
the co-author, but no further details to add to the published information
Neri-Mejia 2016 An RCT of 3 different types of oxytocin administration (IM, IV and infusion)
Ramirez 2001 Insufficient information on the numbers included in each of the 3 arms, and the method of management
for the expectant arm
Vasegh 2005 Insufficient information
CCT: controlled cord traction; CS: caesarean section; IM: intramuscular;IV: intravenous; PPH: postpartum haemorrhage; RCT:
randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Rosario 1973
Methods
Participants
Interventions
Outcomes
Notes Awaiting a copy of the paper
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D A T A A N D A N A L Y S E S
Comparison 1. Active versus expectant management of 3rd stage of labour (all women)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary postpartum
haemorrhage (PPH) at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
3 4636 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.14, 0.87]
1.1 Higher-income setting 3 4636 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.14, 0.87]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL 24-72
hours postpartum
2 1572 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.30, 0.83]
4.1 Higher-income setting 2 1572 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.30, 0.83]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal
special/intensive care
2 3207 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.60, 1.11]
5.1 Higher-income setting 2 3207 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.60, 1.11]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
2 3142 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.55, 1.68]
6.1 Higher-income setting 2 3142 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.55, 1.68]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Severe primary PPH after
placental delivery and up to 24
hours (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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9 Severe primary PPH at time
of birth and up to 24 hours
(clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Primary blood loss ≥ 500
mL at time of birth (clinically
estimated or measured)
3 4636 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.27, 0.44]
10.1 Higher-income setting 3 4636 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.27, 0.44]
10.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Primary blood loss ≥ 500
mL after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Primary blood loss ≥ 500 mL
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Mean maternal blood loss
(mL) at time of birth (clinically
estimated or measured)
2 2941 Mean Difference (IV, Random, 95% CI) -78.80 [-95.96, -61.
64]
13.1 Higher-income setting 2 2941 Mean Difference (IV, Random, 95% CI) -78.80 [-95.96, -61.
64]
13.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Mean maternal blood loss
(mL) after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Mean maternal blood loss (mL
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Maternal blood transfusion 4 4829 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.22, 0.55]
16.1 Higher-income setting 4 4829 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.22, 0.55]
16.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Clinical signs of severe blood
loss
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Therapeutic uterotonics during
third stage and/or within 24
hours
4 4829 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.15, 0.23]
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18.1 Higher-income setting 4 4829 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.15, 0.23]
18.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Mean length of third stage 1 1429 Mean Difference (IV, Random, 95% CI) -0.30 [-1.87, 1.27]
19.1 Higher-income setting 1 1429 Mean Difference (IV, Random, 95% CI) -0.30 [-1.87, 1.27]
19.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Manual removal of placenta as
defined by study authors
4 4829 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.57, 5.56]
20.1 Higher-income setting 4 4829 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.57, 5.56]
20.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Postnatal diastolic blood
pressure > 90 mmHg between
birth of baby and discharge
from the labour ward
3 4636 Risk Ratio (M-H, Random, 95% CI) 4.10 [1.63, 10.30]
21.1 Higher-income setting 3 4636 Risk Ratio (M-H, Random, 95% CI) 4.10 [1.63, 10.30]
21.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22 Postnatal vomiting between
birth of baby and discharge
from the labour ward
3 4636 Risk Ratio (M-H, Random, 95% CI) 2.47 [1.36, 4.48]
22.1 Higher-income setting 3 4636 Risk Ratio (M-H, Random, 95% CI) 2.47 [1.36, 4.48]
22.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23 Any analgesia between birth of
the baby and discharge from
labour ward
1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
23.1 Higher-income setting 1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
23.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24 Women’s assessment of pain
during third stage as reported
by study authors
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25 Secondary blood loss/any
vaginal bleeding needing
treatment (after 24 hours and
up to 6 weeks)
3 4636 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.40, 2.99]
25.1 Higher-income setting 3 4636 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.40, 2.99]
25.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26 Amount of lochia either
estimated or measured after 24
hours and up to discharge from
hospital
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
27 Surgical evacuation of retained
products of conception
3 4636 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.32, 1.71]
27.1 Higher-income setting 3 4636 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.32, 1.71]
27.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 Afterpains - abdominal pain
associated with the contracting
uterus in the postpartum
period
1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
28.1 Higher-income setting 1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
28.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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29 Apgar score < 7 at 5 minutes 1 1695 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.38, 2.66]
29.1 Higher-income setting 1 1695 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.38, 2.66]
29.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30 Birthweight 2 3207 Mean Difference (IV, Random, 95% CI) -76.90 [-108.51, -
45.30]
30.1 Higher-income setting 2 3207 Mean Difference (IV, Random, 95% CI) -76.90 [-108.51, -
45.30]
30.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
31 Neonatal encephalopathy
assessed using Sarnat staging
(Sarnat 1976; Table 1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32 Neonatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33 Intraventricular haemorrhage
- Papille grade III/IV - (for
infants born before 34 weeks’
gestation only)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34 Number of infants who
received a red blood cell
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35 Infant Hb level at 24 to 72
hours
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36 Infant Hb level at 3-6 months 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37 Infant iron indices (ferritin) at
3 to 6 months.
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38 Exclusive breastfeeding at
discharge from hospital
1 1695 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.96, 1.07]
38.1 Higher-income setting 1 1695 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.96, 1.07]
38.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 Neurodevelopmental, cognitive
or developmental outcomes
assessed after age 18 months
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40 Return to hospital as in- or
outpatient because of bleeding
(not pre-specified)
2 2941 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.29, 3.79]
40.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.29, 3.79]
40.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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41 Postnatal maternal mean Hb
(outcome not pre-specified)
3 4062 Mean Difference (IV, Random, 95% CI) 0.52 [0.44, 0.60]
41.1 Higher-income setting 3 4062 Mean Difference (IV, Random, 95% CI) 0.52 [0.44, 0.60]
41.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
2 2941 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.05, 2.17]
1.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.05, 2.17]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
1 193 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.47]
4.1 Higher-income setting 1 193 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.47]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal
special/intensive care
1 1512 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.55, 1.88]
5.1 Higher-income setting 1 1512 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.55, 1.88]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
1 1447 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.78, 2.18]
6.1 Higher-income setting 1 1447 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.78, 2.18]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Severe primary PPH after
placental delivery and up to 24
hours (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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9 Severe primary PPH at time
of birth and up to 24 hours
(clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Primary blood loss ≥ 500
mL at time of birth (clinically
estimated or measured)
2 2941 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.20, 0.56]
10.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.20, 0.56]
10.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Primary blood loss ≥ 500
mL after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Primary blood loss ≥ 500 mL
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Mean maternal blood loss (mL
at the time of birth, clinically
estimated or measured
2 2941 Mean Difference (IV, Random, 95% CI) -78.80 [-95.96, -61.
64]
13.1 Higher-income setting 2 2941 Mean Difference (IV, Random, 95% CI) -78.80 [-95.96, -61.
64]
13.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Mean maternal blood loss
(mL) after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Mean maternal blood loss (mL)
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Maternal blood transfusion 3 3134 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.10, 0.88]
16.1 Higher-income setting 3 3134 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.10, 0.88]
16.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Clinical signs of severe blood
loss
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Therapeutic uterotonics during
third stage and/or within 24
hours
3 3134 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.11, 0.21]
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18.1 Higher-income setting 3 3134 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.11, 0.21]
18.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Mean length of third stage 1 1429 Mean Difference (IV, Random, 95% CI) -0.30 [-1.87, 1.27]
19.1 Higher-income setting 1 1429 Mean Difference (IV, Random, 95% CI) -0.30 [-1.87, 1.27]
19.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Manual removal of placenta as
defined by study authors
3 3134 Risk Ratio (M-H, Random, 95% CI) 3.58 [0.42, 30.61]
20.1 Higher-income setting 3 3134 Risk Ratio (M-H, Random, 95% CI) 3.58 [0.42, 30.61]
20.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Postnatal diastolic blood
pressure > 90 mmHg between
birth of baby and discharge
from the labour ward
2 2941 Risk Ratio (M-H, Random, 95% CI) 7.00 [2.99, 16.43]
21.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 7.00 [2.99, 16.43]
21.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22 Postnatal vomiting between
birth of baby and discharge
from the labour ward.
2 2941 Risk Ratio (M-H, Random, 95% CI) 5.63 [0.69, 46.08]
22.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 5.63 [0.69, 46.08]
22.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23 Any analgesia between birth of
the baby and up to discharge
from labour ward
1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
23.1 Higher-income setting 1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
23.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24 Women’s assessment of pain
during third stage as reported
by study authors
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25 Secondary blood loss/any
vaginal bleeding needing
treatment (after 24 hours and
up to 6 weeks)
2 2941 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.69, 4.60]
25.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.69, 4.60]
25.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26 Amount of lochia either
estimated or measured after 24
hours and up to discharge from
hospital
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
27 Surgical evacuation of retained
products of conception
2 2941 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.12, 3.98]
27.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.12, 3.98]
27.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 Afterpains - abdominal pain
associated with the contracting
uterus in the postpartum
period
1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
28.1 Higher-income setting 1 1429 Risk Ratio (M-H, Random, 95% CI) 2.53 [1.34, 4.78]
28.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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29 Apgar score < 7 at 5 minutes 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30 Birthweight 1 1512 Mean Difference (IV, Random, 95% CI) -67.0 [-114.13, -19.
87]
30.1 Higher-income setting 1 1512 Mean Difference (IV, Random, 95% CI) -67.0 [-114.13, -19.
87]
30.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
31 Neonatal encephalopathy
assessed using Sarnat staging
(Sarnat 1976; Table 1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32 Neonatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33 Intraventricular haemorrhage
- Papille grade III/IV - (for
infants born before 34 weeks’
gestation only)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34 Number of infants exposed
to one or more red blood cell
transfusions
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35 Infant Hb level at 24 to 72
hours
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36 Infant Hb level at 3-6 months 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37 Infant iron indices (ferritin) at
3 to 6 months.
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38 Exclusive breastfeeding at
discharge from hospital
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 Neurodevelopmental, cognitive
or developmental outcomes
assessed after age 18 months
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40 Return to hospital as in- or
outpatient because of bleeding
(not pre-specified)
2 2941 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.29, 3.79]
40.1 Higher-income setting 2 2941 Risk Ratio (M-H, Random, 95% CI) 2.21 [1.29, 3.79]
40.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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41 Postnatal maternal mean Hb
(outcome not pre-specified)
2 2683 Mean Difference (IV, Random, 95% CI) 0.5 [0.41, 0.59]
41.1 Higher-income setting 2 2683 Mean Difference (IV, Random, 95% CI) 0.5 [0.41, 0.59]
41.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Active versus mixed management of 3rd stage (early uterotonic, delayed cord clamping, controlled
cord traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 4. Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, con-
trolled cord traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 5. Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no
controlled cord traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Maternal blood transfusion 1 654 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.17, 3.32]
8.1 Higher-income setting 1 654 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.17, 3.32]
8.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Therapeutic uterotonics during
third stage and/or within 24
hours
1 654 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.55, 1.48]
9.1 Higher-income setting 1 654 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.55, 1.48]
9.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Mean length of third stage 1 654 Mean Difference (IV, Random, 95% CI) -5.15 [-5.71, -4.59]
10.1 Higher-income setting 1 654 Mean Difference (IV, Random, 95% CI) -5.15 [-5.71, -4.59]
10.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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11 Manual removal of placenta as
defined by study authors
1 654 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.11, 3.96]
11.1 Higher-income setting 1 654 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.11, 3.96]
11.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Surgical evacuation of retained
products of conception
1 654 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.36, 134.98]
12.1 Higher-income setting 1 654 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.36, 134.98]
12.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Birthweight 1 654 Mean Difference (IV, Random, 95% CI) 68.0 [23.87, 112.13]
13.1 Higher-income setting 1 654 Mean Difference (IV, Random, 95% CI) 68.0 [23.87, 112.13]
13.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Postnatal maternal mean Hb 1 654 Mean Difference (IV, Random, 95% CI) 0.69 [0.58, 0.80]
14.1 Higher-income setting 1 654 Mean Difference (IV, Random, 95% CI) 0.69 [0.58, 0.80]
14.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Expectant versus mixed management (early uterotonic, delayed cord clamping, controlled cord
traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Expectant versus mixed management (delayed uterotonic, delayed cord clamping, controlled cord
traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 8. Expectant versus mixed management (delayed uterotonic, delayed cord clamping, no controlled
cord traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 9. Active versus mixed management (uterotonic after placental delivery, immediate cord clamping
and no controlled cord traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
1 1648 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.09, 0.55]
1.1 Higher-income setting 1 1648 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.09, 0.55]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Severe primary PPH after
placental delivery and up to 24
hours (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Severe primary PPH at time
of birth and up to 24 hours
(clinically estimated or
measured blood loss ≥1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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9.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Primary blood loss ≥ 500
mL at time of birth (clinically
estimated or measured)
1 1648 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.38, 0.74]
10.1 Higher-income setting 1 1648 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.38, 0.74]
10.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Primary blood loss ≥ 500
mL after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Primary blood loss ≥ 500 mL
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Mean maternal blood loss
(mL) at time of birth (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Mean maternal blood loss
(mL) after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Mean maternal blood loss (mL)
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Maternal blood transfusion 1 1648 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.03, 2.22]
16.1 Higher-income setting 1 1648 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.03, 2.22]
16.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Clinical signs of severe blood
loss
1 1648 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.05, 1.17]
17.1 Higher-income setting 1 1648 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.05, 1.17]
17.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Therapeutic uterotonics during
third stage and/or within 24
hours
1 1648 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.26, 0.77]
18.1 Higher-income setting 1 1648 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.26, 0.77]
18.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Mean length of third stage 1 1648 Mean Difference (IV, Random, 95% CI) -10.0 [-10.24, -9.76]
19.1 Higher-income setting 1 1648 Mean Difference (IV, Random, 95% CI) -10.0 [-10.24, -9.76]
19.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20 Manual removal of placenta as
defined by study authors
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Postnatal diastolic blood
pressure > 90 mmHg between
birth of baby and discharge
from the labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22 Postnatal vomiting between
birth of baby and discharge
from the labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23 Any analgesia between birth of
the baby and discharge from
labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24 Women’s assessment of pain
during third stage as reported
by study authors
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25 Secondary blood loss/any
vaginal bleeding needing
treatment (after 24 hours and
up to 6 weeks)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26 Amount of lochia either
estimated or measured after 24
hours and up to discharge from
hospital
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
27 Surgical evacuation of retained
products of conception
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 Afterpains - abdominal pain
associated with the contracting
uterus in the postpartum
period
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29 Apgar score < 7 at 5 minutes 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30 Birthweight 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
30.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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30.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
31 Neonatal encephalopathy
assessed using Sarnat staging
(Sarnat 1976; Table 1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32 Neonatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33 Intraventricular haemorrhage
- Papille grade III/IV - (for
infants born before 34 weeks’
gestation only)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34 Number of infants who
received a red blood cell
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35 Infant Hb level at 24 to 72
hours
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36 Infant Hb level at 3-6 months 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37 Infant iron indices (ferritin) at
3 to 6 months
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38 Exclusive breastfeeding at
discharge from hospital
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 Neurodevelopmental, cognitive
or developmental outcomes
assessed after age 18 months
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40 Return to hospital as in- or
outpatient because of bleeding
(not pre-specified)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
41 Postnatal maternal mean Hb
(outcome not pre-specified)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
41.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
41.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 10. Active versus mixed management (no routine uterotonic, early cord clamping, no controlled
cord traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
1 1621 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.48, 1.24]
1.1 Higher-income setting 1 1621 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.48, 1.24]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
1 1631 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.75, 2.01]
4.1 Higher-income setting 1 1631 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.75, 2.01]
4.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Severe primary PPH after
placental delivery and up to 24
hours (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Severe primary PPH at time
of birth and up to 24 hours
(clinically estimated or
measured blood loss ≥1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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9.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Primary blood loss ≥ 500
mL at time of birth (clinically
estimated or measured)
1 1621 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.40, 0.66]
10.1 Higher-income setting 1 1621 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.40, 0.66]
10.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Primary blood loss ≥ 500
mL after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Primary blood loss ≥ 500 mL
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Mean maternal blood loss
(mL) at time of birth (clinically
estimated or measured)
1 1621 Mean Difference (IV, Random, 95% CI) -94.0 [-126.57, -61.
43]
13.1 Higher-income setting 1 1621 Mean Difference (IV, Random, 95% CI) -94.0 [-126.57, -61.
43]
13.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Mean maternal blood loss
(mL) after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Mean maternal blood loss (mL)
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Maternal blood transfusion 1 1631 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.43, 1.46]
16.1 Higher-income setting 1 1631 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.43, 1.46]
16.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Clinical signs of severe blood
loss
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Therapeutic uterotonics during
third stage and/or within 24
hours
1 1631 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.33, 0.48]
18.1 Higher-income setting 1 1631 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.33, 0.48]
18.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Mean length of third stage 1 1631 Mean Difference (IV, Random, 95% CI) -1.60 [-3.08, -0.12]
19.1 Higher-income setting 1 1631 Mean Difference (IV, Random, 95% CI) -1.60 [-3.08, -0.12]
19.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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20 Manual removal of placenta as
defined by study authors
1 1631 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.71, 2.21]
20.1 Higher-income setting 1 1631 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.71, 2.21]
20.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Postnatal diastolic blood
pressure > 90 mmHg between
birth of baby and discharge
from the labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22 Postnatal vomiting between
birth of baby and discharge
from the labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23 Any analgesia between birth of
the baby and discharge from
labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24 Women’s assessment of pain
during third stage as reported
by study authors
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25 Secondary blood loss/any
vaginal bleeding needing
treatment (after 24 hours and
up to 6 weeks)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26 Amount of lochia either
estimated or measured after 24
hours and up to discharge from
hospital
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
27 Surgical evacuation of retained
products of conception
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 Not prespecified: afterpains at
2 hours after birth (id 20458)
1 1425 Mean Difference (IV, Random, 95% CI) -2.80 [-4.62, -0.98]
28.1 Higher-income setting 1 1425 Mean Difference (IV, Random, 95% CI) -2.80 [-4.62, -0.98]
28.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
29 Not pre-specified: afterpains
the day after birth (id 20458)
1 1336 Mean Difference (IV, Random, 95% CI) -3.0 [-5.33, -0.67]
29.1 Higher-income setting 1 1336 Mean Difference (IV, Random, 95% CI) -3.0 [-5.33, -0.67]
29.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
30 Apgar score < 7 at 5 minutes 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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31 Birthweight 1 1631 Mean Difference (IV, Random, 95% CI) 15.0 [-28.88, 58.88]
31.1 Higher-income setting 1 1631 Mean Difference (IV, Random, 95% CI) 15.0 [-28.88, 58.88]
31.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
32 Neonatal encephalopathy
assessed using Sarnat staging
(Sarnat 1976; Table 1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33 Neonatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34 Intraventricular haemorrhage
- Papille grade III/IV - (for
infants born before 34 weeks’
gestation only)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35 Number of infants who
received a red blood cell
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
36 Infant Hb level at 24 to 72
hours
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37 Infant Hb level at 3-6 months 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
38 Infant iron indices (ferritin) at
3 to 6 months.
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 Exclusive breastfeeding at
discharge from hospital
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40 Neurodevelopmental, cognitive
or developmental outcomes
assessed after age 18 months
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
41 Return to hospital as in- or
outpatient because of bleeding
(not pre-specified)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
42 Postnatal maternal mean Hb
(outcome not pre-specified)
1 1631 Mean Difference (IV, Random, 95% CI) 0.28 [0.14, 0.42]
42.1 Higher-income setting 1 1631 Mean Difference (IV, Random, 95% CI) 0.28 [0.14, 0.42]
42.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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43 Severe primary PPH after
placental delivery and up to 2
hours (clinically estimated or
measured blood loss ≥ 1000
mL) - not pre-specified
1 1621 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.39, 0.74]
43.1 Higher-income setting 1 1621 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.39, 0.74]
43.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
44 Severe primary PPH at
time of birth and up to 2
hours (clinically estimated or
measured blood loss ≥1000
mL) - not pre-specified
1 1621 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.47, 0.78]
44.1 Higher-income setting 1 1621 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.47, 0.78]
44.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
45 Mean blood loss (mL)
(clinically estimated or
measured at birth and up to 2
hours (not pre-specified)
1 1621 Mean Difference (IV, Random, 95% CI) -49.0 [-75.52, -22.
48]
45.1 Higher-income setting 1 1621 Mean Difference (IV, Random, 95% CI) -49.0 [-75.52, -22.
48]
45.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Active versus mixed management (no routine uterotonic, early cord clamping, controlled cord
traction)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe primary PPH at time of
birth (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Very severe primary PPH at time
of birth (clinically estimated or
measured blood loss ≥ 2500
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Maternal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Maternal Hb < 9 g/dL at 24-72
hr
1 130 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.34, 1.90]
4.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Lower-income setting 1 130 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.34, 1.90]
5 Admission to neonatal special/
intensive care
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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5.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Neonatal jaundice requiring
phototherapy or exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal polycythaemia treated
with dilutional exchange
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Severe primary PPH after
placental delivery and up to 24
hours (clinically estimated or
measured blood loss ≥ 1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Severe primary PPH at time
of birth and up to 24 hours
(clinically estimated or
measured blood loss ≥1000
mL)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Primary blood loss ≥ 500
mL at time of birth (clinically
estimated or measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Primary blood loss ≥ 500
mL after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Primary blood loss ≥ 500 mL
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
13 Mean maternal blood loss
(mL) at time of birth (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Mean maternal blood loss
(mL) after delivery of placenta
and up to 24 hours (clinically
estimated or measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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14.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Mean maternal blood loss (mL)
at time of birth and up to 24
hours (clinically estimated or
measured)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Maternal blood transfusion 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17 Clinical signs of severe blood
loss
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18 Therapeutic uterotonics during
third stage and/or within 24
hours
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19 Mean length of third stage 1 130 Mean Difference (IV, Random, 95% CI) -8.12 [-9.72, -6.52]
19.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Lower-income setting 1 130 Mean Difference (IV, Random, 95% CI) -8.12 [-9.72, -6.52]
20 Manual removal of placenta as
defined by study authors
1 130 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.65]
20.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Lower-income setting 1 130 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.06, 15.65]
21 Postnatal diastolic blood
pressure > 90 mmHg between
birth of baby and discharge
from the labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22 Postnatal vomiting between
birth of baby and discharge
from the labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23 Any analgesia between birth of
the baby and discharge from
labour ward
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
23.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24 Women’s assessment of pain
during third stage as reported
by study authors
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
24.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25 Secondary blood loss/any
vaginal bleeding needing
treatment (after 24 hours and
up to 6 weeks)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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25.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
25.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
26 Amount of lochia either
estimated or measured after 24
hours and up to discharge from
hospital
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
27 Surgical evacuation of retained
products of conception
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28 Afterpains - abdominal pain
associated with the contracting
uterus in the postpartum
period
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29 Apgar score < 7 at 5 minutes 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
30 Birthweight 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
30.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
30.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
31 Neonatal encephalopathy
assessed using Sarnat staging
(Sarnat 1976; Table 1)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32 Neonatal mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33 Intraventricular haemorrhage
- Papille grade III/IV - (for
infants born before 34 weeks’
gestation only)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34 Number of infants who
received a red blood cell
transfusion
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
35 Infant Hb level at 24 to 72
hours
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36 Infant Hb level at 3-6 months 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
36.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37 Infant iron indices (ferritin) at
3 to 6 months.
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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37.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38 Exclusive breastfeeding at
discharge from hospital
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
38.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39 Neurodevelopmental, cognitive
or developmental outcomes
assessed after age 18 months
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40 Return to hospital as in- or
outpatient because of bleeding
(not pre-specified)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.1 Higher-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.2 Lower-income setting 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
41 Postnatal maternal mean Hb
(outcome not pre-specified)
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
41.1 Higher-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
41.2 Lower-income setting 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 1 Severe primary postpartum haemorrhage (PPH) at time of birth (clinically estimated or
measured blood loss ≥ 1000 mL).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 1 Severe primary postpartum haemorrhage (PPH) at time of birth (clinically estimated or measured blood loss≥ 1000 mL)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 1/705 11/724 15.3 % 0.09 [ 0.01, 0.72 ]
Prendiville 1988 7/846 26/849 40.2 % 0.27 [ 0.12, 0.62 ]
Rogers 1998 13/748 20/764 44.5 % 0.66 [ 0.33, 1.32 ]
Subtotal (95% CI) 2299 2337 100.0 % 0.34 [ 0.14, 0.87 ]
Total events: 21 (Active management), 57 (Expectant management)
Heterogeneity: Tau2 = 0.38; Chi2 = 5.01, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2299 2337 100.0 % 0.34 [ 0.14, 0.87 ]
Total events: 21 (Active management), 57 (Expectant management)
Heterogeneity: Tau2 = 0.38; Chi2 = 5.01, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours active Favours expectant
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Analysis 1.4. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 4 Maternal Hb < 9 g/dL 24-72 hours postpartum.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 4 Maternal Hb < 9 g/dL 24-72 hours postpartum
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Prendiville 1988 27/685 51/694 94.5 % 0.54 [ 0.34, 0.84 ]
Thilaganathan 1993 1/103 5/90 5.5 % 0.17 [ 0.02, 1.47 ]
Subtotal (95% CI) 788 784 100.0 % 0.50 [ 0.30, 0.83 ]
Total events: 28 (Active management), 56 (Expectant management)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 2.67 (P = 0.0076)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 788 784 100.0 % 0.50 [ 0.30, 0.83 ]
Total events: 28 (Active management), 56 (Expectant management)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 2.67 (P = 0.0076)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 5 Admission to neonatal special/intensive care.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 5 Admission to neonatal special/intensive care
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Prendiville 1988 48/846 64/849 74.1 % 0.75 [ 0.52, 1.08 ]
Rogers 1998 20/748 20/764 25.9 % 1.02 [ 0.55, 1.88 ]
Subtotal (95% CI) 1594 1613 100.0 % 0.81 [ 0.60, 1.11 ]
Total events: 68 (Active management), 84 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1594 1613 100.0 % 0.81 [ 0.60, 1.11 ]
Total events: 68 (Active management), 84 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 6 Neonatal jaundice requiring phototherapy or exchange transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 6 Neonatal jaundice requiring phototherapy or exchange transfusion
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Prendiville 1988 39/846 53/849 54.0 % 0.74 [ 0.49, 1.10 ]
Rogers 1998 32/716 25/731 46.0 % 1.31 [ 0.78, 2.18 ]
Subtotal (95% CI) 1562 1580 100.0 % 0.96 [ 0.55, 1.68 ]
Total events: 71 (Active management), 78 (Expectant management)
Heterogeneity: Tau2 = 0.11; Chi2 = 2.94, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1562 1580 100.0 % 0.96 [ 0.55, 1.68 ]
Total events: 71 (Active management), 78 (Expectant management)
Heterogeneity: Tau2 = 0.11; Chi2 = 2.94, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 10 Primary blood loss ≥ 500 mL at time of birth (clinically estimated or measured).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 10 Primary blood loss≥ 500 mL at time of birth (clinically estimated or measured)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 14/705 60/724 16.9 % 0.24 [ 0.14, 0.42 ]
Prendiville 1988 50/846 152/849 41.9 % 0.33 [ 0.24, 0.45 ]
Rogers 1998 51/748 126/764 41.2 % 0.41 [ 0.30, 0.56 ]
Subtotal (95% CI) 2299 2337 100.0 % 0.34 [ 0.27, 0.44 ]
Total events: 115 (Active management), 338 (Expectant management)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.95, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 8.14 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2299 2337 100.0 % 0.34 [ 0.27, 0.44 ]
Total events: 115 (Active management), 338 (Expectant management)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.95, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 8.14 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours active Favours expectant
94Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.13. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 13 Mean maternal blood loss (mL) at time of birth (clinically estimated or measured).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 13 Mean maternal blood loss (mL) at time of birth (clinically estimated or measured)
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Begley 1990 705 148.9 (127.1) 724 234.8 (223.9) 60.3 % -85.90 [ -104.72, -67.08 ]
Rogers 1998 748 268.5 (246.1) 764 336.5 (243.2) 39.7 % -68.00 [ -92.67, -43.33 ]
Subtotal (95% CI) 1453 1488 100.0 % -78.80 [ -95.96, -61.64 ]
Heterogeneity: Tau2 = 34.93; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 9.00 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % -78.80 [ -95.96, -61.64 ]
Heterogeneity: Tau2 = 34.93; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 9.00 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 16 Maternal blood transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 16 Maternal blood transfusion
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 1/705 3/724 4.2 % 0.34 [ 0.04, 3.28 ]
Prendiville 1988 18/846 48/849 75.0 % 0.38 [ 0.22, 0.64 ]
Rogers 1998 4/748 20/764 18.7 % 0.20 [ 0.07, 0.59 ]
Thilaganathan 1993 1/103 0/90 2.1 % 2.63 [ 0.11, 63.64 ]
Subtotal (95% CI) 2402 2427 100.0 % 0.35 [ 0.22, 0.55 ]
Total events: 24 (Active management), 71 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.58, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.47 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2402 2427 100.0 % 0.35 [ 0.22, 0.55 ]
Total events: 24 (Active management), 71 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.58, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 18 Therapeutic uterotonics during third stage and/or within 24 hours.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 18 Therapeutic uterotonics during third stage and/or within 24 hours
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 14/705 93/724 14.8 % 0.15 [ 0.09, 0.27 ]
Prendiville 1988 54/846 252/849 58.3 % 0.22 [ 0.16, 0.28 ]
Rogers 1998 24/748 161/764 25.9 % 0.15 [ 0.10, 0.23 ]
Thilaganathan 1993 1/103 7/90 1.0 % 0.12 [ 0.02, 1.00 ]
Subtotal (95% CI) 2402 2427 100.0 % 0.19 [ 0.15, 0.23 ]
Total events: 93 (Active management), 513 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.53, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 15.52 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2402 2427 100.0 % 0.19 [ 0.15, 0.23 ]
Total events: 93 (Active management), 513 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.53, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 15.52 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 19 Mean length of third stage.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 19 Mean length of third stage
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min] N Mean(SD)[min] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Begley 1990 705 11.26 (19.62) 724 11.56 (8.41) 100.0 % -0.30 [ -1.87, 1.27 ]
Subtotal (95% CI) 705 724 100.0 % -0.30 [ -1.87, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 705 724 100.0 % -0.30 [ -1.87, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 20 Manual removal of placenta as defined by study authors.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 20 Manual removal of placenta as defined by study authors
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 19/705 1/724 18.1 % 19.51 [ 2.62, 145.36 ]
Prendiville 1988 16/846 22/849 36.7 % 0.73 [ 0.39, 1.38 ]
Rogers 1998 15/748 13/764 35.4 % 1.18 [ 0.56, 2.46 ]
Thilaganathan 1993 1/103 0/90 9.8 % 2.63 [ 0.11, 63.64 ]
Subtotal (95% CI) 2402 2427 100.0 % 1.78 [ 0.57, 5.56 ]
Total events: 51 (Active management), 36 (Expectant management)
Heterogeneity: Tau2 = 0.82; Chi2 = 11.17, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.99 (P = 0.32)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2402 2427 100.0 % 1.78 [ 0.57, 5.56 ]
Total events: 51 (Active management), 36 (Expectant management)
Heterogeneity: Tau2 = 0.82; Chi2 = 11.17, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 21 Postnatal diastolic blood pressure > 90 mmHg between birth of baby and discharge from the
labour ward.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 21 Postnatal diastolic blood pressure > 90 mmHg between birth of baby and discharge from the labour ward
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 35/705 5/724 40.7 % 7.19 [ 2.83, 18.24 ]
Prendiville 1988 17/846 8/849 44.3 % 2.13 [ 0.93, 4.91 ]
Rogers 1998 6/748 1/764 14.9 % 6.13 [ 0.74, 50.78 ]
Subtotal (95% CI) 2299 2337 100.0 % 4.10 [ 1.63, 10.30 ]
Total events: 58 (Active management), 14 (Expectant management)
Heterogeneity: Tau2 = 0.32; Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 3.00 (P = 0.0027)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2299 2337 100.0 % 4.10 [ 1.63, 10.30 ]
Total events: 58 (Active management), 14 (Expectant management)
Heterogeneity: Tau2 = 0.32; Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 22 Postnatal vomiting between birth of baby and discharge from the labour ward.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 22 Postnatal vomiting between birth of baby and discharge from the labour ward
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 12/705 0/724 4.2 % 25.67 [ 1.52, 432.78 ]
Prendiville 1988 102/846 55/849 54.3 % 1.86 [ 1.36, 2.55 ]
Rogers 1998 47/748 17/764 41.6 % 2.82 [ 1.64, 4.87 ]
Subtotal (95% CI) 2299 2337 100.0 % 2.47 [ 1.36, 4.48 ]
Total events: 161 (Active management), 72 (Expectant management)
Heterogeneity: Tau2 = 0.14; Chi2 = 4.92, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 2.97 (P = 0.0029)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2299 2337 100.0 % 2.47 [ 1.36, 4.48 ]
Total events: 161 (Active management), 72 (Expectant management)
Heterogeneity: Tau2 = 0.14; Chi2 = 4.92, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 23 Any analgesia between birth of the baby and discharge from labour ward.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 23 Any analgesia between birth of the baby and discharge from labour ward
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 32/705 13/724 100.0 % 2.53 [ 1.34, 4.78 ]
Subtotal (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 25 Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and up to 6 weeks).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 25 Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and up to 6 weeks)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 35/705 12/724 33.7 % 3.00 [ 1.57, 5.72 ]
Prendiville 1988 6/846 18/849 29.5 % 0.33 [ 0.13, 0.84 ]
Rogers 1998 48/748 43/764 36.9 % 1.14 [ 0.77, 1.70 ]
Subtotal (95% CI) 2299 2337 100.0 % 1.10 [ 0.40, 2.99 ]
Total events: 89 (Active management), 73 (Expectant management)
Heterogeneity: Tau2 = 0.67; Chi2 = 15.11, df = 2 (P = 0.00052); I2 =87%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2299 2337 100.0 % 1.10 [ 0.40, 2.99 ]
Total events: 89 (Active management), 73 (Expectant management)
Heterogeneity: Tau2 = 0.67; Chi2 = 15.11, df = 2 (P = 0.00052); I2 =87%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 1.27. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 27 Surgical evacuation of retained products of conception.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 27 Surgical evacuation of retained products of conception
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 2/705 8/724 20.8 % 0.26 [ 0.05, 1.20 ]
Prendiville 1988 11/846 16/849 44.8 % 0.69 [ 0.32, 1.48 ]
Rogers 1998 9/748 6/764 34.4 % 1.53 [ 0.55, 4.28 ]
Subtotal (95% CI) 2299 2337 100.0 % 0.74 [ 0.32, 1.71 ]
Total events: 22 (Active management), 30 (Expectant management)
Heterogeneity: Tau2 = 0.26; Chi2 = 3.75, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2299 2337 100.0 % 0.74 [ 0.32, 1.71 ]
Total events: 22 (Active management), 30 (Expectant management)
Heterogeneity: Tau2 = 0.26; Chi2 = 3.75, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 28 Afterpains - abdominal pain associated with the contracting uterus in the postpartum period.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 28 Afterpains - abdominal pain associated with the contracting uterus in the postpartum period
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 32/705 13/724 100.0 % 2.53 [ 1.34, 4.78 ]
Subtotal (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 29 Apgar score < 7 at 5 minutes.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 29 Apgar score < 7 at 5 minutes
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Prendiville 1988 8/846 8/849 100.0 % 1.00 [ 0.38, 2.66 ]
Subtotal (95% CI) 846 849 100.0 % 1.00 [ 0.38, 2.66 ]
Total events: 8 (Active management), 8 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 846 849 100.0 % 1.00 [ 0.38, 2.66 ]
Total events: 8 (Active management), 8 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 30 Birthweight.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 30 Birthweight
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g] N Mean(SD)[g] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Prendiville 1988 846 3337 (451) 849 3422 (444) 55.0 % -85.00 [ -127.61, -42.39 ]
Rogers 1998 748 3454 (465) 764 3521 (470) 45.0 % -67.00 [ -114.13, -19.87 ]
Subtotal (95% CI) 1594 1613 100.0 % -76.90 [ -108.51, -45.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.77 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1594 1613 100.0 % -76.90 [ -108.51, -45.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.77 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours expectant Favours active
107Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.38. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 38 Exclusive breastfeeding at discharge from hospital.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 38 Exclusive breastfeeding at discharge from hospital
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Prendiville 1988 637/846 632/849 100.0 % 1.01 [ 0.96, 1.07 ]
Subtotal (95% CI) 846 849 100.0 % 1.01 [ 0.96, 1.07 ]
Total events: 637 (Active management), 632 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 846 849 100.0 % 1.01 [ 0.96, 1.07 ]
Total events: 637 (Active management), 632 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.40. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 40 Return to hospital as in- or outpatient because of bleeding (not pre-specified).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 40 Return to hospital as in- or outpatient because of bleeding (not pre-specified)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 29/705 14/724 73.1 % 2.13 [ 1.13, 3.99 ]
Rogers 1998 12/748 5/764 26.9 % 2.45 [ 0.87, 6.92 ]
Subtotal (95% CI) 1453 1488 100.0 % 2.21 [ 1.29, 3.79 ]
Total events: 41 (Active management), 19 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 2.21 [ 1.29, 3.79 ]
Total events: 41 (Active management), 19 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 1.41. Comparison 1 Active versus expectant management of 3rd stage of labour (all women),
Outcome 41 Postnatal maternal mean Hb (outcome not pre-specified).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 1 Active versus expectant management of 3rd stage of labour (all women)
Outcome: 41 Postnatal maternal mean Hb (outcome not pre-specified)
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Begley 1990 618 12.59 (1.13) 645 12.09 (1.23) 40.3 % 0.50 [ 0.37, 0.63 ]
Prendiville 1988 685 11.7 (2.2) 694 11.1 (1.4) 18.0 % 0.60 [ 0.41, 0.79 ]
Rogers 1998 702 11.2 (1.06) 718 10.7 (1.38) 41.8 % 0.50 [ 0.37, 0.63 ]
Subtotal (95% CI) 2005 2057 100.0 % 0.52 [ 0.44, 0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 12.29 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2005 2057 100.0 % 0.52 [ 0.44, 0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 12.29 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low risk),
Outcome 1 Severe primary PPH at time of birth (clinically estimated or measured blood loss ≥ 1000 mL).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 1 Severe primary PPH at time of birth (clinically estimated or measured blood loss≥ 1000 mL)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 1/705 11/724 38.3 % 0.09 [ 0.01, 0.72 ]
Rogers 1998 13/748 20/764 61.7 % 0.66 [ 0.33, 1.32 ]
Subtotal (95% CI) 1453 1488 100.0 % 0.31 [ 0.05, 2.17 ]
Total events: 14 (Active management), 31 (Expectant management)
Heterogeneity: Tau2 = 1.46; Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 0.31 [ 0.05, 2.17 ]
Total events: 14 (Active management), 31 (Expectant management)
Heterogeneity: Tau2 = 1.46; Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 4 Maternal Hb < 9 g/dL at 24-72 hr.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 4 Maternal Hb < 9 g/dL at 24-72 hr
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Thilaganathan 1993 1/103 5/90 100.0 % 0.17 [ 0.02, 1.47 ]
Subtotal (95% CI) 103 90 100.0 % 0.17 [ 0.02, 1.47 ]
Total events: 1 (Active management), 5 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 103 90 100.0 % 0.17 [ 0.02, 1.47 ]
Total events: 1 (Active management), 5 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 5 Admission to neonatal special/intensive care.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 5 Admission to neonatal special/intensive care
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Rogers 1998 20/748 20/764 100.0 % 1.02 [ 0.55, 1.88 ]
Subtotal (95% CI) 748 764 100.0 % 1.02 [ 0.55, 1.88 ]
Total events: 20 (Active management), 20 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 748 764 100.0 % 1.02 [ 0.55, 1.88 ]
Total events: 20 (Active management), 20 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 6 Neonatal jaundice requiring phototherapy or exchange transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 6 Neonatal jaundice requiring phototherapy or exchange transfusion
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Rogers 1998 32/716 25/731 100.0 % 1.31 [ 0.78, 2.18 ]
Subtotal (95% CI) 716 731 100.0 % 1.31 [ 0.78, 2.18 ]
Total events: 32 (Active management), 25 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 716 731 100.0 % 1.31 [ 0.78, 2.18 ]
Total events: 32 (Active management), 25 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 10 Primary blood loss ≥ 500 mL at time of birth (clinically estimated or measured).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 10 Primary blood loss≥ 500 mL at time of birth (clinically estimated or measured)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 14/705 60/724 39.9 % 0.24 [ 0.14, 0.42 ]
Rogers 1998 51/748 126/764 60.1 % 0.41 [ 0.30, 0.56 ]
Subtotal (95% CI) 1453 1488 100.0 % 0.33 [ 0.20, 0.56 ]
Total events: 65 (Active management), 186 (Expectant management)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.73, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 4.10 (P = 0.000041)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 0.33 [ 0.20, 0.56 ]
Total events: 65 (Active management), 186 (Expectant management)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.73, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 4.10 (P = 0.000041)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 13 Mean maternal blood loss (mL at the time of birth, clinically estimated or measured.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 13 Mean maternal blood loss (mL at the time of birth, clinically estimated or measured
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Begley 1990 705 148.9 (127.1) 724 234.8 (223.9) 60.3 % -85.90 [ -104.72, -67.08 ]
Rogers 1998 748 268.5 (246.1) 764 336.5 (243.2) 39.7 % -68.00 [ -92.67, -43.33 ]
Subtotal (95% CI) 1453 1488 100.0 % -78.80 [ -95.96, -61.64 ]
Heterogeneity: Tau2 = 34.93; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 9.00 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % -78.80 [ -95.96, -61.64 ]
Heterogeneity: Tau2 = 34.93; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 9.00 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 16 Maternal blood transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 16 Maternal blood transfusion
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 1/705 3/724 20.5 % 0.34 [ 0.04, 3.28 ]
Rogers 1998 4/748 20/764 68.7 % 0.20 [ 0.07, 0.59 ]
Thilaganathan 1993 1/103 0/90 10.8 % 2.63 [ 0.11, 63.64 ]
Subtotal (95% CI) 1556 1578 100.0 % 0.30 [ 0.10, 0.88 ]
Total events: 6 (Active management), 23 (Expectant management)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.26, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1556 1578 100.0 % 0.30 [ 0.10, 0.88 ]
Total events: 6 (Active management), 23 (Expectant management)
Heterogeneity: Tau2 = 0.14; Chi2 = 2.26, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 18 Therapeutic uterotonics during third stage and/or within 24 hours.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 18 Therapeutic uterotonics during third stage and/or within 24 hours
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 14/705 93/724 35.4 % 0.15 [ 0.09, 0.27 ]
Rogers 1998 24/748 161/764 62.1 % 0.15 [ 0.10, 0.23 ]
Thilaganathan 1993 1/103 7/90 2.5 % 0.12 [ 0.02, 1.00 ]
Subtotal (95% CI) 1556 1578 100.0 % 0.15 [ 0.11, 0.21 ]
Total events: 39 (Active management), 261 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 11.23 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1556 1578 100.0 % 0.15 [ 0.11, 0.21 ]
Total events: 39 (Active management), 261 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 11.23 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 19 Mean length of third stage.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 19 Mean length of third stage
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min] N Mean(SD)[min] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Begley 1990 705 11.26 (19.62) 724 11.56 (8.41) 100.0 % -0.30 [ -1.87, 1.27 ]
Subtotal (95% CI) 705 724 100.0 % -0.30 [ -1.87, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 705 724 100.0 % -0.30 [ -1.87, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 20 Manual removal of placenta as defined by study authors.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 20 Manual removal of placenta as defined by study authors
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 19/705 1/724 33.0 % 19.51 [ 2.62, 145.36 ]
Rogers 1998 15/748 13/764 44.0 % 1.18 [ 0.56, 2.46 ]
Thilaganathan 1993 1/103 0/90 22.9 % 2.63 [ 0.11, 63.64 ]
Subtotal (95% CI) 1556 1578 100.0 % 3.58 [ 0.42, 30.61 ]
Total events: 35 (Active management), 14 (Expectant management)
Heterogeneity: Tau2 = 2.58; Chi2 = 8.01, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.16 (P = 0.24)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1556 1578 100.0 % 3.58 [ 0.42, 30.61 ]
Total events: 35 (Active management), 14 (Expectant management)
Heterogeneity: Tau2 = 2.58; Chi2 = 8.01, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.16 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 21 Postnatal diastolic blood pressure > 90 mmHg between birth of baby and discharge from
the labour ward.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 21 Postnatal diastolic blood pressure > 90 mmHg between birth of baby and discharge from the labour ward
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 35/705 5/724 83.8 % 7.19 [ 2.83, 18.24 ]
Rogers 1998 6/748 1/764 16.2 % 6.13 [ 0.74, 50.78 ]
Subtotal (95% CI) 1453 1488 100.0 % 7.00 [ 2.99, 16.43 ]
Total events: 41 (Active management), 6 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 7.00 [ 2.99, 16.43 ]
Total events: 41 (Active management), 6 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 22 Postnatal vomiting between birth of baby and discharge from the labour ward..
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 22 Postnatal vomiting between birth of baby and discharge from the labour ward.
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 12/705 0/724 31.3 % 25.67 [ 1.52, 432.78 ]
Rogers 1998 47/748 17/764 68.7 % 2.82 [ 1.64, 4.87 ]
Subtotal (95% CI) 1453 1488 100.0 % 5.63 [ 0.69, 46.08 ]
Total events: 59 (Active management), 17 (Expectant management)
Heterogeneity: Tau2 = 1.60; Chi2 = 2.48, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 1.61 (P = 0.11)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 5.63 [ 0.69, 46.08 ]
Total events: 59 (Active management), 17 (Expectant management)
Heterogeneity: Tau2 = 1.60; Chi2 = 2.48, df = 1 (P = 0.12); I2 =60%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.23. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 23 Any analgesia between birth of the baby and up to discharge from labour ward.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 23 Any analgesia between birth of the baby and up to discharge from labour ward
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 32/705 13/724 100.0 % 2.53 [ 1.34, 4.78 ]
Subtotal (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
Test for subgroup differences: Not applicable
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Analysis 2.25. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 25 Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and up to 6
weeks).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 25 Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and up to 6 weeks)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 35/705 12/724 46.4 % 3.00 [ 1.57, 5.72 ]
Rogers 1998 48/748 43/764 53.6 % 1.14 [ 0.77, 1.70 ]
Subtotal (95% CI) 1453 1488 100.0 % 1.78 [ 0.69, 4.60 ]
Total events: 83 (Active management), 55 (Expectant management)
Heterogeneity: Tau2 = 0.39; Chi2 = 6.24, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 1.78 [ 0.69, 4.60 ]
Total events: 83 (Active management), 55 (Expectant management)
Heterogeneity: Tau2 = 0.39; Chi2 = 6.24, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 2.27. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 27 Surgical evacuation of retained products of conception.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 27 Surgical evacuation of retained products of conception
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 2/705 8/724 44.6 % 0.26 [ 0.05, 1.20 ]
Rogers 1998 9/748 6/764 55.4 % 1.53 [ 0.55, 4.28 ]
Subtotal (95% CI) 1453 1488 100.0 % 0.69 [ 0.12, 3.98 ]
Total events: 11 (Active management), 14 (Expectant management)
Heterogeneity: Tau2 = 1.17; Chi2 = 3.61, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 0.69 [ 0.12, 3.98 ]
Total events: 11 (Active management), 14 (Expectant management)
Heterogeneity: Tau2 = 1.17; Chi2 = 3.61, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 2.28. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 28 Afterpains - abdominal pain associated with the contracting uterus in the postpartum
period.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 28 Afterpains - abdominal pain associated with the contracting uterus in the postpartum period
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 32/705 13/724 100.0 % 2.53 [ 1.34, 4.78 ]
Subtotal (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 705 724 100.0 % 2.53 [ 1.34, 4.78 ]
Total events: 32 (Active management), 13 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
Test for subgroup differences: Not applicable
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Analysis 2.30. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 30 Birthweight.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 30 Birthweight
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g] N Mean(SD)[g] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Rogers 1998 748 3454 (465) 764 3521 (470) 100.0 % -67.00 [ -114.13, -19.87 ]
Subtotal (95% CI) 748 764 100.0 % -67.00 [ -114.13, -19.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0053)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 748 764 100.0 % -67.00 [ -114.13, -19.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Not applicable
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Analysis 2.40. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 40 Return to hospital as in- or outpatient because of bleeding (not pre-specified).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 40 Return to hospital as in- or outpatient because of bleeding (not pre-specified)
Study or subgroup Active management
Expectant
manage-
ment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Begley 1990 29/705 14/724 73.1 % 2.13 [ 1.13, 3.99 ]
Rogers 1998 12/748 5/764 26.9 % 2.45 [ 0.87, 6.92 ]
Subtotal (95% CI) 1453 1488 100.0 % 2.21 [ 1.29, 3.79 ]
Total events: 41 (Active management), 19 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Expectant management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1453 1488 100.0 % 2.21 [ 1.29, 3.79 ]
Total events: 41 (Active management), 19 (Expectant management)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 2.41. Comparison 2 Active versus expectant management of 3rd stage of labour (women at low
risk), Outcome 41 Postnatal maternal mean Hb (outcome not pre-specified).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 2 Active versus expectant management of 3rd stage of labour (women at low risk)
Outcome: 41 Postnatal maternal mean Hb (outcome not pre-specified)
Study or subgroup Active management
Expectant
manage-
ment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Begley 1990 618 12.59 (1.13) 645 12.09 (1.23) 49.1 % 0.50 [ 0.37, 0.63 ]
Rogers 1998 702 11.2 (1.06) 718 10.7 (1.38) 50.9 % 0.50 [ 0.37, 0.63 ]
Subtotal (95% CI) 1320 1363 100.0 % 0.50 [ 0.41, 0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 10.74 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1320 1363 100.0 % 0.50 [ 0.41, 0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 10.74 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.8. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 8 Maternal blood transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 8 Maternal blood transfusion
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Yildirim 2016 3/327 4/327 100.0 % 0.75 [ 0.17, 3.32 ]
Subtotal (95% CI) 327 327 100.0 % 0.75 [ 0.17, 3.32 ]
Total events: 3 (Active management), 4 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % 0.75 [ 0.17, 3.32 ]
Total events: 3 (Active management), 4 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 9 Therapeutic uterotonics during third stage and/or
within 24 hours.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 9 Therapeutic uterotonics during third stage and/or within 24 hours
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Yildirim 2016 27/327 30/327 100.0 % 0.90 [ 0.55, 1.48 ]
Subtotal (95% CI) 327 327 100.0 % 0.90 [ 0.55, 1.48 ]
Total events: 27 (Active management), 30 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % 0.90 [ 0.55, 1.48 ]
Total events: 27 (Active management), 30 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 10 Mean length of third stage.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 10 Mean length of third stage
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min] N Mean(SD)[min] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Yildirim 2016 327 4.11 (2.32) 327 9.26 (4.59) 100.0 % -5.15 [ -5.71, -4.59 ]
Subtotal (95% CI) 327 327 100.0 % -5.15 [ -5.71, -4.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 18.11 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % -5.15 [ -5.71, -4.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 18.11 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 11 Manual removal of placenta as defined by study
authors.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 11 Manual removal of placenta as defined by study authors
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Yildirim 2016 2/327 3/327 100.0 % 0.67 [ 0.11, 3.96 ]
Subtotal (95% CI) 327 327 100.0 % 0.67 [ 0.11, 3.96 ]
Total events: 2 (Active management), 3 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % 0.67 [ 0.11, 3.96 ]
Total events: 2 (Active management), 3 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 12 Surgical evacuation of retained products of
conception.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 12 Surgical evacuation of retained products of conception
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Yildirim 2016 3/327 0/327 100.0 % 7.00 [ 0.36, 134.98 ]
Subtotal (95% CI) 327 327 100.0 % 7.00 [ 0.36, 134.98 ]
Total events: 3 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % 7.00 [ 0.36, 134.98 ]
Total events: 3 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 13 Birthweight.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 13 Birthweight
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g] N Mean(SD)[g] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Yildirim 2016 327 3316 (258) 327 3248 (315) 100.0 % 68.00 [ 23.87, 112.13 ]
Subtotal (95% CI) 327 327 100.0 % 68.00 [ 23.87, 112.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % 68.00 [ 23.87, 112.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
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Analysis 5.14. Comparison 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed
cord clamping, no controlled cord traction), Outcome 14 Postnatal maternal mean Hb.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 5 Active versus mixed management of 3rd stage (delayed uterotonic, delayed cord clamping, no controlled cord traction)
Outcome: 14 Postnatal maternal mean Hb
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Yildirim 2016 327 10.78 (0.68) 327 10.09 (0.72) 100.0 % 0.69 [ 0.58, 0.80 ]
Subtotal (95% CI) 327 327 100.0 % 0.69 [ 0.58, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.60 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 327 327 100.0 % 0.69 [ 0.58, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Active versus mixed management (uterotonic after placental delivery,
immediate cord clamping and no controlled cord traction) , Outcome 1 Severe primary PPH at time of birth
(clinically estimated or measured blood loss ≥ 1000 mL).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping and no controlled cord traction)
Outcome: 1 Severe primary PPH at time of birth (clinically estimated or measured blood loss≥ 1000 mL)
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Khan 1997 6/827 26/821 100.0 % 0.23 [ 0.09, 0.55 ]
Subtotal (95% CI) 827 821 100.0 % 0.23 [ 0.09, 0.55 ]
Total events: 6 (Active management), 26 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 827 821 100.0 % 0.23 [ 0.09, 0.55 ]
Total events: 6 (Active management), 26 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 9.10. Comparison 9 Active versus mixed management (uterotonic after placental delivery,
immediate cord clamping and no controlled cord traction) , Outcome 10 Primary blood loss ≥ 500 mL at
time of birth (clinically estimated or measured).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping and no controlled cord traction)
Outcome: 10 Primary blood loss≥ 500 mL at time of birth (clinically estimated or measured)
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Khan 1997 48/827 90/821 100.0 % 0.53 [ 0.38, 0.74 ]
Subtotal (95% CI) 827 821 100.0 % 0.53 [ 0.38, 0.74 ]
Total events: 48 (Active management), 90 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00021)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 827 821 100.0 % 0.53 [ 0.38, 0.74 ]
Total events: 48 (Active management), 90 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.70 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 9.16. Comparison 9 Active versus mixed management (uterotonic after placental delivery,
immediate cord clamping and no controlled cord traction) , Outcome 16 Maternal blood transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping and no controlled cord traction)
Outcome: 16 Maternal blood transfusion
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Khan 1997 1/827 4/821 100.0 % 0.25 [ 0.03, 2.22 ]
Subtotal (95% CI) 827 821 100.0 % 0.25 [ 0.03, 2.22 ]
Total events: 1 (Active management), 4 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 827 821 100.0 % 0.25 [ 0.03, 2.22 ]
Total events: 1 (Active management), 4 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 9.17. Comparison 9 Active versus mixed management (uterotonic after placental delivery,
immediate cord clamping and no controlled cord traction) , Outcome 17 Clinical signs of severe blood loss.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping and no controlled cord traction)
Outcome: 17 Clinical signs of severe blood loss
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Khan 1997 2/827 8/821 100.0 % 0.25 [ 0.05, 1.17 ]
Subtotal (95% CI) 827 821 100.0 % 0.25 [ 0.05, 1.17 ]
Total events: 2 (Active management), 8 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 827 821 100.0 % 0.25 [ 0.05, 1.17 ]
Total events: 2 (Active management), 8 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 9.18. Comparison 9 Active versus mixed management (uterotonic after placental delivery,
immediate cord clamping and no controlled cord traction) , Outcome 18 Therapeutic uterotonics during
third stage and/or within 24 hours.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping and no controlled cord traction)
Outcome: 18 Therapeutic uterotonics during third stage and/or within 24 hours
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Khan 1997 19/827 42/821 100.0 % 0.45 [ 0.26, 0.77 ]
Subtotal (95% CI) 827 821 100.0 % 0.45 [ 0.26, 0.77 ]
Total events: 19 (Active management), 42 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 827 821 100.0 % 0.45 [ 0.26, 0.77 ]
Total events: 19 (Active management), 42 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 9.19. Comparison 9 Active versus mixed management (uterotonic after placental delivery,
immediate cord clamping and no controlled cord traction) , Outcome 19 Mean length of third stage.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 9 Active versus mixed management (uterotonic after placental delivery, immediate cord clamping and no controlled cord traction)
Outcome: 19 Mean length of third stage
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min] N Mean(SD)[min] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Khan 1997 827 4 (2.5) 821 14 (2.5) 100.0 % -10.00 [ -10.24, -9.76 ]
Subtotal (95% CI) 827 821 100.0 % -10.00 [ -10.24, -9.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 81.19 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 827 821 100.0 % -10.00 [ -10.24, -9.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 81.19 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 1 Severe primary PPH at time of birth (clinically estimated
or measured blood loss ≥ 1000 mL).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 1 Severe primary PPH at time of birth (clinically estimated or measured blood loss≥ 1000 mL)
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 29/804 38/817 100.0 % 0.78 [ 0.48, 1.24 ]
Subtotal (95% CI) 804 817 100.0 % 0.78 [ 0.48, 1.24 ]
Total events: 29 (Active management), 38 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 804 817 100.0 % 0.78 [ 0.48, 1.24 ]
Total events: 29 (Active management), 38 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 4 Maternal Hb < 9 g/dL at 24-72 hr.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 4 Maternal Hb < 9 g/dL at 24-72 hr
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 34/810 28/821 100.0 % 1.23 [ 0.75, 2.01 ]
Subtotal (95% CI) 810 821 100.0 % 1.23 [ 0.75, 2.01 ]
Total events: 34 (Active management), 28 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % 1.23 [ 0.75, 2.01 ]
Total events: 34 (Active management), 28 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 10.10. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 10 Primary blood loss ≥ 500 mL at time of birth (clinically
estimated or measured).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 10 Primary blood loss≥ 500 mL at time of birth (clinically estimated or measured)
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 79/804 156/817 100.0 % 0.51 [ 0.40, 0.66 ]
Subtotal (95% CI) 804 817 100.0 % 0.51 [ 0.40, 0.66 ]
Total events: 79 (Active management), 156 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 5.16 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 804 817 100.0 % 0.51 [ 0.40, 0.66 ]
Total events: 79 (Active management), 156 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 5.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.13. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 13 Mean maternal blood loss (mL) at time of birth (clinically
estimated or measured).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 13 Mean maternal blood loss (mL) at time of birth (clinically estimated or measured)
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 804 301 (306.5) 817 395 (360.8) 100.0 % -94.00 [ -126.57, -61.43 ]
Subtotal (95% CI) 804 817 100.0 % -94.00 [ -126.57, -61.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.66 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 804 817 100.0 % -94.00 [ -126.57, -61.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.16. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 16 Maternal blood transfusion.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 16 Maternal blood transfusion
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 18/810 23/821 100.0 % 0.79 [ 0.43, 1.46 ]
Subtotal (95% CI) 810 821 100.0 % 0.79 [ 0.43, 1.46 ]
Total events: 18 (Active management), 23 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % 0.79 [ 0.43, 1.46 ]
Total events: 18 (Active management), 23 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 10.18. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 18 Therapeutic uterotonics during third stage and/or within
24 hours.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 18 Therapeutic uterotonics during third stage and/or within 24 hours
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 121/810 311/821 100.0 % 0.39 [ 0.33, 0.48 ]
Subtotal (95% CI) 810 821 100.0 % 0.39 [ 0.33, 0.48 ]
Total events: 121 (Active management), 311 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 9.79 (P < 0.00001)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % 0.39 [ 0.33, 0.48 ]
Total events: 121 (Active management), 311 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 9.79 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.19. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 19 Mean length of third stage.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 19 Mean length of third stage
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min] N Mean(SD)[min] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 810 14.6 (15.8) 821 16.2 (14.76) 100.0 % -1.60 [ -3.08, -0.12 ]
Subtotal (95% CI) 810 821 100.0 % -1.60 [ -3.08, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % -1.60 [ -3.08, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
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Analysis 10.20. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 20 Manual removal of placenta as defined by study authors.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 20 Manual removal of placenta as defined by study authors
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 26/810 21/821 100.0 % 1.25 [ 0.71, 2.21 ]
Subtotal (95% CI) 810 821 100.0 % 1.25 [ 0.71, 2.21 ]
Total events: 26 (Active management), 21 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % 1.25 [ 0.71, 2.21 ]
Total events: 26 (Active management), 21 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours active Favours mixed
150Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.28. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 28 Not prespecified: afterpains at 2 hours after birth (id
20458).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 28 Not prespecified: afterpains at 2 hours after birth (id 20458)
Study or subgroup Active Mixed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 713 10.4 (16.4) 712 13.2 (18.6) 100.0 % -2.80 [ -4.62, -0.98 ]
Subtotal (95% CI) 713 712 100.0 % -2.80 [ -4.62, -0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.0026)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 713 712 100.0 % -2.80 [ -4.62, -0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Not applicable
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Analysis 10.29. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 29 Not pre-specified: afterpains the day after birth (id 20458).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 29 Not pre-specified: afterpains the day after birth (id 20458)
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 663 26.1 (21.6) 673 29.1 (21.8) 100.0 % -3.00 [ -5.33, -0.67 ]
Subtotal (95% CI) 663 673 100.0 % -3.00 [ -5.33, -0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.53 (P = 0.012)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 663 673 100.0 % -3.00 [ -5.33, -0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.53 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 10.31. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 31 Birthweight.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 31 Birthweight
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD)[g] N Mean(SD)[g] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 810 3600 (458.2) 821 3585 (445.8) 100.0 % 15.00 [ -28.88, 58.88 ]
Subtotal (95% CI) 810 821 100.0 % 15.00 [ -28.88, 58.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % 15.00 [ -28.88, 58.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours mixed Favours active
153Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.42. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 42 Postnatal maternal mean Hb (outcome not pre-specified).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 42 Postnatal maternal mean Hb (outcome not pre-specified)
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 810 11.8 (1.45) 821 11.52 (1.43) 100.0 % 0.28 [ 0.14, 0.42 ]
Subtotal (95% CI) 810 821 100.0 % 0.28 [ 0.14, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000086)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 810 821 100.0 % 0.28 [ 0.14, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000086)
Test for subgroup differences: Not applicable
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Analysis 10.43. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 43 Severe primary PPH after placental delivery and up to 2
hours (clinically estimated or measured blood loss ≥ 1000 mL) - not pre-specified.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 43 Severe primary PPH after placental delivery and up to 2 hours (clinically estimated or measured blood loss≥ 1000 mL) - not pre-specified
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 53/804 100/817 100.0 % 0.54 [ 0.39, 0.74 ]
Subtotal (95% CI) 804 817 100.0 % 0.54 [ 0.39, 0.74 ]
Total events: 53 (Active management), 100 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.81 (P = 0.00014)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 804 817 100.0 % 0.54 [ 0.39, 0.74 ]
Total events: 53 (Active management), 100 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.81 (P = 0.00014)
Test for subgroup differences: Not applicable
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Analysis 10.44. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 44 Severe primary PPH at time of birth and up to 2 hours
(clinically estimated or measured blood loss ≥1000 mL) - not pre-specified.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 44 Severe primary PPH at time of birth and up to 2 hours (clinically estimated or measured blood loss≥1000 mL) - not pre-specified
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Jangsten 2011 82/804 138/817 100.0 % 0.60 [ 0.47, 0.78 ]
Subtotal (95% CI) 804 817 100.0 % 0.60 [ 0.47, 0.78 ]
Total events: 82 (Active management), 138 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.87 (P = 0.00011)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 804 817 100.0 % 0.60 [ 0.47, 0.78 ]
Total events: 82 (Active management), 138 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 10.45. Comparison 10 Active versus mixed management (no routine uterotonic, early cord
clamping, no controlled cord traction), Outcome 45 Mean blood loss (mL) (clinically estimated or measured at
birth and up to 2 hours (not pre-specified).
Review: Active versus expectant management for women in the third stage of labour
Comparison: 10 Active versus mixed management (no routine uterotonic, early cord clamping, no controlled cord traction)
Outcome: 45 Mean blood loss (mL) (clinically estimated or measured at birth and up to 2 hours (not pre-specified)
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Jangsten 2011 804 233 (255) 817 282 (288.9) 100.0 % -49.00 [ -75.52, -22.48 ]
Subtotal (95% CI) 804 817 100.0 % -49.00 [ -75.52, -22.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.62 (P = 0.00029)
2 Lower-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 804 817 100.0 % -49.00 [ -75.52, -22.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.62 (P = 0.00029)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Active versus mixed management (no routine uterotonic, early cord
clamping, controlled cord traction), Outcome 4 Maternal Hb < 9 g/dL at 24-72 hr.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 11 Active versus mixed management (no routine uterotonic, early cord clamping, controlled cord traction)
Outcome: 4 Maternal Hb < 9 g/dL at 24-72 hr
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Lower-income setting
Jerbi 2007 8/65 10/65 100.0 % 0.80 [ 0.34, 1.90 ]
Subtotal (95% CI) 65 65 100.0 % 0.80 [ 0.34, 1.90 ]
Total events: 8 (Active management), 10 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 65 65 100.0 % 0.80 [ 0.34, 1.90 ]
Total events: 8 (Active management), 10 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 11.19. Comparison 11 Active versus mixed management (no routine uterotonic, early cord
clamping, controlled cord traction), Outcome 19 Mean length of third stage.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 11 Active versus mixed management (no routine uterotonic, early cord clamping, controlled cord traction)
Outcome: 19 Mean length of third stage
Study or subgroup Active management Mixed management
Mean
Difference Weight
Mean
Difference
N Mean(SD)[min] N Mean(SD)[min] IV,Random,95% CI IV,Random,95% CI
1 Higher-income setting
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Lower-income setting
Jerbi 2007 65 2.46 (4.28) 65 10.58 (5) 100.0 % -8.12 [ -9.72, -6.52 ]
Subtotal (95% CI) 65 65 100.0 % -8.12 [ -9.72, -6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.95 (P < 0.00001)
Total (95% CI) 65 65 100.0 % -8.12 [ -9.72, -6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.95 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.20. Comparison 11 Active versus mixed management (no routine uterotonic, early cord
clamping, controlled cord traction), Outcome 20 Manual removal of placenta as defined by study authors.
Review: Active versus expectant management for women in the third stage of labour
Comparison: 11 Active versus mixed management (no routine uterotonic, early cord clamping, controlled cord traction)
Outcome: 20 Manual removal of placenta as defined by study authors
Study or subgroup Active management Mixed management Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Higher-income setting
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active management), 0 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Lower-income setting
Jerbi 2007 1/65 1/65 100.0 % 1.00 [ 0.06, 15.65 ]
Subtotal (95% CI) 65 65 100.0 % 1.00 [ 0.06, 15.65 ]
Total events: 1 (Active management), 1 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 65 65 100.0 % 1.00 [ 0.06, 15.65 ]
Total events: 1 (Active management), 1 (Mixed management)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours active Favours mixed
A D D I T I O N A L T A B L E S
Table 1. Terms and definitions used in this review
Terms Definitions used in this review
Expectant management of third stage of labour • A prophylactic uterotonic agent is not administered
• Umbilical cord is neither clamped nor cut until the
placenta has been delivered or until cord pulsation has ceased
• Placenta is delivered spontaneously with the aid of gravity
and sometimes by maternal effort
Active management of third stage of labour • The routine administration of a prophylactic uterotonic
drug just before, with, or immediately after, the birth of the baby
• Early cord clamping and cutting
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Table 1. Terms and definitions used in this review (Continued)
• Controlled cord traction to deliver the placenta
Mixed management of third stage of labour A mixture of some of the components of both active and expec-
tant management of third stage of labour, but without exclusively
containing all the components of either. There can be a number
of different mixed third stage managements, for example:
• early prophylactic uterotonic drug, cord clamping when
pulsation has ceased and controlled cord traction
• delayed prophylactic uterotonic drug, cord clamping when
pulsation has ceased and controlled cord traction
Early prophylactic uterotonic Prophylactic uterotonic drug administered just before, with, or
immediately after, the birth of the infant
Delayed prophylactic uterotonic Prophylactic uterotonic drug administered after the cord pulsation
has ceased
Early cord clamping The applicationof a clamp to the umbilical cordwithin 60 seconds
of the birth of the infant (McDonald 2013)
Delayed cord clamping The application of a clamp to the umbilical cord more than 1
minute after birth or when cord pulsation has ceased (McDonald
2013)
Sarnat staging for hypoxic ischaemic encephalopathy (Sarnat
1976)
• Stage 1 (mild): hyper-alertness, hyper-reflexia, dilated
pupils, tachycardia, absence of seizures
• Stage 2 (moderate): lethargy, hyper-reflexia, miosis,
bradycardia, seizures, hypotonia with weak suck and Moro
reflexes
• Stage 3 (severe): stupor, flaccidity, small to mid-position
pupils which react poorly to light, decreased stretch reflexes,
hypothermia and absent Moro
Table 2. Varying managements used in studies in the main analysis compared with the study’s planned regime of management
Study Active management
protocol
Expectant management
protocol
Active management
used
Expectant management
used
Begley 1990 • IV ergometrine 0.5
mg immediately
following birth
• Try to clamp cord
within 30 seconds
• When uterus
contracted, attempt
CCT
• Try not to give any
special instructions re
• No oxytocic drug
routinely
• Try to leave cord
attached to baby until
pulsation has ceased
• Placenta may be
delivered by maternal
effort or gentle
controlled cord traction
once separated
• All given IV
ergometrine before
delivery of placenta
• 89% cord clamped
and cut
• 93% CCT and 5%
maternal effort
• 7% upright and
93% recumbent
• 14% were given
ergometrine for
treatment, not
prophylactically, 6 (0.
83%) before placenta
delivered
• Cord left
unclamped till pulsation
ceased 42%
161Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Varying managements used in studies in the main analysis compared with the study’s planned regime of management
(Continued)
posture • Encourage mother
to breastfeed. Help her
to kneel/sit/squa
• Placenta delivered
by maternal effort 32%
and gentle CCT 66%
• 11% upright
Prendiville 1988 • IM syntometrine (5
units oxytocin + 0.5 mg
ergometrine) (IM 10
units oxytocin if raised
BP) Immediately after
birth of anterior shoulder
• Clamp cord 30
seconds after birth
• CCT when uterus
contracted
• Try not to give
oxytocic
• Try to leave cord
attached to baby until
placenta delivered
• Try not to use CCT
or any manual
interference with uterus
at the fundus
• Encourage mother
to adopt posture aiding
delivery with gravity
• If placenta not
delivered spontaneously
wait, try putting baby to
breast, and encourage
maternal effort as above
• Full active
management (99%)
• 99% cord clamped
and cut before delivery
of placenta
• 99% CCT
• 217 (26%) upright
• Full expectant
management 403 (48%)
• Full active
management 168 (20%)
• 278 (32%) had
mixed management
• Cord left
unclamped till pulsation
ceased 48%
• Placenta delivered
by maternal effort 60%
and CCT 40%
• 416 (49%) upright
• 30% received
uterotonic for treatment
Rogers 1998 • IM syntometrine (5
units oxytocin + 0.5 mg
ergometrine)¬(IM 10
units oxytocin if raised
blood pressure)
• As soon as possible
after birth of anterior
shoulder (within 2
minutes of birth)
• Immediate cord
clamping and cutting
• CCT or maternal
effort
• Women
randomised to upright
and recumbent in both
arms
• No uterotonic drug
• No cord clamping
until after pulsation
ceased
• Delivery of placenta
within 1 hour by
maternal effort
• 699 (93.4%) had
full active management
• 2 (0.3%) had fully
expectant management
• 47 (6.2%) had
mixed
• 95% given
prophylactic uterotonic
before delivery of
placenta
• 93% cord clamped
before pulsation ceased
• 46% CCT
• 44% upright (when
placenta delivered)
• 488 (63.9%) had
full expectant
management
• 19 (2.5%) had fully
active management
• 257 (33.6%) had
mixed
• 21% received
oxytocic for treatment, 2.
5% prophylactically
• Cord left
unclamped till pulsation
ceased 70%
• Placenta delivered
by CCT 12%
• 43% upright (when
placenta delivered)
Thilaganathan 1993 • IM oxytocin 10
units at delivery of
anterior shoulder
• Immediate cord
clamping and cutting
• CCT as soon as the
uterus was contracted
firmly - repeated every 2-
• No oxytocic prior
to delivery of placenta
• Cord clamped and
cut after delivery
• No CCT
• No fundal massage
• Maternal expulsion
after signs of separation
No information No information
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Table 2. Varying managements used in studies in the main analysis compared with the study’s planned regime of management
(Continued)
3 minutes • IV infusion of
oxytocin 10 units in 500
mL normal saline given
slowly
BP: blood pressure; CCT: controlled cord traction; IM: intramuscular; IV: intravenous
A P P E N D I C E S
Appendix 1. Search methods - ICTRP and ClinicalTrials.gov
ICTRP
postpartum h(a)emorrhage
third AND stage AND labo(u)r AND bleeding
active AND expectant AND third
active AND expectant AND labo(u)r
ClinicalTrials.gov
Advanced search
Interventional studies | postpartum hemorrhage
Interventional studies | third stage | labor
Interventional studies | bleeding | labor
F E E D B A C K
Mc’Alpine, 31 August 2002
Summary
I have some questions. In the four included studies, how many women were in each study and when were the studies done? Was a
comparison made between maternity hospitals, birth centres, and home delivery? For postpartum haemorrhage of more than 500 mls,
what does “relative risk 0.38, 95% confidence interval 0.32 to 0.46” mean in terms of numbers?
Why do you conclude that active management should be the ’routine’ management of choice in a maternity hospital? What are the
implications for other settings?
[Summary of comments from Elizabeth McAlpine, August 2002]
Reply
Reply from Cecily Begley in December 2009: The number of women in each study can be found in the analyses graphs in this updated
review, and the overall numbers of studies and women included for each outcome are also reported in the text. Dates for the studies
are included in the references. All the studies were in hospital settings and we found no studies of midwifery-led birth centres or home
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births. We have included this information on study settings in the ‘Characteristics of Included studies’ and at appropriate places in the
text of the review. Our estimate of the relative risk of blood loss greater than 500 mL is slightly different from the previous version
of the review because we have used a random-effects analysis. We also report the ‘Numbers needed to treat’ under ‘Summary of main
results’ for the outcomes of severe primary PPH and postnatal Hb < 9 g/dL; we hope this addresses the meaning of the relative risk
and confidence intervals for these outcomes. Our conclusions differ from the previous review as we have included additional outcomes
which show a balance of benefits and harms and we have used new systematic review methodology. Our findings refer to hospital
settings because this is where the included studies were undertaken. We cannot provide evidence-based information for other settings.
Contributors
Cecily Begley
Matthews, December 2004
Summary
My anecdotal observation, having changed my practice to include physiological management of the third stage, is that women who
choose this option have a decrease in the amount of lochia postpartum and a shorter duration of vaginal discharge. I have not seen any
studies that could confirm or refute this.
[Comment received from Mary Jo Matthews, December 2004]
Reply
We have included in the update of the review the outcome ‘Amount of lochia > 24 hours and up to discharge from hospital [mL]’;
however, none of the included studies assessed this outcome, so we have, therefore, no evidence to confirm or refute this observation.
Contributors
Cecily Begley
Van Wyk, 4 March 2009
Summary
This review was last updated in 2000, and comments sent in 2002 and 2004 have not been addressed. The authors stated in 2007 that
an update is in progress. We are concerned about the validity of the review findings.
[Summary of feedback from Susan van Wyk on behalf of the Masters Clinical Epidemiology class, Stellenbosch University, February
2009]
Reply
A new team took over this review in December 2008. We have now updated this review and addressed these comments from 2002 and
2004. Our conclusions differ from the previous review as we have included additional outcomes which show a balance of benefits and
harms and we have used new systematic review methodology. The delay has arisen from our needing to produce a new protocol for the
review prior to undertaking the update.
Contributors
Reply from Cecily Begley, December 2009
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WH A T ’ S N E W
Date Event Description
22 January 2018 New search has been performed Search updated and five new trial reports identified.
Three were clinical trials registry reports of studies al-
ready assessed.We excluded one new trial in comparison
5. We are still unable to source the full-text of Rosario
1973. One new study has been included in this update
(Yildirim 2016).
All details were updated in line with the new Cochrane
requirements. We changed one section of risk of bias
for two papers and updated the ’Summary of findings’
table footnotes with this information, and included the
setting. Dr Linda Biesty joined the team. We had erro-
neously referred to the comparison, ’women at low risk
of excessive bleeding’ as a “subgroup” in the text, so we
altered this
22 January 2018 New citation required but conclusions have not changed Main conclusions have not changed. Language to reflect
the GRADE assessments of the quality of the evidence
was added, as was a sentence on the conclusions in rela-
tion to the comparison of women at low risk of excessive
bleeding
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 7, 2010
Date Event Description
20 October 2014 New search has been performed Search updated. We included a further publication on
one of the already included studies and now include
data on after-pains for this comparison (Jangsten 2011)
. We updated the risk of bias for all included studies
to assess both performance bias and detection bias. We
have included a ’Summary of findings’ table in this up-
date
20 October 2014 New citation required but conclusions have not
changed
Three references identified and one included for this
update (a new paper from a trial already included) and
two were excluded
17 August 2011 New citation required but conclusions have not
changed
Deirdre Murphy and Susan MacDonald stepped down
as authors. Andrew Weeks joined the team
165Active versus expectant management for women in the third stage of labour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
17 August 2011 New search has been performed Search updated in February 2011: two new studies
included (Jangsten 2011; Jerbi 2007); four excluded
(Abdel-Aleem 2010; Hoffman 2006; Ramirez 2001;
Vasegh 2005); and one added to Studies awaiting
classification.
Protocol section updated - see Differences between
protocol and review.
10 May 2010 Feedback has been incorporated Feedback on the previous version of this review added,
along with replies from the new review team
C O N T R I B U T I O N S O F A U T H O R S
Cecily Begley (CB) drafted the background section and all other authors contributed to editing the text. All review authors contributed
to the drafting of the inclusion criteria for the review. Gill Gyte (GG) and Declan Devane (DD) added the methodology section with
other authors commenting. CB and GG abstracted and pooled data. WilliamMcGuire checked data entry, DD prepared the ’Summary
of findings’ table, which was checked by Andrew Weeks. GG, DD and CB wrote the results section with other authors commenting.
CB and GG wrote the discussion and implications sections, with input from all authors. For this update, GG and LB updated the RoB
sections, DD and LB updated the methods, AW and CB updated the data entry and analysis, CB and WM updated the SoF table.
Cecily Begley is the guarantor of the review.
D E C L A R A T I O N S O F I N T E R E S T
Cecily Begley: was the lead researcher on the ’Dublin trial’ (Begley 1990). Gill Gyte, Declan Devane, and a member of the Cochrane
Pregnancy and ChildbirthGroup’s staff independently reviewed Begley’s paper and agreed inclusion in the review. GG andDD extracted
data.
Gill Gyte: I have written extensively on third-stage management and was a co-applicant on a five year study of care at preterm birth
which included a pilot randomised controlled trial of delayed cord clamping with immediate neonatal care with cord intact versus
early cord clamping (funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research
funding scheme [RPPG-0609-10107]). I am currently a Public and Patient Involvement representative on the Trial Management Group
on a Health Technology Assessment funded clinical trial of carboprost versus oxytocin as first line treatment of primary postpartum
haemorrhage, led by Professor Andrew Weeks based at University of Liverpool, UK. I also received royalties from John Wiley & Sons
in respect of ‘A Cochrane Pocketbook - Pregnancy and Childbirth’ Hofmeyr GJ et al. 2008.
Declan Devane: was a member of the Data Monitoring Board for the Cord pilot trial - immediate versus deferred cord clamping for
very preterm birth (before 32 weeks’ gestation). (The study is not included in this review.)
William McGuire: none known
Andrew Weeks: has been on a programme grant related to the timing of cord clamping, as well as investigating the use of misoprostol
for postpartum haemorrhage prophylaxis in rural Uganda (Weeks AD, Ditai J, Ononge S, Faragher B, Frye LJ, Durocher J, Mirembe
FM, Byamugisha J,Winikoff B, Alfirevic Z. TheMamaMiso study of self-administered misoprostol to prevent bleeding after childbirth
in rural Uganda: a community-based, placebo-controlled randomised trial. BMC Pregnancy Childbirth. 2015 Sep 14;15:219). He is
also one of nine designers of a small resuscitation trolley (the BASICS trolley; Weeks AD, Watt P, Yoxall CW, Gallagher A, Burleigh A,
Bewley S, Heuchan AM, Duley L. Innovation in immediate neonatal care: development of the Bedside Assessment, Stabilisation and
Initial Cardiorespiratory Support (BASICS) trolley. BMJ Innov. 2015 Apr;1(2):53-58) that allows neonatal resuscitation with an intact
cord and the inventor of the PPH Butterfly, a device to allow minimally invasive uterine compression to treat postpartum haemorrhage
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(Cunningham C, Watt P, Aflaifel N, Collins S, Lambert D, Porter J, Lavender T, Fisher T, Weeks A. PPH Butterfly: a novel device to
treat postpartum haemorrhage through uterine compression. BMJ Innov. 2017 Feb;3(1):45-54.).
Linda M Biesty: none known.
S O U R C E S O F S U P P O R T
Internal sources
• (GG) The University of Liverpool, UK.
External sources
• (GG) National Institute for Health Research, UK.
2009 Version of this review was supported by the NIHR NHS Cochrane Collaboration Programme Grant Scheme award for NHS-
prioritised centrally-managed, pregnancy and childbirth systematic reviews: CPGS02
• Human Reproduction Programme. World Health Organization. Geneva, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not carry out additional searching as proposed. We decided after looking at the variation in the interventions and controls
used in the studies that we had clinical heterogeneity between the studies (Table 1) and so we have used a random-effects meta-analysis
throughout the review.
We have changed the labels on the secondary outcomes of ’Primary postpartum haemorrhage (> 500 mL)’ and ’Secondary postpartum
haemorrhage (> 500 mL)’ to ’Primary maternal blood loss > 500 mL’ and ’Secondary maternal blood loss > 500 mL’ respectively. This is
because we believe that in research the term ’haemorrhage’ should be reserved for excessive blood loss. We have also included reference
to the mean Hb values in order to provide an outcome that was calculated by blinded personnel.
We have modified the wording in the methods sections for ’Assessment of heterogeneity’, ’Assessment of reporting biases’ and ’Data
synthesis’ to update them with the new methods being used by the group, developed in conjunction with the group’s statisticians,
Simon Gates and Richard Riley. We have used these new methods in the review.
We decided to reduce the number of outcomes, in line with the Cochrane Handbook of Systematic Reviews of Interventions’ recommen-
dations. We made the following changes to outcomes.
Nine primary outcomes reduced to seven
Clinical signs of severe blood loss at the time of birth, e.g. woman feeling breathless, weak, faint, pale, exhausted: moved to secondary
outcomes list.
Evidence of acidaemia indicated by a pH less than seven or base deficit greater than 12 mmol/L in umbilical arterial cord blood, or (c)
neonatal blood sample in first hour of life, or both: removed.
Apgar score less than 7 at five minutes, and neonatal (’hypoxic ischaemic’) encephalopathy assessed using Sarnat staging: moved to
secondary outcomes list.
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Changes to primary outcomes
All PPH amounts and mean blood losses are now expressed at three time periods “at the time of the birth”, “after delivery of placenta
and up to 24 hours”, and “at the time of birth and up to 24 hours”. This was done because it was noted that the two primary outcomes
“Severe primary PPH (clinically estimated or measured blood loss greater than or equal to 1000 mL at time of birth and up to 24
hours)” and “Very severe primary PPH (clinically estimated or measured blood loss greater than or equal to 2500 mL at time of birth
and up to 24 hours)”, which were based on the international definition of postpartum haemorrhage (PPH) could, in fact, provide
misleading results if study authors measured or estimated blood loss at birth, and over a period of some hours in the first 24 hours, and
added all amounts together to provide an overall PPH rate. While this estimate could also be useful, it raises the PPH rate artificially
in comparison with studies that do not do this. Accordingly, we have changed the first two primary outcomes to “Severe primary
postpartum haemorrhage (clinically estimated or measured blood loss greater than or equal to 1000 mL at time of birth)” and “Very
severe primary PPH (clinically estimated or measured blood loss greater than or equal to 2500 mL at time of birth)” and have included
the original definitions as secondary outcomes.
“Maternal Hb concentration less than 9 g/dL 24 to 48 hours postpartum” changed to “Maternal Hb concentration less than 9 g/dL
24 to 72 hours postpartum” - as Hb levels may be taken within the first three days postnatal, rather than the first two.
Secondary outcomes deleted (to reduce number of outcomes)
1. Iron therapy during the puerperium.
2. Length of the third stage greater than or equal to 60 minutes.
3. Nausea between birth of baby and discharge from the labour ward.
4. Headache between birth of baby and discharge from the labour ward.
5. Maternal views of third-stage management (assessed using a validated questionnaire).
6. Maternal Hb concentration less than 9 g/dL postdischarge and up to six weeks.
7. Sequelae of PPH (length of stay; infection; re-admission).
8. Infant Hb level and iron indices beyond three months.
Changes to secondary outcomes
“Administration of oral or rectal analgesia (e.g. paracetamol, codeine, non-steroidals) between birth of the baby and discharge from
the labour ward” and “Administration of opiate analgesia between birth of the baby and discharge from the labour ward” combined as
“Administration of any analgesia between birth of the baby and discharge from the labour ward”.
“Secondary blood loss equal to or greater than 500 mL (clinically estimated or measured after 24 hours and before six weeks)” and
“Any vaginal bleeding needing treatment (after 24 hours and before six weeks)” and “Uterotonic treatment after 24 hours and before
six weeks” combined as “Secondary blood loss/any vaginal bleeding needing treatment (after 24 hours and before six weeks)”.
“Infant Hb level (Hb) at 24 to 48 hours” changed to “at 24 to 72 hours”, as Hb levels may be taken within the first three days postnatal,
rather than the first two.
“Intraventricular haemorrhage (preterm infants): (i) grade III/IV; (ii) all grades (Sarnat 1976)” changed to “Papille grade III/IV
intraventricular haemorrhage (for infants born before 34 weeks’ gestation only)”.
“Transfusion requirements (preterm infants): (i) number of infants exposed to one or more red blood cell transfusions; (ii) number of
transfusions per infant; (iii) number of donors to whom the infant was exposed” changed to “Number of infants who received a red
blood cell transfusion”.
“Breastfeeding at discharge from hospital and at interval assessments until six months” changed to “Exclusive breastfeeding at discharge
from hospital”.
New secondary outcomes included
“Neonatal mortality” included
Search methods
For the 2018 update we added in an additional search of ClinicalTrials.gov and theWHO International Clinical Trials Registry Platform
( ICTRP).
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Types of interventions
We included the following three comparisons as we added studies that had used them to this review update (2018).
Comparison 9: active versus mixed management of the third stage of labour with uterotonic after placental delivery, immediate cord
clamping and no controlled cord traction
Comparison 10: active versus mixed management of the third stage of labour with no routine uterotonic, early cord clamping, no
controlled cord traction.
Comparison 11: active versus mixedmanagement of the third stage of labour with no routine uterotonic, early cord clamping, controlled
cord traction.
We deleted the fifth subgroup analysis ‘low risk of PPH versus high risk of PPH’ as we realised that the analysis of studies undertaken
with women in the low risk group was in fact a separate comparison.
We changed the original subgroups of ’high-income country’ and ’low-income country’ to ’higher-income setting’ and ’lower-income
setting’, based on the World Bank definitions, with the border between the lower-middle-income and upper-middle-income being the
cut-off point ( World Bank definitions 2018).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Watchful Waiting; Birth Weight; Constriction; Delivery, Obstetric [adverse effects; ∗methods]; Labor Stage, Third [∗physiology];
Oxytocics [∗administration & dosage; adverse effects]; Placenta; Postpartum Hemorrhage [∗prevention & control]; Randomized
Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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